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Abstract
In the first 3 years of the Obama Administration, 2009–2011, the number of warning
letters issued to pharmaceutical firms for manufacturing and quality issues increased by
81% to 49 letters. Only 9 letters were issued in the last 3 years of the George W. Bush
Administration. Shortfalls in compliance and product quality led to medicine shortages
that affected patients’ treatment and health. This quantitative study sought to learn to
what extent, if any, the independent variables, management behaviors and financial
indicators at pharmaceutical firms in the United States, correlated with, or predicted, the
dependent variable, compliance with the FDA regulations. FDA’s enforcement actions on
the firms were the treatment event. A shift in the relationship between the variables
occurred after the FDA interventions, which highlighted a new level of compliance. Of
the 1144 SurveyMonkey invitations sent to the members of the International Society of
Pharmaceutical Engineers, only 21 completed the survey’s 133 questions. Three research
questions were addressed using correlations and linear regressions. The theory of planned
behavior was applied to correlate behavioral constructs with the compliance of the firms
leading to the rejection of the null hypothesis. By establishing an inverse relation between
financial indicators and the firms’ level of compliance, the study offers awareness and
insight to senior leaders regarding their behaviors and the decision-making process.
Enhancing managers’ decision-making processes in light of their beliefs, along with their
control over financial indicators, could reinforce the presence of effective quality systems
among pharmaceutical manufacturers minimizing medicine shortages.
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Chapter 1: Introduction to the Study
Since 2009, interventions and enforcement actions against U. S. pharmaceutical
manufacturers by the Food and Drug Administration (FDA) have increased. Many of the
interventions were due to a lack of compliance with current good manufacturing practices
(CGMP). In short, patented or generic pharmaceuticals sold to the public were not
available or were substandard in quality. Attitudes and behaviors of management in
pharmaceutical firms with an over-commitment to financial results have led to the lack of
the expected compliance with regulations, thus declining organizational performance.
This performance has a direct impact on internal and external stakeholders, which needs
to be addressed to achieve the desired positive social change of avoiding shortages of
medicines. Pharmaceutical management consists of all individuals that have the authority
to make-decisions that could impact compliance with the FDA regulations and to direct
financial decisions within the pharmaceutical firms. According to Pollack (2013), the
drug shortages were caused by (a) pharmaceutical management decisions to limit
investments in enhanced quality systems and (b) insufficient manufacturing capacity.
To project the complexity of addressing the change process, management
decision-making processes, and possible theoretical frameworks need to be implemented
by pharmaceutical management. The essential change process to avoid medicine
shortages has to evolve through the typical change cycle of what, how, and why (Kezar,
2001). The potential impact on stakeholders, especially drug shortages, constituted the
“why” for conducting this study. Influencing the organizational performance, by
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modifying management behaviors and financial indicators, is expected to minimize or
eliminate the impact on stakeholders, leading to positive social change.
Chapter 1 includes the background of the study, the specific details of the problem
statement, and the purpose of the study. Then, the impact on social change by the study
was followed by the theoretical framework of the study, the research questions and
hypotheses, and the design that guided this quantitative study. Chapter 1 concludes with
the definitions, scope of the study, assumptions, limitations, and delimitations in this
study.
Background of the Study
A series of FDA interventions and enforcement actions against pharmaceutical
manufacturers in the past 5–6 years led to medicine shortages in the United States
(Nguyen, Seoane-Vazquez, Rodriguez-Monguio, & Montagne, 2013). Manufacturing
shortfalls made essential medicines unavailable for the treatment of patients (FDA,
2013). Manufacturing shortfalls implied that quality management and manufacturing
systems were not empowered or properly staffed to adequately support the critical
functions of the pharmaceutical firms (Woodcock, 2012). The loss of sales, penalties, and
cost of remediation directly influenced the profit, and thus affected the worth of the
stockholders and the firms’ market value.
In this dissertation, I promoted positive social change by influencing the
elimination or minimization of medicine shortages. Medicine shortages placed the
patients’ health in significant danger (FDA, 2011). Also, medicines that are substandard
in quality, purity, strength, and identity do not address the intended health treatment
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(Woodcock, 2012). Given that the firms’ revenues were affected, both the patients and
the stockholders could be perceived as the victims of management decisions.
Pharmaceutical manufacturing management’s attitude towards limited compliance and
based on extreme control over the cost of goods presented the challenge and disconnect
in the management decision-making process. Burd and Chrai (2004) challenged the
attitudes and behaviors of pharmaceutical management, as well as their drive for financial
results. For pharmaceutical firms, lack of compliance with FDA regulations could be
devastating. The results could include loss of the market value of the firms, loss of sales,
diminished reputation, and increased expenses to recover or achieve remediation. If an
FDA intervention were to evolve into a consent decree, which is a legal agreement to
resolve the shortfalls in compliance by the firm, the magnitude of all these elements
could multiply and become an unacceptable historical benchmark within the industry.
Problem Statement
The general problem investigated in this study was a significant increase in the
number of pharmaceutical firms cited for noncompliance with federal quality guidelines
during the past 5-6 years. In the first 3 years of the Obama Administration, 2009 through
2011, the number of warning letters issued for manufacturing and quality issues increased
from 9 letters (in the last 3 years of the George W. Bush Administration) to 49 letters
(Nguyen, Seoane-Vazquez, Rodriguez-Monguio, & Montagne, 2013), for an increase of
about 81%. This percentage reflected FDA’s emphasis on assuring compliance by the
pharmaceutical companies. The lack of compliance with CGMP led to pharmaceuticals
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manufacturing facility closures, loss on revenues, unavoidable penalty fees, loss of
reputation, and significant investments to address remediation of their non-conformances
to the FDA regulations (Asotra, Cossin, & Yacobi, 2012). The FDA, in a letter, dated
October 31, 2011, to pharmaceuticals manufacturers, indicated that about 54% of drug
shortages were a result of manufacturers’ quality issues (Food Drug Administration
[FDA], 2011). Collectively, the evidence suggested that the number of FDA interventions
and enforcement actions, against pharmaceutical manufacturers, have increased in the
recent years.
The specific problem addressed in this study related to shortfalls in compliance
performance and product quality leading to medicine shortages that affected patients’
treatment and health. According to Pollack (2013) the shortfall in investment decisions
for enhancing quality systems and the limited manufacturing capacity caused the
medicine shortages. Price competition to attain market share, financial benefits on market
value, and management incentives skewed against investing in plant improvements drove
pharmaceutical manufacturing leaders’ decisions and behaviors away from compliance
(Asotra, Cossin, & Yacobi, 2012). Senior leaders’ attitudes towards the lack of focus on
quality systems prevail in their management decision-making process (Woodstock,
2012). Mehta (2013) suggested that implementing the principles and guidelines
developed by the International Conference on Harmonization could be a significant step
in facilitating senior leaders’ understanding of the compliance expectations. Correcting
CGMP violations by the pharmaceutical manufacturing leaders implies that productivity-
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financial indicators need assessment and that management behaviors require
modification.
Purpose of the Study
The purpose of this quantitative study was to determine to what extent, if any,
management behavior and financial indicators at the pharmaceutical firms were
correlated with their compliance with FDA regulations. From the review of the literature,
the gap consisted in the limited research that would create awareness and offer guidance
to managers in their decision-making process and risk assessment process regarding their
(a) FDA compliance responsibility, (b) corporate financial mandate, and (c) stakeholders’
expectations. This research was driven by the limited information on what are the
interdependencies or correlations between the need to grow revenue and the behaviors
within the pharmaceutical management decision-making process.
Management’s resolve to meet the firms’ intended quality, integrity, strength, and
purity influences the level of compliance. Other factors include the pressures to enhance
productivity, fund research, support marketing plans, and reduce the cost of goods.
FDA’s enforcement actions were used as the treatment event to reestablish the expected
level of compliance. A shift in the relationship between the variables was expected after
the FDA intervention, thus highlighting the new level of compliance. The resulting level
of compliance is expected to enhance the financial performance of the pharmaceutical
firms and minimize drug shortages.
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Significance of the Study
This research study was directed to address an area of limited research on the
management behaviors and financial decision-making of senior management in
pharmaceuticals companies. Management behaviors and financial decision-making could
have led to significant shortages of medicines in the last 5-6 years. Drug shortage events
increased from 61 in 2005 (Barlas, 2014) to 251 in 2011 (FDA, 2013). According to
Woodcock (2012), many of these medicine shortages were caused directly by shortfalls
in compliance with FDA regulations. The outcome of the study provided insight to the
management decision process on what senior leaders’ behaviors should be considered
and accentuated the need to modify financial drivers, which limit the presence of
effective quality systems in pharmaceutical manufacturing companies.
For pharmaceutical firms, lack of compliance with the FDA regulations could be
devastating. Lack of compliance could impact sales and reputation, and could increase in
the level of expenses to recover or achieve remediation. These performance indicators
also correlated to the market value of the firms. If the FDA intervention escalates into a
consent decree, the magnitude of all these elements could multiply and become an
unacceptable historical benchmark within the industry. Legal actions against
pharmaceutical firms’ leadership could be inevitable. This study pursued the potential to
highlight the undesired behaviors in management and accentuated the concept that
compliance is a competitive business advantage for the pharmaceutical companies.
This study could raise the awareness of pharmaceutical management about how
their decisions, based on their attitudes and behaviors, could avoid interruptions in the
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supply of some essential patented or generic drugs. The social responsibility of the
organization would be perceived to be non-existent and detached from the mission of
providing quality medicines for the treatment of patients. Some examples of the
experienced shortages are Tylenol for cold symptoms in 2011, Doxil for ovarian cancer
in 2012, and Levoxyl for thyroid hormone replacement in 2013 (FDA, 2013). The goal of
this study was to provide clarity about the desired behaviors to management. The findings
of the study are expected to transform leadership tactics to meet the organization goals
and mission, while sustaining compliance with the CGMP regulations.
The target of the study, as previously described, was directed to avoid placing the
patients in danger with medicine shortages (Hensley, 2011). In their study, Becker et al.
(2013) found that the number of oncology drug shortages affecting patients’ treatments
increased from 2010 to 2011. Also, stockholders’ equity could be affected if management
does not recognize the detachment from their mission leading to the costs associated with
the FDA intervention and high financial penalties. The effectiveness of this study
depended on the degree of honesty in the participants’ responses and on how well the
responses represented the actual behavior or intended future actions of the participants.
Secret agendas were not detected. Unscrupulous managers could have presented an
obstacle to enhance quality systems and compliance as indicated by Woodcock (2012).
The actual performance could continue with old practices and behaviors, leading to poor
product quality and further medicine shortages, while increasing the risk to patients and
the losses to stockholders.

8
The study has implications for positive social change directed to encourage
managers of pharmaceutical organizations to operate and behave in compliance with the
FDA regulations. The main potential social change was to avoid having medicine
shortages, due to decisions about non-compliance by pharmaceutical manufacturing
management. Avoiding shortages of patented or generic medicines would minimize or
eliminate the risk to patients’ health.
Research Questions and Hypotheses
In this quantitative study, I sought to determine the correlation, if any, between
the management behaviors and financial indicators of pharmaceutical firms that have
been impacted by FDA enforcement actions. The compliance present in the
pharmaceutical firms prior to the FDA intervention were compared to the compliance
after the FDA intervention to better understand its influence on the firms’ compliance
with the CGMP regulations. The independent variables that could lead to enforcement
actions by the FDA were the behavior of the pharmaceutical managers and the firms’
financial indicators. The dependent variable was the level of compliance of the
pharmaceutical company.
• Correlations between management (independent variable) behaviors and
compliance (dependent variable):
Research Question 1 (RQ1): To what extent, if any, does management
behaviors correlate to compliance with FDA regulations at the pharmaceutical
firms in the United States?
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H1₀: r = 0. There is no difference in management behaviors towards
compliance at pharmaceutical firms, as a result of FDA enforcement actions in
the United States.
H1₁: r ≠ 0. There are differences in management behaviors towards
compliance at pharmaceutical firms, as a result of FDA enforcement actions in
the United States.
• Correlations between financial indicators (independent variable) and compliance
(dependent variable):
Research Question 2 (RQ2): To what extent, if any, do financial indicators
correlate to compliance with FDA regulations at the pharmaceutical firms in
the United States?
H2₀: r = 0. There is no difference in compliance with FDA related to financial
indicators at pharmaceutical firms, as a result of FDA enforcement actions in
the United States.
H2₁: r ≠ 0. There are differences in compliance with FDA related to financial
indicators before and after the FDA enforcement actions in the United States.
• Financial indicators (independent variable) impact on compliance (dependent
variable):
Research Question 3 (RQ3): To what extent, if any, do financial indicators
impact compliance with FDA regulations at the pharmaceutical firms in the
United States?
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H3₀: β₁ = β₂ = … = β7 = 0. There is no impact in compliance with FDA
related to financial indicators at pharmaceutical firms, as a result of FDA
enforcement actions in the United States.
H3₁: At least one β₁ ≠ 0. There is an impact in compliance with FDA related
to financial indicators before and after the FDA enforcement actions in the
United States.
The βs in Hypothesis 3 were the regression coefficients of the following multiple
regression equation:

Y  0  1 X1  2 X 2  3 X 3  4 X 4  5 X 5  6 X 6  7 X 7  
Where,
Y= FDA related compliance
X1 = Cost of goods
X2 = Investment
X3 = Process compliance
X4 = Change in sales
X5 = Change in revenues
X6 = Change in market value of the firms
X7 = Change in stockholders equity
ԑ = Error of the regression

(1)

11
Theoretical Framework
The purpose of a theoretical framework is to identify a theory that could relate the
independent and the dependent variables (Creswell, 2009). Creswell indicated that a
deductive approach should apply when selecting the theoretical framework for a
quantitative study. Frankfort-Nachmias and Nachmias (2008) suggested that a systematic
link between the conceptual and operational definitions is needed for a practical approach
to the theory. In this study, the theory before research approach was applied as written by
Frankfort-Nachmias and Nachmias (2008). This systematic approach allowed assessing
and predicting the interrelation between the selected variables.
The theory of planned behavior (TPB) was developed by Ajzen (1991). In this
study, it was used to assess behaviors of the pharmaceutical managers. The central point
of TPB is that there is a direct relationship between intention and actual behavior. TPB
highlights that any behavior could be explained and that behaviors are not difficult to
predict. For this study, the intention of the pharmaceutical industry management to
comply with the regulations of the FDA, as well as the financial limitations and
complexity, created an excellent scenario to assess with TPB.
As presented by Langham, Paulsen, and Härtel (2012), the relationship between
intention and actual behavior is essential to the understanding of the willingness to
comply and of the actual action of non-compliance. Consequently, predicting intention to
comply is as important as predicting the actual compliance behavior. TPB also evaluates
the topic of behavioral control, including the concepts of perceived behavioral control
and actual control. Perceived behavioral control consists of the individual’s ability to
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control behavior and willingness to apply the required behavior. Actual control is
essential for investigating behaviors that require the individual to overcome performance
hurdles. Attitudes and values are specific elements in this approach. Understanding the
factors that led to the unwillingness to comply or drive to ignore compliance facilitate the
probable prevention measures accompanying any FDA intervention. TPB provided
mechanisms of comparison, correlation, and prediction to understand how to reinforce
the intention that could modify future compliance.
Nature of the Study
The nature of the study intended to address the research questions to raise
management’s awareness avoiding interruptions in the supply of some essential patented
or generic pharmaceutical drugs. The study highlighted that (a) avoiding FDA actions
provides business sustainability and (b) compliance is a competitive advantage for
pharmaceutical companies. The design of the research sought to predict the outcome of
the dependent variable, that is, compliance with FDA regulations.
Selection of Study Methodology
The comparison between experimental methods could be centered in two foci,
either in an exploratory study of a new topic (qualitative) or on the degree of achieving or
understanding the causation relation between variables (quantitative). The quantitative
research method predicts, investigates relationships between variables, or assesses
possible impacts or influences on outcomes. The qualitative research method is an
approach to study the implicit, as well as the explicit of the targeted study or phenomena.
The qualitative method evaluates personal perceptions and people’s experiences as their
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reality (Patton, 2002). Typically, the qualitative data interprets words during the
quantitative data analyzes numbers. The significant difference is that qualitative research
is inductive and quantitative research is deductive (Colorado State University, 2012).
Both research strategies consider research questions and purpose of the study. However,
in qualitative research, a hypothesis is not used. Quantitative research method requires
hypotheses to predict or direct the study (Creswell, 2009).
To address the research question and test the hypotheses of this quantitative study,
a deductive approach was adequate to confirm the correlation between the variables. The
responses from the participants were the input to the data analysis. Based on the
correlations between management behaviors and financial indicators on the compliance
with the CGMP regulations, I was able to determine the firms’ compliance before and
after the FDA intervention with the pharmaceutical company. Management attitudes and
financial metrics required statistical instruments and probability methods to predict the
mindset of management and the financial indicators about the outcomes of compliance
with FDA regulations.
Study Design and Variables
The study consisted of a correlation design including the application of statistical
tools. This approach allowed making comparative statistical analysis to establish
correlations and make predictions after a treatment, the FDA intervention. The variability
in this study and the goal to predict outcomes also led to the application of regression line
analyses. For this study, the compliance conditions prior to the FDA intervention were
the scenarios that led to enforcement actions by the FDA. The independent variables or
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predictors were management behaviors and financial indicators. The treatment event was
the application of the enforcement action by the FDA. The level of compliance of the
firms was the dependent variable or outcome.
Other quantitative methods were evaluated for the study but found not appropriate
to test the research questions and hypotheses of the study. The concept that the FDA
intervention could create a change in behaviors was the primary design parameter. The
control over the extrinsic and intrinsic factors was very limited about companies’ sizes,
organizational structures, and the portfolio of products. Consequently, a classical
experiment design did not apply in this study. Considering cross-sectional design, the
independent variable cannot be typically manipulated to establish before and after
comparisons. As stated by Frankfort-Nachmias and Nachmias (2008), there is a need to
incorporate control and manipulation over the independent variables to be able to infer
causation from them. The cross-sectional design did not apply to the study since the focus
was in the influence generated between the variables by the FDA intervention.
Since a pre-experimental design is the weakest in the validity of the design
(Frankfort-Nachmias & Nachmias, 2008), it did not applied. The causation could not be
easily defined. Time implementation of treatment was not applicable since the FDA
intervention tends to occur in one instance, while pursuing the desired compliance. The
target was to study the correlation in the variables with emphasis driving towards the
compliance outcome from the FDA intervention. Comparison of the compliance
conditions pre-intervention of the FDA (pre-FDA) and post-intervention of the FDA
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(post-FDA) in the pharmaceutical organization were evident because of the outcome of
the FDA intervention.
Definitions
Definitions for the study were aligned to the FDA definitions of the corresponding
regulations or guidance. Terms like management and medicine are associated with the
relevant FDA definition. Citations from the FDA documents allowed assurance that the
definitions’ terms were clear for the intent of the study.
CGMP Regulations:
The CGMP regulations for drugs contain minimum requirements for the methods,
facilities, and controls used in manufacturing, processing, and packing of a drug
product. The regulations make sure that a product is safe for use, and that it has
the ingredients and strength it claims to have. (Food Drug Administration [FDA],
2012, “Drug Applications and Current,” para. 1).
Compliance with CGMP:
Decisions regarding compliance with CGMP regulations are based upon
inspection of the facilities, sample analyzes, and compliance history of the firms.
(FDA, 2012, “Drug Applications and Current,” para. 2).
FDA Form 483:
An FDA Form 483 is issued to firms’ management at the conclusion of an
inspection when an investigator(s) has observed any conditions that in their
judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act
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and related Acts. (Food Drug Administration [FDA], 2013, “Frequently Asked
Questions,” para. 1).
High management agent (management):
…(A) an officer or director of a corporation or an association, (B) a partner of a
partnership, or (C) any employee or other agent of a corporation, association, or
partnership, having duties such that the conduct of such officer, director, partner,
employee, or agent may fairly be assumed to represent the policy of the
corporation, association, or partnership, and (2) includes persons having
management responsibility for - (A) submissions to the Food and Drug
Administration regarding the development or approval of any drug product, (B)
production, quality assurance, or quality control of any drug product,… (FDA,
2012, “FD&C Act,” p. 35).
Warning Letter:
…a correspondence that notifies regulated industry about violations that FDA has
documented during its inspections or investigations. A Warning Letter is one of
the Agency’s principal means of achieving prompt voluntary compliance with the
Act. (Food Drug Administration [FDA], 2012, “Regulatory Procedures Manual,”
p. 5).
Scope of the Study
The scope of the study addressed the process to determine to what extent, if any,
pharmaceutical management’s behaviors and financial indicators correlated to
compliance with the FDA regulations at the pharmaceutical firms. Shortfalls in
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compliance with FDA regulations have led to significant shortages of medicines to
patients in the last five years (FDA, 2013). Pollack (2013) indicated that these medicine
shortages have been a direct consequence of shortfalls in compliance with the FDA
regulations. The population for the study consisted of the pharmaceutical firms that were
been impacted by FDA enforcement activities due to manufacturing violations. All listed
members of the International Society of Pharmaceutical Engineers (ISPE) in public U. S.
pharmaceutical firms were invited to participate in the survey: executives and operational
managers who had the authority to make compliance and financial decisions.
The survey instrument consisted of a four-section survey, structured as a Likerttype scaled questionnaire. Two sections focused on the behavior of the participants and
the financial indicators of the pharmaceutical firms in the pre-FDA and post-FDA
interventions. The third section collected demographical information from the
participants. The fourth section focused in the firms’ historical compliance.
The TPB questionnaire guidelines developed by Fishbein and Ajzen (2010) were
modified for the behavioral section of the survey instrument. Ajzen (2002) suggested the
essential elements for the construction of a survey for a TPB questionnaire, including the
use of a pilot study to set the potential drivers of the behaviors. The conducted pilot study
enhanced the level of clarity, content validity, and feedback on the questions in the
instrument as indicated by Creswell (2009). The financial indicators’ sections of the
intended survey instrument were based on typical indicators that could be impacted by
the expenses needed to support remediation from FDA interventions. The validity and
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reliability of the intended survey instrument were essential to allow for the
trustworthiness of the data as explained by Frankfort-Nachmias and Nachmias (2008).
For the sampling size determination of completed surveys, three approaches were
followed to address the three research questions and hypotheses. For research questions
one and two, the sampling size determination of completed surveys considered Krejcie &
Morgan (1970) equation and Cohen’s power (1992) as the basis for calculation. The
sample size of completed surveys for RQ3 was established by using G*Power software
(Faul, Erdfelder, Lang, & Buchner, 2014).
The study population consisted of pharmaceuticals firms that have been impacted
within the last 5–6 years by enforcement activities from the FDA in the United States.
This population was estimated to be about 272 pharmaceutical manufacturing firms based
on the FDA information (FDA, 2015). The sampling size of completed surveys indicated
by Krejcie & Morgan (1970) to be considered was about 160. The intended survey
participants were selected from executives and operational management levels of the
firms. These participants, based on their self-disclosed position titles in the ISPE
database, had the authority to make compliance and financial decisions for their firms.
SurveyMonkey was the electronic survey applied to estimate the optimum sample
size assuming a normal distribution. For a target of 160 completed questionnaire, the
SurveyMonkey sampling estimator initially indicated that the number of potential
participants should be about 400 at a 90% confidence level and a 5% margin of error.
This sample of 400 participants projected about 162 completed surveys with a 90%
probability that the sample of participants could reflect the attitudes of the intended
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population. Also, the margin of error of 5% intended to minimize the deviation from the
true value at the selected confidence limit of 90%. For this scenario, the expected
response rate based on SurveyMonkey sampling estimator implied a participation of
40.5%.
A response rate of 40.5% was initially considered too optimistic. The expected
response rate was set at 20% to ensure the probability of attaining the targeted 160
completed surveys. This scenario required about 800 participants at 20% response rate.
The SurveyMonkey sampling estimator indicated that for 800 targeted participants at a
90% confidence level, the margin of error could be expected at 6%. As a precaution,
1144 members in the directory of the International Society of Pharmaceutical Engineers
(ISPE) were invited to complete the survey. These participants had an e-mail address and
meet the participants’ criteria.
Assumptions of the Study
The assumptions included elements related to participants and financial
indicators. In this study, I made the following six assumptions:


The responses to the pilot study and the main survey were honest.



The participants were not to expect any repercussions from their supervisors
or senior officials of the pharmaceutical company for participating in the
study.



The participants were assumed to have the same definition of the compliance
elements as presented in the definitions section based on the FDA.
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Also, the survey participants, based on their position titles, had the authority
to make compliance and financial decisions within the pharmaceutical firms.



Financial information provided by the participants was based on the complete
financial disclosure by the pharmaceutical firms and not in their perceptions.



The financial responses provided by the participants was accurate illustrating
the financial indicators of the firms, before and after the FDA intervention.
Limitations of the Study

Limitations that were not controlled by the researcher included accessibility by
intended participants to the Internet or the presence of a firewall on the Internet. Access
to participants’ e-mails was obtained from the International Society of Pharmaceutical
Engineers (ISPE), a professional organization related to pharmaceutical firms under the
FDA regulation. The managers of the targeted pharmaceuticals firms were expected to be
members of the professional organizations.
The length of the main study proved to be a major limitation. The pilot study had
about 40 questions. The main study had 133 questions. The number of participants that
initiated the survey was about 90 of which 45 progressed through all the questions. Only
21 participants provided completed surveys for the study. This low participation had a
significant impact to the completeness of the study.
The low level of participation limited the study depth and significance of the
findings. The rationale for the low participation could have been to the sensitivity of the
topic in the pharmaceutical industry for the shortfall of quality product to the patients.
Also, the participants could had personal concerns on the confidentiality of the survey,
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despite the consent form with the IRB endorsement. In the technical side of
communications, the internet firewalls in the pharmaceutical firms limiting e-mails to
reach the participants. The limited participation was a major obstacle for the assessment
of the financial indicators.
Timely access to FDA reports about a particular firms might be limited by the
time to process the information. By using the FDA public database for all intervention
with pharmaceutical firms in the last 5–6 years provided a reasonable level of
completeness and minimized the constrained by the complexity of the FDA interventions
to the pharmaceutical firms. Typically, FDA information from a given intervention to a
pharmaceutical firms could take 6–8 months before publication or post on the FDA web
page.
Delimitations of the Study
Privately owned and international pharmaceutical sites that had received FDA
interventions were not part of the study. The financial results of privately owned
pharmaceutical firms are not available. The focus of the research study included only
pharmaceutical companies in the United States. Personal interviews were not performed
due to participants’ limited accessibility.
Any new FDA intervention or medicine shortage that might occur concurrently to
this study was not be included. Concurrent FDA interventions might not have triggered
remediation expenses at the time of the study through 2015. Changes in behaviors of the
pharmaceutical management might not have occurred concurrently with the FDA
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intervention. The time required to develop a remediation plan by the affected firms, and
the actual execution of the plan, makes concurrent FDA interventions inaccessible.
Summary
By conducting this quantitative experimental research study, the findings allowed
me to determine to what extent, if any, management behaviors and financial indicators
correlate with compliance with FDA regulations at pharmaceutical firms. Chapter 1
included the background of the general problem and the specific area of study. The
purpose and the significance of the study led the discussion into the positive social
change to patients, managers, and stockholders of the pharmaceutical firms. The section
on the nature of the study allowed me to highlight the justification for a quantitative
approach to the research and data analysis. The three research questions and the
hypotheses to address the problem statement were listed. The assumptions, limitations,
and delimitations of the study were presented to clarify the scope of the study.
The gap was addressed in this study by providing awareness and guidance to
managers on their behaviors, decisions, and risk assessment processes, when considering
their FDA compliance responsibility, corporate financial mandate, and stakeholders’
expectations. The expected managers’ modified behaviors could lead to a reduction in
the number of FDA interventions and enforcement actions, against pharmaceutical
manufacturers, resulting in fewer medicines’ shortages to patients.
Chapter 2 includes the literature review conducted to identify existing research on
the dependent variable, the independent variables, and the theoretical framework. The
gap in the literature is discussed in Chapter 2. The section on the theoretical framework
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presents the theory of planned behavior utilized to develop and execute this quantitative
study. Also, in Chapter 2, an analysis of issues, trends, and concepts formalize the
literature review for what needs to change, the how to change, and the why to change.
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Chapter 2: Literature Review
Chapter 2 contains an in-depth review of the literature on the problem statement
revealing the gap in the literature, which was addressed by this study. The discussion
about the independent variables and the dependent variable emphasized the expected
correlations. The FDA strategy of enforcement since 2009 and its relation to drug
shortages was summarized from the literature (Roman, 2014). The theory of planned
behavior and the approach to change management were detailed, and the implication of
the study discussed. In the last sections of Chapter 2, change models, continuous
improvement strategy, and managing change resistant or impediments are presented.
Strengths and weaknesses of the variables, as found in the literature, facilitated
the introduction to the literature discussion. I analyzed issues, trends, and concepts to
manage the review of the literature. Details of the influence of the independent variables
and their correlation with the level of compliance were analyzed. The theoretical
framework literature review provided the basis for the research tools supporting the
selected research methodology. The relevance of the study and its impact on social
change was presented to address the research gap in the literature and clarify what needed
to be changed.
Interventions and enforcement actions against pharmaceutical manufacturers by
the FDA are due to the lack of compliance with CGMP (Woodstock, 2012). The
correlation between attitudes and management behaviors with an over commitment to
financial results lead towards a lack of the expected compliance with regulations. This
performance needs to be modified to achieve the desired positive social change of
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avoiding medicine shortages. As presented by Asotra, Cossin, and Yacobi (2012), focus
on financials with low CGMP compliance also leads to an undesired financial
performance, which has a direct impact on stockholders.
The required change process to attain the desired state of avoiding medicine
shortages has to evolve through the typical life change cycle of what, how, and why
(Kezar, 2001). Management trends and possible theoretical frameworks were presented to
project the complexity of addressing the change process. The future impacts on the
stakeholders were the “why” to conduct the study, delineating the required attributes that
influenced the organizational performance to achieve positive social change.
Literature Search Strategy
Research databases, associated with management and business, were used.
ABI/Inform Global and ProQuest were the most used databases in the literature search
process. Walden University’s library and Goggle Scholar were the main search engines in
this effort. A search log, in ReadCube® and in Word, provided indexing of the literature
by creating clusters of relevance by topic. The search log included article information and
comments on significant ideas. The search log served as the vehicle to review, reflect,
and plan the direction of the next stage of the literature search strategy. The process was
repeated to reinforce the link between the selected literature pieces, emphasizing each
specific topic and accentuating the interrelations of the variables.
In Table 1, the span of the references that were evaluated and researched is
presented. Potential articles from the databases search and the keywords applied to the
Goggle Scholar were over 700 sources. The total of references included in this study was
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101. A total of 39 peers reviewed articles, 26 professional organizational articles, 13
Internet pages, and 12 government documents constituted the platform of the literature
review for this study. A total of 11 books were also consulted to enhance the theoretical
basis of the study, especially in the areas of behaviors, change management, and
motivation. The focus of the literature search was based mainly on current sources. The
reference list consists of 62% of sources less than five years for the current situation, and
of 38% older references. About 21% of the references are from the last year 2014, 2015,
and 2016. The references focused in the description of the problem statement, the
variables of the correlation, subject matter experts, the theoretical framework for the
study, and management topics. The totals in Table 1 include the referenced articles in this
study.
Table 1
Evaluated and Research Literature
Peer- Reviewed
Articles

Professional
Organizational
Articles

Books

Internet
Pages

Government
Documents

5

17

0

6

9

5

2

0

1

1

2

4

1

0

2

Theory (TPB)

8

2

2

2

0

Change and
Management
Theories

19

1

8

4

0

Totals

39

26

11

13

12

Problem
Statement
Dependent
Variable
Independent
Variables
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Table 2 presents the list of the keywords used in the research. Keyword alerts
were set to maintain a continuous search the keywords with emphasis on FDA, change,
and medicine shortages, theory of planned behavior and CGMP compliance. Google
Scholar’s listing was frequently revised to ensure updates for the literature review. The
independent variables, management behavior and financial indicators as related to the
study presented limited options.
Table 2
Keywords Used for Research
Problem
Statement

Dependent
Variable

Warning
Letters
FDA

CGMP
Compliance

Medicine
Shortages

Independent
Variables
Behavior

Theories
Framework

Management
Theories/Method

Theory of Planned
Behavior

Financial
Indicators

Change

Organizational
Structure

Background of the Literature Review
The number of FDA interventions and enforcement actions against
pharmaceutical manufacturers has led to several medicine shortages. The lack of
compliance with CGMP has resulted in facility closures, loss of revenues, unavoidable
penalty fees, and significant investments to address remediation of the violations of the
FDA regulations (Burd & Chrai, 2004). In addition, the loss of sales, penalties, and cost
of remediation influence directly the profit line, impacting the worth of the stockholders
and the firms’ market value. Achieving and maintaining FDA compliance makes business
sense and provide a competitive advantage as discussed by Smart (2013). The primary
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social impact is that essential patented drugs or generic pharmaceutical drugs, provided to
the general public, could have been substandard for quality, purity, strength, and identity,
placing the patient health in significant danger and probably not addressing the intended
treatment.
The purpose of this quantitative dissertation research study was to determine to
what extent, if any, management behaviors and financial indicators correlated to
compliance with FDA regulations at the pharmaceutical firms that have been impacted by
FDA enforcement actions in the United States. This quantitative design was directed
towards correlations and regression analyses. The conditions before to the FDA
intervention in the pharmaceutical firms were compared to the conditions after the FDA
intervention to predict compliance with the CGMP regulations. The independent
variables that could lead to enforcement actions by the FDA were behaviors of the
pharmaceutical managers and the firms’ financial indicators. The level of compliance of
the pharmaceutical company was the dependent variable.
In Figure 1, a conceptual map is presented to illustrate the interrelations between
the variables, management behaviors, and leadership skills, leading to the need for
change management to drive the expected behaviors and compliance with the FDA. The
problems affecting pharmaceutical-organizational performance were considered to be
attitudes and management behaviors with an over-commitment by pharmaceutical
management to financial results, leading to a lack of the required compliance with
regulations. The problem statement had a direct impact on stakeholders. The impact on
stakeholders needed to be addressed to achieve the desired positive social change of
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avoiding medicine shortages. Management trends to address “what is needed” were listed
in the bottom-right of Figure 1. Areas that could be studied and possible theoretical
frameworks (How is it done) were enumerated in the bottom-center of Figure 1 to project
the complexity of addressing the change process. The desired impacts that are listed in
the left-bottom of Figure 1 were the “why is it needed” to conduct the study, delineating
the attributes influencing the firms’ performance to achieve positive social change.
From the concept map in Figure 1, the use of change management and
adaptability emphasized the need and reinforced the notion that ethical behaviors need to
be modified. The benefit from the concept map structure (Novak & Cañas, 2006) was
obtained by the hierarchical flow from the initial problem position to the outcome in the
concept map. The concept map provided a means to capture the transition from the
problem (“as is”) to the outcome (“desired state”). By addressing the problem statement
to achieve social positive change, leaders of pharmaceutical organizations, who are
involved with FDA interventions, should modify their behaviors and financial metrics,
avoiding medicine shortages to patients and minimizing risk to stockholders.

30
Management Factors Affecting
Organizational Performance

Attitudes and
Behavior

Over Commitment
to Financial Results

Problem
Statement

Impact on Stakeholders:
 Patients – Shortage of Medicines and Product Quality
 FDA – Violation of Regulations by the Organization
 Stockholders – Loss of Equity

What is
needed?

 Transformational
Leadership
 Contingency Leadership
 Learning Organization
from Archetypes and
Interdependencies
 Self-Assessment of
Leaders
 Evaluation of Policies
 Clarification of Goals
and Rewards

How is it
done?

 Pursuing Adaptability and
Flexibility – From Crisis
Management to Compliance
Management
 Applying Change
Management – Change
Process Control – Monitoring
and Measuring Progress
 Aligning Mission of the
Organization with
Performance
 Sharing Vision

 Willingness to Change

 Reinforcing Ethics and Goals

 Capacity for Adapting

 Optimizing Work Climate
and Delegation

Trends to Address
Current Problems

 Implementing Learning
Organization

Why is it
needed?

 Positive Social Change
 Corporate Social
Responsibility
 No Medicine Shortages
 Product Quality to
Patients
 Stockholders’ Equity
 Reputation of the Firms

 Long-term
Sustainability

Desired Impact of the
Study on Stakeholders

Possible Areas to Study and
Apply Theoretical Framework

Figure 1. Conceptual map of the problem statement and the change process elements to
influence the sustainability of the change.
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Gap in the Literature
From the review of the literature, the gap was the lack of research providing
awareness and guidance to managers in their decision and in their risk assessment
process, regarding their FDA compliance responsibility, corporate financial mandate, and
stakeholders’ expectations within the pharmaceutical manufacturing industry. The
approach to determine the gap to prompt the research was based on the limited
information available on what drives non-compliance decisions in pharmaceutical
organizations that have experienced FDA interventions. The limited published data on the
interdependencies between the need to grow revenue and the intent to behave within
senior management decision process in the pharmaceutical manufacturing industry drove
the development of this research. The short-term financial pressures, the high costs of
innovation, and the firms’ reputation have been identified as causes, but no direct
research on the correlation with behavior has been published that can be directly
associated with the pharmaceutical industry.
The avoidance of medicine shortages drove the need to understand what
motivated or distracted management from compliance behavior. There are published
studies in behavior related to tax evasions (Langham, Paulsen, & Härtel, 2012), academic
misconduct (Stone, Jawahar, & Kisamore, 2009), digital piracy (Yoon, 2011), and
Sarbanes-Oxley (Hess, 2007). These studies were used in this dissertation study as
templates for approaching the study in the pharmaceutical organizations by also applying
Ajzen (1991)’s theory of planned behavior. This study addressed a gap in the literature
related to the limited direct studies providing awareness and guidance to pharmaceutical
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manufacturing industry managers in their decision and risk assessment processes. The
study specifically addressed the gap in regards to the pharmaceutical manufacturing
industry managers’ FDA compliance responsibility, corporate financial mandate, and
stakeholders’ expectations.
Dependent Variable
The selected statistical tools, correlations and regression analyses, provided
clarity in the relationships between the variables. The purpose of the study was to predict
the outcome of the dependent variable, compliance with the FDA. Linear regressions
provided the assessment between the pre-FDA conditions and the post-FDA conditions
focusing on the scenarios before and after of the FDA intervention. With the selected
study design, the correlations and linear regression method were applied twice, pre-FDA
and post-FDA interventions. All variables were considered continuous in the pre-FDA
and post-FDA interventions.
Compliance by pharmaceutical management with the FDA regulations in the
production of medicines pursues the intended integrity, purity, and quality of the products
for the expected medical treatment of the patients’ conditions (FDA, 2013). Management
decision-making in the manufacturing processes within the pharmaceutical organization
need to demonstrate alignment to the expectations of the FDA regulations. The trust of
the public in both the FDA and the pharmaceutical firms can be considered as a “given”
fact as perceived by the patients, the medical community, and the investors in the
pharmaceutical company.
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The manufacturing of medicines follows a very intensive process of research for a
given disease cure: discovery of a molecular entity, clinical trials in animals and human
volunteers, and approval process by the FDA. Once the medicine is defined and as part of
the development, a production process is defined and validated to manufacture the
medicine always to the same level of the approved-intended integrity, purity, and quality.
FDA regulations (FDA, 2013) indicated to the pharmaceutical organizations to always
follow the same validated manufacturing processes and systems. The execution by the
pharmaceutical management of production processes and systems is obliged to follow the
CGMPs. The pharmaceutical organization and its management are expected to apply,
implement, and follow the CGMP at all times.
Manufacturing of medicines requires significant investment in facilities,
personnel know-how, equipment, active medicine ingredients, and other raw materials.
The investments in these factors in addition to on-going operational manufacturing
expenses, as energy and distribution mechanisms represent cash flow, which is not
recovered until the medicine is sold to the end users, the patients. The CGMPs
expectations require a significant level of documentation as evidence of compliance.
Procedures, training records, and data integrity in the laboratories demand precise and
current documentation (Dutton, 2014). Computerized systems have also become a
significant investment and operational expense in the production operations to
demonstrate compliance to achieve the intended product quality as indicated by the FDA
announcement (FDA, 2016).
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The operational cash flow for manufacturing is typically represented by the idea
of the cost of goods, including the depreciation of capital investment and inventory cost
of material in the process. Allocation of funds to achieve the manufacturing of medicines
is added to the cost of sales and other significant accounting entries in the pharmaceutical
company’s income statement and balance sheet. Controlling the cost of goods is an
established operational practice to achieve an acceptable competitive financial position
by the firms. Management reward programs and employees’ performance is based on
continuous improvements that are typically biased towards cost improvements, besides
improvement in processes and systems. The general assumption is that the product
quality and quality systems that warrant consistency are not to be impacted by the
improvement changes. Removing process variability like in Lean-6-Sigma initiatives is
promoted to improve consistency and reduce cost (Longo, 2012). The principles are
reasonable, but the rewards to the incumbent managers are typically based on dollars
saved in production. Compliance with CGMPs is promoted as non-negotiable, but not
necessarily, a high factor for the basis of the rewards and performance recognition from
the business improvements.
Pharmaceutical management also has to achieve a balance between cost of sales,
like promotion and sales personnel, and the cost of goods to maintain products
competitiveness at adequate pricing strategy, especially in a global platform. Medicine
pricing practices around the world receive pressure from local governments and
competition. Except for Medicare practices, these pricing pressures are usually not a
strong influence (Graham, 2012). In addition, the financial market expectations of a
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return on investment to stockholders augment the financial pressures on the
pharmaceutical management. The decision on where to use the cash flow between these
business pressures and the cost of goods requirements has led to scenarios in which
quality systems and production capacity have been second priority, as concluded by
Pollack (2013) and Woodstock and Wonsinka (2013).
The purpose of compliance and the written policies, directing the conduct to the
best decision for the patient, has been expressed in pharmaceutical companies’ vision and
mission statements. These statements and policies have been deployed with the internal
stakeholders, like employees, and with the external stakeholders, such as patients and
stockholders, to gain trust and credibility (Pfizer, 2015; Johnson and Johnson, 2015;
Bristol Myers-Squibb, 2015). The challenge, to maintain a balance to assure compliance
with CGMPs and with the business expectations, creates a relationship influencing actual
management behaviors and quality systems’ robustness in pharmaceutical companies.
Compliance with FDA regulations, CGMPs, requires commitment and firmness in
management in front of financial pressures (Asotra, Cossin, & Yacobi, 2012). The
balance between intended behavior and actual behavior by management in the
pharmaceutical organizations, in which FDA has initiated regulatory intervention, needed
to be better understood. The information about which FDA interventions have impacted
pharmaceutical organizations can be found in the FDA web page and through the
Freedom of Information Act. For those companies that are public financial firms, the
financial reports are public. These financial reports include the cost of goods, as well as
other essential elements in their published profit statements and balance sheet. Public
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press releases are also available from the management of these firms, addressing their
approach to correct and align with the CGMP regulations as stated by the FDA
interventions (Impax, 2014; Novartis, 2012; Ben Venue, 2011). The firms’ reaction to the
FDA observations about the lack of conformance leads to corrective action with
significant financial impact typically documented in the firms’ financial reports.
The level of sustainability of the corrective actions by the pharmaceutical
organizations that has been impacted by FDA regulatory interventions depends on the
degree of change that management embraces and accepts (Asotra, Cossin, & Yacobi,
2012). The compliance history, following the initial FDA regulatory intervention,
allowed measuring the effectiveness of the change in behavior. Financial indicators from
the published financial reports could also provide the information of the new level of cost
of goods and investment in manufacturing to attain the desired state of operations in
compliance, indicating a more robust level of quality systems in the production of the
medicines. For this study, I depended on the participants’ knowledge and recollection of
the information regarding financial indicators in their forms.
The interrelation of the degree of compliance with the predictors, behaviors and
financial indicators, caused changes in the correlations and the regression analyses in this
study. The intent of the study was to predict the outcome of the dependent variable,
compliance with the FDA. Considering that there was a logical expectation that the FDA
intervention was going to force a change in management attitudes, the changes in
correlations and linear regression analyses were not a surprise. The analysis of the TPB
questionnaire responses allowed to compare the relationships before and after the FDA
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intervention. Concurrently, the financial indicators information collected in the survey
provided the financial environment of the firms before and after the FDA intervention.
Also, establishing the regression line, between the variables after the treatment, could
assist on assessing the long-term effect in compliance, allowing for follow-ups and selfcorrections by the firms.
An electronic survey was be the vehicle utilized for management attitude
assessment, due to the limited accessibility to the participants (pharmaceutical
management). The cost of remediation and financial indicators from the survey assisted
in determining the financial correlations. Figure 2 illustrates the interrelations and
expected outcome between the independent variables, the dependent variable, and the
FDA intervention.
FDA
Intervention
Independent

Dependent

Outcome
CGMP compliance

Management Behaviors
CGMP compliance
Financial Indicators
Number of Drug Shortages: pre-FDA
post-FDA
Figure 2. Interrelations of variables and outcome as a reaction to the FDA intervention in
the pharmaceutical firms.
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As discussed by Woodcock (2012), manufacturing shortfalls implied that quality
management and systems were not empowered or properly staffed to support adequately
the critical functions within the pharmaceutical company. Many of the drug shortages
events have been associated with manufacturers issues (Woodcock, 2012). Historical
trends of drug shortages represent an increase from 61 shortages in 2005 (Barlas, 2014)
to 251 shortages in 2011 (FDA, 2013). The FDA issues warning letters if the
pharmaceutical firms has not addressed the violations observed during FDA audits to the
manufacturing establishments or facilities. These violations, listed on Form 483 of the
FDA audit, indicate that the quality management and systems in the audited
pharmaceutical firms were below expectations, implying low CGMP compliance. From
2009 to 2010, the FDA’s observed violations in the operations of medicine manufacturers
increased from 550 to 646 (Huitt, 2014). In the first three years of Obama’s
administration, 2009 through 2011, the number of warning letters issued for
manufacturing and quality issues increased to 49 letters versus nine letters in the last
three years of George W. Bush’s administration (Nguyen, Seoane-Vazquez, RodriguezMonguio, & Montagne, 2013). In a brief look over the past 15 years, the previously
referred FDA interventions through a Warning Letter can be summarized in the timeline
shown in Figure 3.
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1999

Clinton --- Bush

Bush --- Obama
9 Warning Letters

2013

49 Warning Letters

From 65 to 251 drug shortages

1999 Canal Panama
1999 EURO
2000 Y2K Scare
2001 09/11

Great
Recession 2008

Iraq War

Figure 3. Time line between 1999 and 2013 illustrating the trend of warning letters and
medicine shortages in comparison to significant global events.
Independent Variables
The approach to determine the gap for the research was based on the limited
information available on what drives non-compliance in the pharmaceutical organizations
that have experienced FDA interventions. The limited data that prompt this study
consisted on what are the interdependencies between the need to grow revenue and the
intent to behave within the management decision process. The factors of financial shortterm pressures, the high costs of innovation, and the firms’ reputation have been
identified as causes of non-desired behaviors (Hess, 2007; Langham, Paulsen, & Härtel,
2012; Yoon, 2011). No direct research on the correlation with behavior associated with
the pharmaceutical manufacturing has been published.
The purpose of this study was to determine to what extent, if any, the independent
variables, pharmaceutical management’s behaviors and financial indicators correlated to
compliance, the dependent variable, with the FDA regulations at the pharmaceutical
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firms. Compliance with CGMP regulations has led to significant shortages of medicines
to patients in last five years (FDA, 2013). These medicine shortages have been signaled
as a direct consequence of shortfalls in compliance with the FDA regulations
(Woodstock, 2012; Pollack, 2013). Significant efforts to generate risk assessments and
action plans have been created by organizations like the Parenteral Drug Association
(PDA) (Technical Report No.68, 2014) and the International Society of Pharmaceutical
Engineers (ISPE) (Prevention Plan, 2014). These documents addressed several topics like
FDA role, supply and demand, and culture for quality systems. The concern from
Woodcock (2012) that manufacturing is sometimes managed as a second citizen falls into
the category of management’s decision-making and not on shortfalls in intention or
intended behavior.
The study’s potential influence on positive social change was based on the intent
to encourage managers of pharmaceutical organizations to operate and behave with a
sound mental model or thinking pattern. Managers should optimize the financial
performance of the firms while considering the availability and quality of the medicines
that they produce. The avoidance of medicine shortages was the key positive social
change pursued by this research study.
Management Behaviors
In the U.S., corporations are directed legally to pursue profits for their
stockholders (Bakan, 2004). Bakan addressed the legal implications around the fact that
the corporations are set to maximize the returns to the stockholders. The legal concept
implies that it is illegal for a corporation to divert revenues to social responsibilities
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without considering the financial implications to the stockholders. Sfeir-Younis (2009)
discussed that the current compensation systems for management are mainly focused in
rewarding for profit results. There is no mechanism to link society justice and
environmental sustainability to the success of the corporations. In the interview by
Tavanti, Sfeir-Younis (2009) indicated that efforts towards Corporate Social
Responsibility could be perceived as being accompanied by a background of insincerity.
Considering the corporation, Bakan (2004) discussed that the corporations could
be considered manipulative, superficial, and self-interested. Lack of empathy, non-social
considerations, refusal of responsibility, and lack of remorse could be associated with
corporations when setting priorities in front of society’s interests. Bakan (2004)
introduced the need for being skeptical when looking at social responsibility in the annual
reports and management messages. These documents are based on the self-interest of the
corporation that has to be meet financial expectations before any social consideration.
About members of the management team, Bakan (2004) discussed the concept of
double personality or dual moral lives. The corporate manager was expected to behave in
favor of the firms’ stockholders. Once at home, the personal values and interests
prevailed and were focused on the well-being of the community or society. The ability to
navigate in this contradiction in morals, between corporate and personal behaviors, could
be considered a type of schizophrenia, as presented by Bakan.
Even if Maslow’s (2000) Hierarchy of Needs drives the leaders’ motivation to
achieve a self-actualization state, the conflicting pressures of attaining compliance with
CGMP regulations present opposite-directional vectors to personal motivation between
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rewards and personal values. Considering Adler’s (as cited by Boeree, 2007) theory of
complexes and superiority, the leader usually pursue personal motivation by striving for
perfection and overcoming complexes. In this endeavor, if the manager cannot achieve a
positive lifestyle (being of help to others), it could create the sense of not achieving,
leading to personal failure, even in the presence of financial rewards.
The corporation and stockholders’ drive for profit projects, which is a perception
that prevails in the financial environment. The only change in expectations of these
parties could allow the manager to perform and strive for sustainability and balance
between financial goals and compliance with regulations. The decision-making process’s
complexity exponentially grows when considering consumers’ expectations, religion
beliefs, and cultural diversity.
Management is expected to behave with a high sense of ethics. Ethical behavior is
valued and considered as non-negotiable in society. Respect for what others believes and
their dignity as human beings, as presented by Resick, Hanges, Dickson, and Mitchelson
(2006), is considered as an acceptable definition of ethical conduct and behavior.
Leaders’ influence is associated with several factors, including the use of power, the
projection of authority, and having a balanced behavior in front of employees and society
members. Resick et al. (2006) discussed six elements related to ethical leadership. These
traits or characteristics were a character with integrity, ethical awareness, community and
people orientation, motivating, encouraging/empowering, and managing ethical
accountability.
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Providing quality pharmaceutical products projects good citizenship. The firms is
valued and understood as one of caring for the well-being of the patients. The elements
included in this perception range from providing medicine to alleviate the health issues to
attaining an effective treatment of the patient’s medical situation. The intended behavior
to comply with regulations and to manufacture a quality product should lead to the
adequate financial outcomes. The intent to do something versus the actual action could
accentuate that there is a potential disconnect if the drive is for the financial bottom line
and not for compliance.
Making ethical decisions requires values and beliefs that the action taken is the
best option. The definition of the best choice requires a balance between desire linked to
personal satisfaction and financial rewards. The decision to sustain the status quo or
ignore non-compliance behavior by management could create critical impediments to the
organization, leading to FDA interventions. Elements consisting of slow information
flow, change resistance by personnel, loss of customer loyalty, and inflexibility by
leaders in challenging mental models could accentuate the scenario leading to noncompliance. The decision to ignore the current state could be the catalyst for the loss of
resilience and adaptability to change. The climate of the organization to allow for a
prompt response and active participation, in front of the undesired scenario, requires
intensity and transparency to drive the desired behavior at all levels of the organization.
Sharing leadership vision projects a genuine message, which enhances the
enrollment and participation of followers (Senge, 2006). Leaders need to share their
vision and expose their reasoning to demonstrate an honest approach to share the vision
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and sense of urgency, as indicated by Kotter (2007). The management vision should
accentuate compliance with the regulations, and provide the right level of investment for
compliance. Listening to the employees’ opinions should open the dialog towards the
adequate priorities to sustain compliance. A dialogue should minimize tension and
conflict, allowing for transparency in the flow of information between individuals. Open
discussions are required to assess options and make decisions. Sharing the vision is
possible and attainable by encouraging inquiry, advocacy, and reflection, as discussed by
Senge (2006). The scenario of “us-and-them” does not serve or benefits any party, nor the
patients or the stockholders.
Organizational structures can be related to different management theories and the
drivers of behaviors. The selected organizational structure and the leaders’ style dictate
the interrelationships and links within the organization (Morgan, 2006). The
organizational structure influences the thinking, defines the learning, and shapes the
behaviors. Morgan (2006) presented several examples of organizational structures and
the internal interdependencies and expected behaviors using metaphors. “Open-learning”
organizations allowed for participation and sharing of knowledge, dictating behaviors and
adaptability. The perceived controls by the individual and the opinion of others
(including supervisors) according to the TPB were two constructs assessed in this study.
Engle and Nehrt (2011) indicated that when considering emotional intelligence, the
behaviors were mainly driven by the leaders’ ability to control their emotions, while
pursuing maturity and intellectual growth. Elements considered as the base for emotional
intelligence are self-awareness, self-control, and social awareness. To control or regulate
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behaviors, leaders needs to have a significant maturity to appraise their emotions,
understand emotions from others, regulate emotions internally, and take advantage of
emotions to drive performance (Engle & Nehrt, 2011). Leaders should have insight into
the followers’ emotions and feelings, with the corresponding reasons behind them. As per
Engle and Nehrt (2011), being self-confident, in their internal assessment and the
corresponding conclusions is a critical trait in the leaders.
Providing quality pharmaceutical products projects good citizenship. The firms
are valued and understood as one of caring for the well-being of the patients. The
elements included in this perception range from providing medicine to alleviate the health
issues to attaining an effective treatment of the patient’s medical situation. The intended
behavior to comply with regulations and to manufacture a quality product should lead to
the adequate financial outcomes. The intent to do something versus the actual action
could accentuate that there is a potential disconnect if the drive is for the financial bottom
line and not for compliance. In this study, thought correlations, linear regressions, and the
theory of plan behavior, the researcher linked the independent variables to the dependent
variable of compliance with the FDA. A comparison was made between the pre-FDA and
post-FDA scenarios regarding the compliance with the FDA regulations.
Financial Indicators
For the pharmaceutical firms, the lost sales, the impact on their reputation, and the
significant level of expenses to recover or achieve remediation of the lack of compliance
with the FDA could be devastating. This scenario could also impact the firms’ market
value. If the FDA intervention escalates into a consent decree, which is a legal action
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against the company, the magnitude of all these elements could multiply and become an
unacceptable historical benchmark within the industry (Asotra, Cossin, & Yacobi, 2012).
Furthermore, legal actions by the FDA against the firms’ leadership could be inevitable
(Burd & Chrai, 2004). This study has the potential to raise the awareness about undesired
behaviors in management and accentuate the concept that compliance is a competitive
business advantage for the pharmaceutical companies.
The complexity of regulations, price pressures, and compressed time to market
contributes to the financial pressures in front of medicine manufacturers (Dutton, 2014;
Duffy, 2014). The cost of development a new drug has been noted to be is some cases up
to 1 billion dollars (Adams & Brantner, 2010). Management decision-making is typically
driven by current cash flow and future opportunities to grow revenue, including decisions
on research and development investments (Scherer, 2001). Thus, optimizing fixed assets
utilization supports both concepts. Controlling or reducing the cost of goods allows a
positive impact on available cash flow to invest in new products research, support
marketing-sales challenges, and neutralize price challenges from the competition and
abroad.
Organizational knowledge is based on the individuals within the organization.
Organizational structure, work climate, and leadership styles have a significant impact on
the growth and performance of employees (Morgan, 2006). Investing in training,
procedural systems, data integrity systems, and equipment requires determination to
continuous improvement while enhancing quality systems (Koberstein, 2014). Also,
attaining the proper quality and operational staff within a manufacturing firms provides

47
consistency and stability of the knowledge base. These elements in pharmaceutical
manufacturing enhance the reliability of quality systems. Manufacturing shortfalls
implies that quality management and systems are not empowered or adequately staffed to
adequate support the critical functions of the pharmaceutical firms (Woodcock, 2012).
The concept of empowerment is linked to the leadership style in elements as trust,
transparency, and sharing (Senge, 2006). Knowledge, the level of staffing, empowerment,
and continuous improvement are essential to attain the level of compliance in front of
complex regulations and global business (Koberstein, 2014). As indicated by Woodcock
(2012), for some management, these factors imply incremental cost and expenses of the
manufacturing systems, instead of continuous improvement in quality systems.
If the attitude to accommodate the investment towards knowledge, facilities, and
equipment is not assessed by management, the new launches or expiration of product
products could create pressures, postponing critical investments. The technological
movement from the traditional chemical manufacturing to cell manufacturing
(biotechnology) has also introduced the need for new facilities with different
technologies, equipment, and personnel knowledge (Merchuck & Toren, 2013). The
minimal education provided by a high school diploma is no longer adequate for
understanding fermentation and enzyme process dynamics in product manufacturing. The
cost of goods and allocation of overheads requires detailed assessment for decisions in
technology, processes, and geographical network strategies (Khinast, Fraser, & Dujmovic
2014). Remodeling an existing facility might not be feasible for the new technology. The
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costs of closure of old chemical facilities and severances pay for the long time employees
add cash flow pressures on pharmaceutical decision makers.
In addition, high waste from production, low reimbursement on investment, and
no proper pricing contracts were some of the inefficiencies driving good-compliance
manufacturers away from producing quality low-cost generic medicines as per Woodcock
in an interview with Koberstein (2014). Management behaviors’ and financial indicators’
impact on compliance and product quality require change management, leading to the
expected outcome of fewer drug shortages. Woodcock also inferred that pharmaceutical
manufacturers that implement high-quality systems could be financial productive by
reducing waste, customer complaints, and product recalls (Koberstein, 2014). Financial
efficiency implied an adequate cost of goods and proper utilization of resources.
Managing financial indicators by attaining financial effectiveness led to a climate of less
operational pressure allowing attention to quality systems.
The elements that could affect the quality of products leading to potential FDA
intervention and undesired product shortages depend on management decisions.
Management decisions that could impact the quality of products are limiting quality
systems in manufacturing, avoiding investment in improvements to facility and
equipment, lacking proper raw material selection, and accepting inadequately
knowledgeable staff. Changes led to reducing operating expenses, even with the intention
of lean manufacturing practices, could drive to limited quality systems (Woodcock,
2012). Quality systems should evolve with technology and consistency in procedures.
Unfortunate, the enhancement to the quality system typically occurs after FDA
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interventions, following evidence that the pharmaceutical company has been operating in
a non-compliance scenario in front of the CGMP regulations (Asotra, Cossin, & Yacobi,
2012). Drivers and decisions to reduce the cost of goods without maintaining a balance
with quality systems could lead to an unconscious situation of applying procedures
without considering all the FDA expectations for a quality product (Woodcock &
Wonsinska, 2013). Although CGMPs are common sense, sometimes management
assumes that all common sense is CGMPs. This mental model leads to non-compliance
and reduction in resources to attain the expected compliance level for product quality and
quality systems within the pharmaceutical organization.
Financial factors like loss of sales to competition or new medicines, as well as
loss in financial value of the firms in the financial markets, could generate significant
financial pressures on the decision makers in the pharmaceutical firms. The reduction in
the pipeline of new products, by the loss of patent of blockbusters medicine products, and
due to growing pricing practices from the globalization of medicine and generics markets
have raised the pressures in the cash flow of the pharmaceutical industry (Duffy, 2014).
Even the generic sector of the pharmaceutical industry is subject to these factors and has
been subject to FDA interventions for non-compliance in the production operations.
The annual pharmaceutical sales, with no-growth or marginal growth from yearto-year, have influences in the financial market value, impacting stockholders’
investment. Reputation of the firms could be significantly affected by FDA interventions,
in relation to the perceived management conduct, undesired behaviors, and lack of social
responsibility of the pharmaceutical firms (Asotra, Cossin, & Yacobi, 2012). Typically,
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operational management changes follow the FDA intervention. The loss in sales could be
caused by patients and the medical community looking for treatment options, avoiding
inferior quality products, or as a reaction to the medicine shortages. Asotra et al. (2012)
indicated that disclosure of these changes influences the credibility and reputation of the
firms with suppliers and investors.
In this quantitative study, the financial indicators of the factors discussed were
assessed for the pre-FDA and post-FDA interventions, by applying correlations and
regression analyses. The pre-FDA conditions are the scenarios (independent variables:
behaviors and financial indicators) that led to enforcement actions by the FDA. The
treatment event was the application of the enforcement action by the FDA. The level of
compliance of the pharmaceutical company was the dependent variable. The postcondition was the outcome after the remediation activity was completed, which could be
measured in behavioral attitude (management “decision making” survey), financial
results (remediation investments and cost from financial statements), and level of
compliance (FDA observations).
FDA Interventions
The FDA interventions examined by this study consisted of an action initiated by
the FDA towards a pharmaceutical firms. These actions were based on the FDA’s
observations obtained during manufacturing facility audits, during assessing of patient
complaints, or during medical patients’ reactions related to the level of compliance in the
manufacturing operations and to the quality of the medicine. The FDA interventions
commonly consist of 483 observations (FDA, 2013, “Frequently Asked Questions,” para.
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1) followed by warning letters (FDA, 2012, “Regulatory Procedures Manual,” p. 5) in
the case that the pharmaceutical firms continue a non-compliance attitude or not address
the observations. In the event that the pharmaceutical firms does not demonstrate
commitment and due diligence to address the FDA actions, a consent decree issued by
the FDA could follow to force a cease and desist to the senior management of the firms.
Arguments relating the FDA as the driver of medicine shortages has gained
strength. The intensity and firmness of the FDA, ensuring that CGMP compliance by the
pharmaceutical firms in recent years, are signaled as the cause of the medicine shortages
(Graham, 2012; Roman, 2014). Graham (2012) went as far as indicating that the FDA
was over-regulating with the increased in inspections to injectable manufacturers.
According to Roman (2014), the FDA’s approach to enforcing instead of working action
plans, especially in critical medicines, promoted shortages of the medicines.
Pharmaceutical manufacturers’ decisions have to be based on a balance of
profitability and market value of the firms. If the FDA intervention leads to an unstable
financial position, the firms could be forced to close and stop manufacturing as in the
case of Ben Venue and Hospira in 2013 (Roy, 2012). Closures and discontinuation of
manufacturing processes led to interruptions in the supply of medicines. Roy (2012) and
Roman (2014) both concluded that the consequence of the FDA intensity and firmness in
ensuring the CGMP regulations was a shortage of critical cancer drugs affecting patients
with no alternate treatment.
Medicine shortages have been associated in recent years, with FDA interventions
to pharmaceutical firms. Roman (2014) indicated that the medicine shortages between
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2010 and 2013 resulted from an unnecessary approach by the FDA. The FDA’s
interventions to assure compliance with CGMPs caused pharmaceutical facilities to
remodel facilities, re-train personnel, and change processes, when the manufactured
drugs’ quality was acceptable and in some cases meeting specifications (Kweder & Dill,
2013). Gottlieb (2013) concluded that the remediation activities led to facility closure and
long recovery of the supply of the critical medicines. Roman (2014) insisted that
negotiation and tolerance by the FDA with the pharmaceutical firms would have avoided
medicine shortages. The interruption in the supply of medicines to patients needs a
different approach.
Haninger, Jessup, and Koehler (2011) focused the shortage of medicines in the
economics relation between supply and demand and not in the FDA interventions.
Manufacturer’s capacity, inventory practices by Group Purchasing Organizations (GPO),
pricing strategies by pharmaceutical firms, and the FDA approval process of new
manufacturer capacity led the rationale in the discussion of this study. Manufacturer’s
quality shortfalls were assessed as a contributor but not the primary factor in the supply
and demand relationship to medicines’ shortages. Although the statistics based on
Medicare indicators supported the arguments, the fact that 54% (FDA, 2011) of the
medicine shortages were associated with manufacturers’ quality problems fell as a
secondary factor. Haninger et al. (2011) indicated that manufacturer’ problems
highlighted by the FDA during manufacturer’s facility inspections need to be assessed
against the risk of affecting the supply of medicines, a message similar to Roman (2014).
The causes prompting management behaviors to create manufacturer’s non-conformance
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issues with the FDA guidelines were not addressed nor recognized as a particular solution
by Haninger et al. (2011). Any relation between the FDA interventions in the
manufacturer firms’ performance remained in the background or as a second theme.
The approach to compliance versus the risk of creating a shortage of medicines
was a growing concern. Several recent studies have concluded that the FDA needs to
balance between firmness of compliance and the benefits of drugs (Gottlieb, 2013;
Roman, 2014; Roy, 2012). In the other side of the argument, Woodcock in an interview
with Koberstein (2014) inferred that high waste from production, low reimbursement on
investment, and no proper pricing contracts are some of the inefficiencies influence
manufacturers away from producing low-cost quality medicines. The cause of the
medicine shortages relates to manufacturing quality shortfalls (Fox & Tyler, 2013 and
Woodcock, 2012). Enhancing CGMP compliance while avoiding patients’ treatments
needs high level of attention by pharmaceutical manufacturers.
A survey conducted by the American Hospital Associations (2011) revealed that
82% of the responding hospital had to delay patients’ treatment because medicine
shortages. The FDA approach towards manufacturing firms that lack compliance or are
not focused on the CGMP expectations on quality was a crucial element in the well-being
of patients, both from the quality as well as the supply of the medicines (Schweitzer,
2013). A proposal by Schweitzer (2013) directed the efforts by the FDA to grade the
manufacturers on a scale from highest quality to unsafe standards. This approach could
provide a measurement of when manufacturing practices need attention and the degree of
modification to maintain supply to avoid medicine shortages. An action plan, as suggest
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by Roman (2014) and Gottlied (2013), might then be implemented to keep supply and
allow reasonable time for the remediation plan to meet the non-conformance found by the
FDA during an inspection of the manufacturer’s facility.
The FDA’s new guideline, published in 2013 and based on the Executive Order
from President Obama (Exec. Order No. 13,588, 2011) for managing medicine shortages,
presented a reasonable approach to address a balance between enforcement,
communication, and medicine availability (Barlas, 2014; Roman, 2014). In this new rule,
Food and Drug Administration Safety and Innovation Act, the FDA requires that the
manufacturing firms have to notify the FDA of upcoming medicine shortages and the
FDA specifies the corresponding timing of the firms’ notifications (FDA, 2013). Rooney
(2014) presented the scenario in which the GPOs have been cooperating with the FDA
and manufacturers to mitigate shortages, raise awareness related to the supply chain, and
facilitate the understanding of the demand for drugs and generic medicines. From another
point of view, Elzawawy (2015) challenged the drivers of the market economics like
GPOs and global regulators to focus on enhancing the incentives to manufacturers by
addressing pricing strategies. Elzawawy (2015), Rooney (2014), and Ventola (2011)
concluded that a reliable supply of essential medicines was the critical responsibility of
all involved.
The FDA role continues to be the same: “FDA ensures the quality of drug
products by carefully monitoring drug manufacturers' compliance with its Current Good
Manufacturing Practice (CGMP) regulations” (FDA, 2012, “Drug Applications and
Current,” para. 1). The FDA published goals for the five years from 2014 through 2018
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that enumerate and emphasize the FDA’s role, including minimizing medicine shortages
(FDA, 2014). A common theme presented by almost all the sources agreed on the need
for communication, coordination, and collaboration. These theme requires commitment
by all parties, the manufacturer’s management, the GPO’s, health providers, and the
FDA.
Theory to Support the Change
Theory of Planned Behavior (TPB)
One method of assessing the predictability of behaviors is by applying the theory
of planned behavior. Ajzen (1991) developed TPB to provide a model of measuring
attitudes and dispositions to predict behavior. TPB infers the existence of a direct
relationship between intention and actual behavior. Also, attitudes and norms can explain
any behavior following the principles of TPB. This study applied TPB to understand and
predict the intention of pharmaceutical management to comply with the FDA regulations.
The structure of the flow diagram supporting TPB is presented in Figure 4.
According to TPB, three types of behaviors direct and influence human behavior: beliefs
(attitudes), normative behaviors, and perceived behavioral control (Ajzen, 2002). The
interrelations between these beliefs influence the intention towards a given behavior.
Intentions are the predecessors of behaviors (Ajzen, 1991). The relation between
intention and behavior depends on the strength of the attitude from behavioral beliefs, the
social pressures leading to subjective beliefs, and the level of perceived control that the
person has in front of the decision process. Actual behavioral control results from the
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limitations or obstacles to perform the intention. If adequate control exists, an
individual’s intention predicts the actual behavior, as a direct outcome.
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Figure 4. A diagram of process flows according to the theory of planned behavior.
Reprinted from “Constructing a theory of planned behavior questionnaire: Conceptual
and methodological considerations.” by I. Ajzen (September 2002), Constructing a
theory of planned behavior questionnaire: Conceptual and methodological considerations.
Copyright 2006 by Iczek Ajzen.
Intentions. Ajzen (1991) indicated that motivational elements create the basis for
intentions. The willingness of a person to execute a behavior and the level of effort
placed in the planning the behavior can be used to infer the probability of the actual
behavior (Ajzen, 1991). The performance of a given behavior depends on the level of
strength of the motivational factors forming the attitude of the person. Ajzen (1991)
emphasized that the intention can only become a behavior if the behavior meets the
condition of the volitional control. The person has to be able to decide if the behavior is
executed or not. The elements or resources influencing volitional control are for example
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time, money, and the cooperation of others (Ajzen, 1985). If these elements are under the
perceived control of the person, the intention should transform into the behavior.
Salient beliefs. TPB relies on the dependent connection between behaviors and
the person’s beliefs (Ajzen, 1991). The beliefs or information relevant to the intended
behavior are the predecessors to the attitudes and perceived controls of the person
towards a given behavior. Ajzen labels the relevant beliefs or information as salient
beliefs. In TPB, intention towards a particular behavior depends on three salient beliefs:
“behavioral beliefs produce a favorable or unfavorable attitude toward the behavior;
normative beliefs result in perceived social pressure or subjective norm; and control
beliefs give rise to perceived behavioral control” (Ajzen, 2002, par. 1). The
determinants of behavior depend on the attitudes, perceived social pressures, and the
control around the intention. According to TPB, the elements inducing a person to
execute or not to execute a desired behavior are the intentions and the perceived controls
that are outcomes of the salient beliefs of the person.
Applications of TPB
Predicting intention to comply with regulations is as important as predicting the
actual compliance behavior. According to Langham, Paulsen, and Härtel (2012), applying
of TPB produces a direct relationship between intention and actual behavior. This
relationship is essential to the understanding of the willingness to comply and of the
actual undesired action of non-compliance. By applying TPB, the researchers also
evaluate the topic of behavioral control including the concepts of perceived behavioral
control and actual control. Perceived behavioral control is directed to the intention to

58
behave. In addition, perceived behavioral control consists of the individual’s ability to
control their behavior and willingness to apply the required behavior (Ajzen, 1991).
Actual control is essential for investigating behaviors that require the individual to
overcome performance hurdles. Langham et al. (2012) concluded that attitudes and
values are essential elements in the application of the TPB approach.
In an academic setting, Stone, Jawahar, and Kisamore (2009) attempted to
demonstrate that academic misconduct seems to be increasing. Stone et al. (2009) also
claimed that identification of factors that influence academic misconduct was a
significant task due to its potential tie to the workplace later on. The study examined
elements that could influence or lead to academic misconduct using TPB (Ajzen, 1991).
Stone et al. (2009) concluded that understanding and reducing academic misconduct
could dictate behaviors and values in future leaders.
Stone, Jawahar, and Kisamore (2009) applied two mediation regression equations.
The population was from a self-selected sample. The data collection was through a
survey. In their survey, Stone et al. used Likert-type scales. Relationships between the
subscales of attitudes, subjective norms, behavioral control, intentions, justifications, and
cheating were analyzed. The Cronbach’s alphas for the six subscales were calculated
establishing the reliability of the questionnaire. All Cronbach’s alpha values were at or
above 0.80. Some elements were signaled as “reversed” to obtain the reported
Cronbach’s alpha values. The Cronbach’s alpha values obtained by Stone et al. (2009)
indicated that the relations between the variables met the expectations for the application
of the TPB questionnaire.
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Stone, Jawahar, and Kisamore (2009) presented convergent validity and
discriminant validity to address the construct validity of their study. Stone et al. (2009)
concluded that the validity of their study was met. Shuttleworth (2013) discussed the
difference between convergent and discriminant validity. Convergent validity tests
whether constructs that should be related are indeed related. Discriminant validity tests
whether believed unrelated constructs are indeed unrelated. In this study, the correlations
between the two predictors and the Cronbach’s alpha values in the questionnaire were
assessed to prove convergent validity. Results of t-tests and the confidence interval tests
should provide a means to test for discriminatory validity.
In an attempt to better understand and predict the intent of taxpayers to comply
with tax regulations in Australia, Langham, Paulsen, and Härtel (2012) used TPB.
Langham et al. (2012) demonstrated that TPB could be a predictor of compliance with
tax regulations, using their findings to develop a particular model describing this process.
For the first equation, multiple regression was performed for the TPB variables (attitude,
norms, and behavioral control). For the second equation to predict compliance, a logistic
regression was utilized, since the researchers indicated that the assumption of normality
was violated. The results presentation and hypotheses discussions were adequate and easy
to follow. Finally, a discriminatory analysis was conducted for each scenario, using a
Wilks’ lambda to establish the correctness of the prediction.
Understanding the factors that lead to unwillingness to comply or drive to ignore
compliance should facilitate the probable prevention measures accompanying any FDA
intervention. Intention and attitudes were assessed in this study. TPB were used to
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identify behaviors to understand better how to predict behavior, reinforce intention, and
probably modify future compliance with the FDA regulations.
Criticisms of the Theory of Planned Behaviors (TPB)
Several researchers have criticized the predictability and applicability of TPB.
Ajzen (2011) analyzed and addressed criticism related to elapsed time, emotions, habits,
personality traits, and background factors. Ajzen concluded that these elements “can
expand and enrich our understanding of human social behavior” (Ajzen, 2011, p. 1124).
Ajzen (2011) did not concur, however, with the argument that elapsed time affects
the predictive validity of the TPB as raised by Conner, Sheeran, Norman, and Armitage
(2000). Ajzen contrasted Conner et al.’s (2000) position with that of Kor and Mullan
(2011), who found that intentions were also affected in short time intervals. In relation to
past behaviors or habits, Ajzen (2011) explained that the basis in TPB relates to recent
beliefs relevant to the intention towards a particular behavior. In contrast, the arguments
in favor of habits by Norman and Cooper (2011) inferred that the frequency of executing
a given behavior creates stability and influences control over the behavior. Ajzen (2011)
concluded the discussion on this topic by indicating that habit’s strength over behaviors
needs further studies.
Rivis, Sheeran, and Armitage (2011) assessed the role of the “big five”
personality traits as a predecessor to intentions and behaviors. Ajzen (2011) judged that
the results indicated small effect between the personality’s traits and behaviors.
Background factors such as demographics and emotions influence beliefs that are
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antecedents to the salient beliefs. Ajzen (2011) explained that the origin of these factors
affects the beliefs and indirectly the attitudes and control that are already part of TPB.
Change in Behavior (What, Why, How)
The required change process to attain the desired state of avoiding medicine
shortages could evolve through the typical life cycle of what, how, and why (Kezar,
2001). Management trends and possible theoretical frameworks presented in Figure 1
project the complexity of addressing the change process. The future impacts on the
stakeholders were the “why” to conduct the study, delineating the required attributes
influencing the management performance to achieve positive social change.
What Needs to Change
The lack of compliance with CGMP has led to pharmaceuticals manufacturing
facility closures, loss of revenues, unavoidable penalty fees, loss of reputation, and
significant investments to address remediation of their violations to the FDA regulations
(Asotra, Cossin, & Yacobi, 2012). Manufacturing shortfalls implied that quality
management and systems are not empowered or properly staffed to support adequately
the critical functions within the pharmaceutical firms (Woodcock, 2012). In the first three
years of the Obama Administration, 2009 through 2011, the number of warning letters
issued to manufacturing and quality issues increased to 49 letters versus nine letters in the
last three years of the George W. Bush Administration (Nguyen, Seoane-Vazquez,
Rodriguez-Monguio, & Montagne, 2013). The FDA, in a letter to pharmaceuticals
manufacturers in October 2011, indicated that about 54% of drug shortages were a result
of manufacturers’ quality problems (FDA, 2011). Collectively, the evidence suggested
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that the number of FDA interventions and enforcement actions against pharmaceutical
manufacturers have increased in the recent years. Also, as shared in Anisfeld (2009), the
FDA has issued warning letters to international generics firms, establishing import bans
of their products into the U.S.
Why the Need for Change
For pharmaceutical firms, the lack of compliance with the FDA regulations could
be devastating. The results from the lack of compliance include loss in sales, impact on
reputation, and an increase in the level of expenses to recover or achieve remediation.
These performance indicators typically also impact the market value of the firms. If the
FDA intervention escalates into a consent decree, Asotra, Cossin, and Yacobi (2012)
explained that the magnitude of all these elements could multiply and become an
unacceptable historical benchmark within the industry.
This dissertation promoted positive social change by eliminating or minimizing
medicine shortages. Medicine shortages place the patients’ health in significant danger.
In addition, medicines that are substandard in quality, purity, and identity probably do not
address the intended treatment (Woodcock, 2012). The potential mistrust by the public on
companies’ lack of commitment towards social responsibilities could be kept to a
minimum.
How to Pursue the Change
The gap between the present situation and the desired state was the basis for
justifying the need for change. How to pursue the desired change could have several
approaches. Market dynamics, survival of the organization, personnel needs, new
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technology, regulatory requirements, or a mixed of all the above items is an excellent
basis to influence the metrics of how the change is pursued. The FDA proposed the
establishing of quality metrics to control operations and change (Koberstein, 2014).
Internal and external elements create the scenario of interdependencies and archetypes to
be dealt with in the road to the desired state as generalized by Senge (2006). The
complexity of designing the strategy of how to pursue change depends on the
understanding of the interdependencies and archetypes.
In the area of motivation and inspiration, Ilies, Judge, and Wagner (2006)
designed a conceptual model to illustrate the impact of transformational leadership on the
motivation of subordinates or followers. The effect of affective and cognitive approach to
motivation was presented in three areas: direction of the action, effort intensity, and
persistence. Charismatic leadership and motivational leadership were linked to actual
followers’ reaction. The analysis focused on how leaders should approach team members
while considering the diversity in attitude and individual skills. The theory of multiple
intelligences, as described by Kornhaber, Krechevsky, and Gardner (1990), could further
highlight the need for an individualized approach to teams. Motivation theories like
Maslow’s (2000) hierarchy of needs could be part of the leaders training.
The organizational goals and working climate drive the change strategy to be
selected and implemented by the organization leaders. The flexibility and adaptability of
the management decision-making process and the existing environmental factors of the
organization create boundaries in the potential change process. As explained by
Chadwick-Coule (2011), the effectiveness of the change process and the sustainability of
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the outcomes are highly dependable on who sets the target, the approach to the execution
of the change, and the impact of the change on stakeholders.
The selection of the change strategy typically depends on leadership style and
organizational structure. Peng and Weichun (2011) concluded that leaders have a
significant influence on organizational performance. In reference to leadership style,
Vroom and Lago (2007) described contingency leadership, and Deluga (1990) studied the
impact of transformational, transactional, and laissez-faire leadership. Morgan (2006)
compared different organization models, emphasizing that the organizational model set
the internal dynamics of operation and change management. For effective change
management, Senge (2006) indicated that sharing vision, effective communication, and
confirming change effectiveness are essential elements. The effectiveness of the change
strategy converse in the integration of all these elements. The implied interdependencies
of these elements provide a robust scenario to ensure the execution of the change strategy
and hopefully, its sustainability.
Resistance to change is a critical item that needs to be understood and managed.
Stakeholders’ mental model of “what is in” for me is a sensitive topic driven by
motivation, individual psychology, emotional intelligence, and learning style. Maslow’s
(2000) hierarchy of needs and the pursuit of self-actualization, as well as Adler’s theory
(as cited by Boeree, 2007) of complex management by striving for superiority, cannot be
ignored by leaders when selecting a change strategy and setting the corresponding
execution plan. The idea is to engage the stakeholders, and not to apply intimidation.
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Motivation and improvement to the self-esteem of the followers could allow
leaders to delegate and grant opportunities for participation. As demonstrated by Leana
(1987), the climate of participation, as well as the willingness for delegation by the
leaders, is associated with the level of trust and the understanding by the leader of the
degree of competence demonstrated by the subordinates. Leaders should consider the
person’s lifestyle to optimize the individual’s motivation. Adler’s (as cited by Boeree,
2007) concept “of being useful” could be linked directly to the organizational climate.
The employee should feel satisfied that is valuable to the team and is in the pursued of
the targeted goals.
Change Models
The selected model of change or strategy to be followed typically includes team
building, new relationships, and technological support. The geographical characteristics
of the organization could also influence the selection of the change model. The
systematic approach to change implementation, execution, and measurement should
attain the desired transformation as summarized by Kupritz and Cowell (2011).
Deming’s Cycle
In the twentieth century, quality and reduction of variability became the backbone
of continuous improvement with concepts like Deming’s improvement cycle and the 14
quality principles, which were followed by many others like Crosby, Shingo, and Peters
(Hussai, 2004). The concept of planning change, for improvement versus purely reacting
to external environment factors or internal weaknesses, became a significant trait to attain
transformation and long-term sustainability of outcomes. Focusing on Deming’s Quality
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Management 14 principles, total quality management (TQM) implies a process of
continuous improvement, by applying the cycle of plan, do, check, and act to the
organizational and leadership transformation to pursue the expected level of compliance
with the FDA regulations. Also, leadership’s adaptability and flexibility are typically
associated with strategic planning and organizational development (Beinhocker, 2006).
These changes could be considered both transformational as well as transactional since
usually a mix of changes is implemented.
Kotter’s Model
Kotter (2007) discussed the critical factors that constitute the model for the change
process. The effectiveness of the implementation depended on essential elements,
requiring attention and monitoring. The eight phases or errors to avoid were integrated to
prevent failure in a change process. Kotter’s (2007) eight phases or errors to avoid
consist of


Establish a sense of urgency



Create a guiding coalition



Develop a vision and strategy



Communicate the change vision



Empower broad-based action



Generate short-term wins



Consolidate gains and produce more change
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These eight phases or errors to avoid are essential to assure the transformation in
behavior to attain the expected level of compliance with the FDA regulations. The
notice of violation from the FDA explicitly set the level of urgency to the operational
management to avoid and minimize the impact to the supply of the medicines and the
revenues of the pharmaceutical firms. The undesired impact on sales and reputation of
the firms most likely results from the FDA intervention, raising the urgency and
expectations of the management of the firms. The next two phases require senior
management to establish a clear guidance and vision on the need to change the behavior
from the supervisors to the operational personnel. Strategies and tactics need to be
developed, leading to changes in processes, styles, and deliverables.
The fourth stage in Kotter’s model is the next critical step: communication. As
stated by Senge (2006), sharing the new vision of compliance and desired behavior
tends to engage all levels of decision-making and operations. Establishing subject matter
experts and delegating to teams should accelerate the transformation, assuming that
management can evolve from crisis management into participative leadership.
The next stage is to set clear short-term targets to highlight a clear direction of
change and the expected level of compliance. The notice of violation from the FDA sets
the general tone. Quality systems need overall review and probably significant changes.
Mehta (2013) suggested that implementing principles and guidelines, as developed by the
International Conference on Harmonization, could be a significant step in facilitating
leaders’ understanding of the compliance expectations. To correct the events of CGMP
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violations implies that productivity indicators, financial metrics need to be assessed while
management behaviors need to be modified.
A systematic review of progress and hurdles during the implementation plan needs
to be established to assure measurement of progress. In addition, a time most be set aside
to adjust in front of any failure or delay. Sensitivity to the employees’ engagement and
citizenship to support the overall change process needs to be recognized to ensure
effectiveness and sustainability of the change. An overall continuous process should
allow management to secure the new compliance behavior and assure sustainability for
the long term.
Continuous Improvement Measurement
To assess continuous improvement, a holistic approach is required across all
disciplines to measure performance. Chan, Qi, Chan, Lau, and Ip (2003) presented a
process-based approach to measuring performance for supply chain management. The
measurements cover the traditional supply chain indicators in cost, time, capacity,
capability, resource utilization, and reliability. Accurate data could be collected to
compare the performance of the two scenarios: before and after the FDA intervention.
The application of this type of tool to measure continuous improvement could support the
process of managing the change process, allowing for adjustment when the indicators are
not as expected. Influencing the change process implies an open flow of information, the
share of knowledge, experimentation, and tolerance of autonomy, allowing fast response
to adapt and adjust as changes are being implemented.
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With the FDA intervention creating new pressures and challenges within the
interdependencies of the organization, planning and reassessment become essential to
monitor progress and reduce pitfalls. The transformation of the attitudes and behaviors
impacts leadership styles and emotional intelligence attributes of the management team.
Understanding the evolution of the change stages and links needed to support, the new
approach to compliance, demands vision and hands-on knowledge. The change process
evolves in stages as the organization learns, accepts, and matures along the
implementation of the associated changes in policies and procedures. Finally, the new
required level of adaptability, flexibility, and tolerance to change challenges the
traditional authority and financial policies of the organization.
Managing Change Resistant or Impediments
The deliverables in this study were compliance behavior to assure medicines
availability for patience, adaptability to handle the financial pressures, and transformation
into a learning organization. The goal was operational compliance with FDA regulations,
which normally in these situations, were well defined by the audits and expectations from
the FDA. The plan to transform behavior and to address the financial pressures requires
transformational leadership approach and tolerance to change, minimizing pitfalls and
resistance to change while sustaining the expected CGMPs regulations from the FDA.
In Figure 5, a concept map representing a Change Implementation Plan is
illustrated. Cicmil (1989) developed the structure of this concept map. Cicmil suggested
that by mapping the what, how, and why the gaps and the impediments would be
exposed, including the vulnerable areas for implementation of the change. The what and
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how refer to project deliverables and implementation process, respectively. The elements
of the implementation process are the identification of the gap, the development and
execution of the implementation of the plan, and the measuring progress.
Organization Slow
Learning Skills
WHY – The NEED

Project – Attain the Desired State

WHAT – Project Deliverables
1) Adaptability
2) Transform to a learning organization

HOW – Implementation Process
1) Defined Gaps
2) Develop and Implement Plan
3) Measure Progress of Change Implementation

Fast Forgetting – back to
current Mental Models

Organized
Resistance:
1) Mental Models
2) Risk of
increased
complexity
3) Path of
Dependence
(Beinhocker, 2006)

Figure 5. Concept map for a complex adaptive system for the implementation of
organizational changes. Source of Concept Map was adapted from “Implementing
organizational change projects: Impediments and gaps” by S. Cicmil, 1999, Strategic
Change, 8(2), page 128. Copyright © 1999 John Wiley & Sons, Ltd.
Summary
Change is an ongoing performance improvement that organizations must
examine. There may be many different styles of change models utilized within an
organization. The goal is to identify that there is a need for change, develop a plan for
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change, implement the plan with effective communication, and evaluate the effectiveness
of the change implemented. The “what, how, and why” of change needs to be an everrotating cycle. Although some people may not like the concept of change; for leadership,
change in behavior is always an opportunity for improvement for long-term sustainability
of the organization.
Chapter 2 contained the literature search strategy that was followed. For the
quantitative study to be performed, the independent variables, the dependent variable, and
the FDA intervention were analyzed. Arguments were presented in which the FDA
interventions could be considered as the cause since the FDA showed to have low
tolerance with manufacturers in front of the impact to the supply of medicines. The
relevance of the study and its impact on social change regarding the research gap in the
literature were further discussed.
The literature review on the theoretical framework addressed the theory utilized
for this quantitative study. Critics of the theory of planned behavior presented arguments
on the weakness of the theory. Counter arguments were discussed from the response of
Ajzen (2011). An analysis of issues, trends, and concepts formalized the literature review
for what needs to change, the how to change, and the why to change assuring an efficient
change management process while managing resistance to change.
In Chapter 3, the research methodology and design are presented in detail. The
research tools to be employed are discussed, including the efforts for validity, the
trustworthiness of the survey, and the Internet tools. Accessibility of the targeted
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participants and the assurance of confidentiality is described. Finally, elements of
confidentiality and data protection are enumerated.
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Chapter 3: Research Method
This quantitative study sought to learn to what extent, if any, management
behaviors and financial pressures at pharmaceutical firms correlated with or predicted
compliance with the FDA regulations avoiding interruptions in the supply of some
essential patented or generic pharmaceutical drugs in the U.S. In Chapter 3, the research
methodology and design were presented in detail. The research tools to be employed
were discussed, including the efforts for validity, the trustworthiness of the survey, and
the Internet tools. Accessibility of the targeted participants and the assurance of
confidentiality was described. Finally, elements of confidentiality and data protection
were enumerated.
The study enhanced the understanding that avoiding FDA interventions provided
business sustainability by analyzing management behaviors. The study also accentuated
the concept that compliance was a competitive business advantage for the pharmaceutical
companies. The design of the research allowed the scenario of predicting the outcome of
the dependent variable, compliance with the FDA regulations.
Research Method and Design
For the study, the selected quantitative research methodology needed to correlate
the variables and predict the outcome. The quantitative research method predicts,
investigates relationships between variables, or assesses possible impacts on outcomes
(Creswell, 2009). This deductive approach to confirm the correlation between the
variables was considered adequate to address the research question and assess the
hypotheses.
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The quantitative study consisted of a research design including correlations and
regression analyses. I applied this statistical tools to make a comparative analysis
between the scenarios before and after the application of a treatment, the FDA
intervention. The expected variability in the study and the desired to predict outcome led
to the application of Cronbach’s alpha and regression line analyses. Also, applying
simple t- test comparisons provided clarity to the correlation. For this study, the pre-FDA
conditions were the scenarios that led to enforcement actions by the FDA. The
independent variables or predictors were management behaviors and financial indicators.
The treatment event was the application of the enforcement action by the FDA. The
dependent variable or outcome was the level of compliance of the firms.
The correlations between management behaviors and financial indicators on the
compliance with the CGMP regulations defined the quality systems before and after the
FDA intervention with the pharmaceutical companies. A multiple linear regressions
provided the assessment between the pre-FDA conditions and the post-FDA conditions,
before and after the FDA intervention. A regression methods were applied twice, preFDA and post-FDA interventions, for comparative statistical analysis to establish patterns
before and after the application of the treatment.
For this study, the pre-FDA conditions were the scenarios that led to enforcement
actions by the FDA. The pre-FDA conditions represent the situations (independent
variables or predictors: management behaviors and financial indicators) that resulted in
enforcement actions by the FDA. The treatment event was the application of the
enforcement action by the FDA. The level of compliance of the firms was the dependent
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variable or outcome. All variables were considered to be continuous at the time. The
post-FDA condition represented the outcome after the remediation activity was
completed, which was measured in the behavioral attitude (TPB) questionnaire
(management “decision-making” survey), financial results [financial indicators section
(i.e. cost of goods, investment, and revenue)], and level of compliance with the FDA
(level of compliance responded by participants).
Considering that there was a logical expectation that the FDA intervention was
going to force a change in management attitudes, an impact on the regression line was
expected, at the application of treatment, the intervention of the FDA. The analysis of the
TPB questionnaire responses allowed to compare the relationships before and after the
FDA intervention. Also, establishing the regression line, between the variables after the
treatment, should assist in assessing the long-term effect on compliance, allowing for
follow-ups and self-corrections by the firms.
Research Questions and Hypotheses
The focus of this quantitative dissertation research study was to determine to what
extent, if any, management behaviors and financial indicators correlated to compliance
with FDA regulations at the pharmaceutical firms in the United States. The conditions
before to the FDA intervention in the pharmaceutical firms was compared to the
conditions after the FDA intervention to predict compliance with the CGMP regulations.
The independent variables that led to enforcement actions by the FDA are management
behaviors of the pharmaceutical managers and the firms’ financial indicators. The
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treatment event was the application of the enforcement action by the FDA. The level of
compliance of the pharmaceutical company was the dependent variable.
 Correlation between management behaviors (independent) and compliance
(dependent):
RQ1: To what extent, if any, does management behaviors correlate to
compliance with FDA regulations at the pharmaceutical firms in the United
States?
H1₀: r = 0. There is no difference in management behaviors towards
compliance at pharmaceutical firms, as a result of FDA enforcement actions in
the United States.
H1₁: r ≠ 0. There are differences in management behaviors towards
compliance at pharmaceutical firms, as a result of FDA enforcement actions in
the United States.
 Correlation between financial indicators (independent) and compliance
(dependent):
RQ2: To what extent, if any, do financial indicators correlate to compliance
with FDA regulations at the pharmaceutical firms in the United States?
H2₀: r = 0. There is no difference in compliance with FDA related to
financial indicators at pharmaceutical firms, as a result of FDA enforcement
actions in the United States.
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H2₁: r ≠ 0. There are differences in compliance with FDA related to financial
indicators before and after the FDA enforcement actions in the United States.
 Financial indicators (independent) impact on compliance (dependent):
RQ3: To what extent, if any, do financial indicators impact compliance with
FDA regulations at the pharmaceutical firms in the United States?
H3₀: β₁ = β₂ = … = βk = 0. There is no impact in compliance with FDA
related to financial indicators at pharmaceutical firms, as a result of FDA
enforcement actions in the United States.
H3₁: At least one β ≠ 0. There is an impact in compliance with FDA related
to financial indicators before and after the FDA enforcement actions in the
United States.
The β in Hypothesis 3 are the regression coefficients of the following multiple regression
equation:

Y  0  1 X1  2 X 2  3 X 3  4 X 4  5 X 5  6 X 6  7 X 7  
Where,
Y= FDA related compliance
X1 = Cost of goods
X2 = Investment
X3 = Process compliance
X4 = Change in sales
X5 = Change in revenues

(2)
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X6 = Change in market value of the firms
X7 = Change in stockholders equity
ԑ = Error of the regression
Pilot Study
A pilot study was conducted to examine clarity of questions to collect feedback
on the questionnaire’s structure and to identify essential beliefs using Likert-type scales.
Ajzen (2002) indicated that a pre-work is required to define the behaviors of interest for
the adequate design of the TPB survey instrument. The pilot study clarified management
behaviors towards compliance with FDA regulations. The pilot study also collected
feedback about financial indicators of the pharmaceutical firms. Demographics of
participants, the degree of compliance, and the type of FDA interventions were requested
in the next sections of the survey instrument. The pilot study confirmed the effectiveness
and completeness of the order of the questions.
To qualify as a participant in the pilot study, participants complied with the same
survey population criteria that was also used for the main study. Participants were
selected from executives and operational management levels who had the authority to
make compliance and financial decisions within pharmaceutical firms, based on their
self-disclosed position titles in the ISPE members’ database. The number of participants
invited to the pilot study was 21. The response rate was 47% for 10 completed surveys.
The 10 responses to the pilot study represented about 6% of the initially targeted usable
responses for the main study of about 160. The pilot study participants’ selection process
was based on convenience sampling that is different from the main study. The need to
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ensure sufficient and reliable replies from the pilot study made it important to recruit
participants who provided usable feedback within 14 days.
The pilot study was conducted similarly to the same intended instrument for the
study. The pilot study was administered through SurveyMonkey, an electronic survey
tool chosen to collect data and facilitate analysis. Trust and desire to participate depended
on the cover letter and personal communication by me with the pilot study’s selected
participants. Also, the pilot study provided feedback on the effectiveness and
completeness related to the message of confidentiality directed to ensure participation
later on in the study questionnaire.
Population and Qualifications
The study population consisted of pharmaceuticals firms that had been impacted
within the last 5-6 years by enforcement activities from the FDA in the United States,
with a specific focus on firms that had experienced FDA interventions related to
manufacturing CGMP violations. The FDA interventions consisted of notification of
deviations (Form 483) with a rating of official action indicated (OAI), following the
FDA’s escalation process as a result of the pharmaceutical firms not responding to these
FDA communications. Audits with ratings of OAI could lead to warning letters or
consent decrees depending on the firms’ response and follow-up actions to the FDA
notifications. In Table 3, a total of 272 OAI audits was summarized for the
pharmaceutical firms between 2010 and early 2015 (FDA, 2015). This number of firms
indicated the targeted population for the main study.
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Table 3
FDA audits with ratings of OAI

FDA Audit
Year

Audits with Official
Action Indicated
(OAI)

2010
2011
2012
2013
2014
2015
Total Audits

86
73
52
47
13
1
272

The intended survey participants was selected from executives and operational
management levels of the pharmaceuticals firms in the United States. ISPE members’
data based was used to select the participants. These participants, based on their selfdisclosed position titles, had the authority to make compliance and financial decisions for
their firms.
Sampling Strategy
The sampling strategy was directed to support the main study in the
pharmaceutical firms in the United States. The main criteria for participation were that
the executives and senior operational management of the firms were expected to have the
authority to make compliance and financial decisions within the firms. The participants’
responses were selected from the completed surveys.
The database of potential participants was obtained from the members’ directory
of the ISPE. Although simple random sampling as suggested by Kanupriya (2012) could
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have been an effective sampling strategy for the study, all ISPE members that meet the
criteria of participants were invited through SurveyMonkey to participate. The
authorization for use of the members’ directory of the ISPE as a member is in Appendix
D.
For the pilot study, convenience sampling approach was the sampling strategy.
This strategy allowed me to select participants based on my personal knowledge. The
participants for the pilot study were considered as experts from the targeted population
who provided the required information to finalize the study questionnaire (FrankfortNachmias & Nachmias, 2008). Based on Ajzen (2002) the pilot study questionnaire
provided a stronger selection of the construct elements for the design of the TPB
questionnaire for the main study.
Sampling Strategies Not Chosen
Systematic Sampling. Systematic sampling, in which a portion of the population
is selected (1/k), was not appropriate for the targeted hypotheses of the main study. The
resulting sample could be impacted by the size of the each pharmaceutical firms or the
characteristics of the FDA interventions. The financial strength of each pharmaceutical
firms could influence the approach to change management to attain the remediation of the
deviations from FDA regulations as noted during the FDA intervention because of the
firms’ manufacturing processes.
Stratified Sampling. Stratified sampling was considered as an alternate when
considering that there could be hierarchical levels of internal authority within the
sampling units at each firms. Nevertheless, the potential differences in the firms’ size and
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each particular organizational structure could make it very difficult to have proportional
sampling and understand the weight between the decision makers. When comparing
different FDA interventions, empowerment to decision makers could depend on the
financial resources of each pharmaceutical firms.
Cluster Sampling. Cluster sampling intent was considered not applicable to the
main study since the cluster approach was not aligned with the targeted participants’
distribution. Although the pharmaceutical industry could be considered as one
population, the individual firms does not necessarily create a cluster scenario for
sampling. The behavior of management was better substantiated through the approach of
including all ISPE members that met the participants’ criteria to minimize any risk of
biases by the individual firms’ financials.
Sampling Size Determination
For the sampling size determination of completed surveys, three approaches were
followed to address the three research questions and hypotheses. For research questions
one and two, the sampling size determination of completed surveys considered Krejcie &
Morgan (1970) equation and Cohen’s power (1992) as the basis for calculation. The
sample size of completed surveys for RQ3 was established by using G*Power software
(Faul, Erdfelder, Lang, & Buchner, 2014).
The intended study population consists of pharmaceuticals firms that had been
impacted within the last five years by enforcement activities from the FDA in the United
States. This population was estimated to be about 272 pharmaceutical manufacturing
firms based on the FDA information (FDA, 2015). The sampling size of completed
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surveys indicated by Krejcie & Morgan (1970) was to be about 160. The intended survey
participants were selected from executives and operational management levels of the
firms, and should have the authority to make compliance and financial decisions for their
firms, based on their self-disclosed position titles in the ISPE members’ database.
Also, an alternate method was utilized to estimate the sample size of completed
surveys for research questions one and two. Cohen’s power (Cohen, 1992) was assessed
as adequate since the population standard deviation is not known. The concept of effect
size is based on the difference between population means. Cohen (1992) indicated that
the effect size could be selected to be 0.5 if the difference of the means is perceived to be.
For the main study, the effect size was not leading to the selection of a smaller effect size
of 0.3. Calculation of the sample population with the application of Cohen’s effect size d
was based on a power (1- β) of 0.80, and a confidence level (α) of 0.05. Assuming that
the groups’ sizes were the same (r =1), the sample population of completed surveys
should have been about 121 with the application of Cohen’s power.
For the research question and Hypothesis 3, a priori power analysis was applied
based on the required expectation of the financial variable impact based on the FDA
intervention in the pharmaceutical firms. The values were set for the statistical power
(strength of the statistical test), α value (probability of the null), and the effect size
(correlation between the variables and the predictor) to determine the sample size. The
selected power of a statistical test represented the probability of correctly rejecting the
null hypothesis, if applicable (Faul, Erdfelder, Lang, & Buchner, 2007). The sample size
of completed surveys for RQ3 was established by using G*Power software (Faul,
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Erdfelder, Lang, & Buchner, 2014). Also, the selected statistical power represented the
probability that the selected statistical test can find a relationship between the variables.
The G*Power software option for the linear regression study assumed a R² that is
different from zero for two predictors in a linear regression. The sample size of
completed surveys was determined to be about 127, based on the selected values for
statistical power of 95%, α of 0.05, and effect size of 0.125. Appendix C presents the
G*Power calculations for the sample determination. The power of 95% provided a
reasonable position to avoid Type II error of not rejecting the null hypothesis when it was
supposed to be rejected. About the effect size, the value of 0.125 was selected to test a
reasonably low correlation between the predictors to enhance the regression model
likeliness of projecting the outcome.
Based on the three approaches for the sampling size determination, the potential
sample sizes of completed surveys were 160 from the method from Krejcie & Morgan
(1970), 121 from the Cohn’s power (1992), and 127 from the G*Power software (Faul,
Erdfelder, Lang, & Buchner, 2014). For the study, the target sample size of completed
surveys was about 160 to ensure that the three research questions and hypotheses were
adequately addressed. My intent was to minimize Type I and Type II errors in the
assessment of the three null hypotheses.
For the intended population, computer accessibility was expected to be high, the
typical time navigating and reading e-mails most likely be constant on a daily basis, and
the probability of gaining the respondent attention is better than by mail or telephone
calls. As explained by Ahern (2005), the benefits of the electronic survey are time
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management, accessibility to sensitive/specific population, and easy and comfort to use
(user-friendly) while minimizing the missing data. The use of an established electronic
survey, SurveyMonkey, facilitated the data management. SurveyMonkey had a
reasonable reputation and could add comfort to the participant, driving the overall level
of participation.
The SurveyMonkey was applied to estimate the optimum sample size assuming a
normal distribution. For the initial target of 160 completed questionnaire, the
SurveyMonkey sampling estimator indicated that the number of potential participants
should be about 400 at a 90% confidence level and a 5% margin of error. This sample of
400 participants projected about 162 completed surveys with a 90% probability that the
sample of participants should reflect the attitudes of the intended population. Also, the
margin of error of 5% intended to minimize the deviation from the true value at the
selected confidence limit of 90%. For this scenario, the expected response rate based on
SurveyMonkey sampling estimator implied a participation of 40.5%.
A response rate of 40.5% was initially considered too optimistic. The expected
response rate was set at 20% to ensure the probability of attaining the targeted 160
completed surveys. This scenario represented about 800 participants at 20% response
rate. The SurveyMonkey sampling estimator indicated that for 800 targeted participants
at a 90% confidence level, the margin of error could be expected at 6%. As a precaution,
1144 members in the directory of the ISPE with an address and meeting the participants’
criteria were invited to complete the main survey.
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Description of the Survey
The survey instrument consisted of four sections, structured as a Likert-type scale
questionnaire. Two sections focused on the behavior of the participants and the financial
indicators of the pharmaceutical firms in the pre-FDA and post-FDA interventions. The
third section collected demographical information from the participants. The fourth
section focused in the firms’ historical compliance.
The period of the survey was an important factor. The participants were expected
to associate personal assessment of behaviors and financial indicators for both the preFDA and post-FDA interventions. The instructions in the survey instrument needed to be
precise providing clarity to optimize the number of usable responses.
The TPB questionnaire by Ajzen (2016) was modified for the behavioral section
of the intended survey instrument. Ajzen (2002) suggested the essential elements for the
construction of the survey for a TPB questionnaire. Consent to apply and modify the TPB
questionnaire for this study was granted by Ajzen (see Appendix A). The financial
indicators section of the planned survey instrument were based on typical indicators that
could be impacted by the expenses needed to support remediation addressing FDA
interventions like the cost of goods and investment in facilities or equipment. Sales,
Revenues, and stockholders’ equity were also be part of the financial indicators.
For the participants, computer accessibility was expected to be high; the typical
time navigating and reading e-mails most likely be constant on a daily basis; and, the
probability of gaining the respondent attention was better than by mail or telephone calls.
The benefits of an electronic survey are time management, accessibility to
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sensitive/particular populations, and being easy and comfortable to use while minimizing
the potential for missing data (Ahern, 2005). The survey was administered through
SurveyMonkey. SurveyMonkey has a reasonable reputation and could add comfort to the
participant driving the overall level of participation.
Appropriateness of the Instrument
The questionnaire structure for assessing management behaviors was developed
following Ajzen’s (2002) guide for constructing a theory of planned behavior
questionnaire. Also, the sample TPB questionnaire from Ajzen (2016) was used. The
permission to use the TPB questionnaire is in Appendix A. Two surveys from the
literature were also used as guides. The first model considered the survey from Stone,
Jawahar, and Kisamore (2009) in which academic misconduct was used trying to predict
future performance as leaders. The second model was from Langham, Paulsen, and
Härtel (2012). In this model, the target was to demonstrate that the TPB could be a
predictor of compliance with tax regulations. In the main study, the questionnaire
constructs considered beliefs (attitudes), normative beliefs, and perceived behavioral
controls.
The questionnaire based on TPB was directed to the elements of salient outcomes
and control factors with the objective to obtain direct measurement of the attitudes
toward the intended behavior, the perceived norm, and the perceived behavioral control
as indicated by Ajzen (2002). The pilot study was be the source of beliefs (attitudes) and
control factors used in the main survey instrument. Past behaviors versus current
behaviors could depend on background changes like organizational structure and working
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climate. A section of general questions was included to help identify future areas of study
affecting behaviors of managers as a result of FDA interventions.
For the financial indicators, a Likert-type scale questionnaire was developed to
create a clear and direct tool for the participant to provide their responses. The scales
were designed to associate in an ordinal relation with each financial indicator’s values.
The elements included for financial indicators consisted of basic business topics like
revenues, the cost of goods and investment in facilities or equipment. The goal was to
provide a questionnaire structure that allowed the participants to compare periods before
and after the FDA intervention for the financial indicators.
The survey instrument consisted of four sections of questions to assess
management behaviors and financial indicators of performance before pre-FDA and postFDA interventions. The responses to the questionnaire were expected to provide feedback
over time while maintaining the participants’ responses aligned to both periods, before
and after the FDA intervention. The third section of the study questionnaire asked for
demographic information of the participants. Section four complied responses about the
FDA experience of the firms.
Validity of Measurements
Attempts to neutralize or compensate for measurement errors could be defined as
evidence or specific conditions in support of the validity. The objective is to enhance the
validity of the instrument about what it is intended to measure (Frankfort-Nachmias &
Nachmias, 2008). There are three types of approaches to address measurement errors:
content validity, empirical validity, and construct validity.
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Content Validity
Content validity is directed to assure that the measurement instrument covers all
intended attributes of the study. Face validity (all questions addresses the properties of
the variables) and sampling validity (all properties of the variables are considered) are the
two areas that need to be considered when addressing concerns around content in the
questions validity of a questionnaire (Frankfort-Nachmias & Nachmias, 2008). An
important challenge is to ensure that the questionnaire addresses all significant aspects of
behavior.
Assessment of the feedback from the pilot study assisted in achieving a significant
content validity. Assuming that all participants had the same level of definition of what is
compliance was difficult to predict. Maintaining neutrality and not pre-setting responses
on the questionnaire by me required neutrality and control over previous mental models.
Empirical Validity
The relationship between the measurement instrument and the actual outcomes
requires attention. Addressing empirical validity is very difficult (Frankfort-Nachmias &
Nachmias, 2008). Predictions via a pilot study was developed with peers in the
pharmaceutical industry to allow comparison of initial expectations with actual measured
results. Even establishing a reference base had its challenges, based on potential biases of
management (participants).
Construct Validity
Construct validity looks for a theoretical framework that could be related to the
intent of the measuring instrument. The TPB (Ajzen, 1991) was used to discuss the
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outcome of the measurements. TPB presented the concepts that allowed me in the study
to link beliefs (attitudes) with the actual behavior, subjective norms with the behavior,
and perceived control over behavior. The correlations and linear regressions provided the
basis to assess the data from the TPB sections of the study questionnaire. The attributes
and assumptions of TPB could affect the study. Assessment of the survey data allowed
defining future research in the topic.
Questionnaire Reliability
Cronbach’s alpha tests correlation to determine the reliability of a scale
questionnaire (Field, 2009). Cronbach’s alpha is not a validity measure. The values for
Cronbach’s alpha range from 0 to 1. Cronbach’s alpha provided the means to assess if the
scale items in the study questionnaire impacted the overall total subscale reliability.
Either eliminating or reversing the phrasing of a negative scale item were assessed to
obtain the Cronbach’s values. All subscales of the Likert-type scale structure of the
questionnaire were included in this assessment with the Cronbach’s alpha tests
correlation.
Protection of the Survey Population
The data collected through the electronic questionnaire was protected by the terms
provided by SurveyMonkey. An individual codification was used to protect each
participant’s responses within SurveyMonkey. All lists of the study’s participants
generated with the SurveyMonkey code will be destroyed by incineration for any printed
master list after five years from the approval of the study. SurveyMonkey confidentiality
terms will also apply in their databases. The electronic lists from my computer will be
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stored in a bank security box for five years on a DVD and in an external memory storage
device. Then, the data will be erased and the storage devices destroyed to assure no
opportunity for data recovery.
Informed Consent
For both the pilot study and the actual survey questionnaire, consent of
participation were sent to the intended participants as part of the electronic method
selected following the approved by Walden University’s Institutional Research Board
(IRB) with approval number 12-28-15-0289564 that expired on December 27, 2016. The
participants had to confirm the consent of participation before commencing the
questionnaire. The consent form provided an introduction of the intent of the study,
clarity that the study was for my Ph.D. program, and informed of the confidentiality of
the data to be provided to each participant. There were two consent forms used for this
study: one for the pilot study and one for the study questionnaire. These consent forms
included the invitation to participate in each survey and were the page of the e-mail
electronic survey. Also, SurveyMonkey system provided the option to the participants to
opt-out of the survey and any future mailing.
As inferred by Ahern (2005), using electronic surveys have challenges in the
areas of confidentiality and in acquiring rights and permission to quote. The use of
established survey web pages, like SurveyMonkey, facilitated conveying the academic
intent and privacy of the study. An opening statement regarding my academic program,
including a reference to the IRB should have provided the opportunity for the participant
to feel comfortable in proceeding to the questionnaire. The IRB of Walden University
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provided the permission to apply the pilot study and the main study questionnaire. A
copy of the study was offered to the participants that completed the main survey and
responded to the dateline of the questionnaire. A need for reminder and follow-up were
conducted after the IRB concurrence. The pilot study questionnaire provided insight to
reinforce the message of confidentiality. In the consent statement, the participants were
informed of their rights to stop their participation at any time. Also, after reading the
instruction at the beginning of the questionnaires within SurveyMonkey, the participants
were given a final option to stop their participation.
Confidentiality
For both the pilot study and the actual questionnaire, the collected data from all
electronic questionnaires were received and tabulated with the participant using the
SurveyMonkey code to assure confidentiality of the responses. Confidentiality follows
the terms provided by SurveyMonkey for their database used. Any printed information or
data regarding the names of the participants will be destroyed by incineration, including
any printed master list. The electronic data files with names in my computer will be
stored on a DVD and in an external memory device. The electronic devices, DVD and a
storage memory stick, will be deposited in a bank security box for five years with the list
of participants and codification matrix. All this data and information will then be erased,
and the storage devices destroyed to assure no means for data recovery.
Data Collection Plan
Data collection is a critical stage in any research study. A data collection plan
consists of the strategy and instrument to collect information that could dictate the
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validity, success, and impact of the study (Frankfort-Nachmias & Nachmias, 2008).
Research data collection should be of having in mind cost effectiveness, confidentiality,
ethics, and accuracy. As concluded by Ahern (2005), survey applications that are wellmanaged and designed through the Internet could provide the expected attributes to some
degree. Also, effective time management in the collection and verification of sources and
data could be achieved with the application of the Internet.
Data collection from participants in this research study required accessibility to a
sensitive population and assuring a high level of confidentiality. However, opportunities
for face-to-face interviews with the intended population of pharmaceutical managers
were very limited due to participants’ accessibility and geographic locations. Mailed
questionnaires have advantages like reduced biases and strong protection of
confidentiality, as listed by Frankfort-Nachmias and Nachmias (2008). The challenge was
to grasp the interest from participants, who have multiple priorities and limited available
time.
Managers in this field normally have an assistant who filters the correspondence.
As a result, the mail survey receives limited response rate. Based in today’s office
environment in the pharmaceutical industry for the intended population, computer
accessibility was expected to be high; the typical time navigating and reading e-mails
most likely be constant on a daily basis; and, the probability of gaining the respondent
attention was better than by mail or telephone calls. The survey was administered through
SurveyMonkey.
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The structure of the electronic survey is complex as explained by Ahern (2005).
The weaknesses of using electronic surveys are mainly in the area of confidentiality and
privacy, the authenticity of the respondent, and acquiring rights and permission to quote.
The introduction to the survey has to be concise while projecting a clear level of
protection and comfort to the respondent. Despite these challenges, Ahern (2005)
summarized the benefits of the electronic survey as time management, accessibility to
sensitive/particular population, easy and comfort to use (user-friendly), and reduces the
missing data.
Expected Duration
The expected duration of the data collection activities, consisting of conducting
the pilot study and of the actual survey process, was expected to take a total of between
30 to 40 days. The pilot survey with the opening statement, including the confidentiality
explanation, was delivered to 21 industry peers. This pilot survey process to gather the
data took 12 days. The data review and formatting of the final questionnaire lasted 34
days. The pilot process took a total of 46 days from the first mailing.
The actual survey execution was expected to last an additional 15 to 20 days.
Recognizing the need to send a reminder to participants might be beneficial, the projected
timeline included reminders through SurveyMonkey every 2-3 days up to 10-12 days.
Due to the low initial partition of the 1144 invitees, the data gathering for the main study
took 65 days after six reminders including a required second IRB review that lasted 38
days. The net extent of the actual data gathering process was 27 days. The total research
lasted 111 days including the pilot study.
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Data Acquisition
The data acquisition instruments consisted of the behavioral attitude (TPB)
questionnaire (management behaviors survey), the change in financial results [financial
indicators section (i.e. cost of goods and investment in equipment and facilities)], and
level of compliance with the FDA (compliance observations). A pre-FDA and post-FDA
survey questionnaire was the vehicle utilized for management attitude (TPB) and
financial indicators. An e-mail approach was employed to reach the participants. The
design to the electronic questionnaire was analyzed to ensure an effective data acquisition
process. The number of questionnaires that were completed, not completed, and wrongly
completed were tabulated to summarize the actual performance of the electronic survey.
Some statistics from the Internet survey tool were provided in the data analysis from
SurveyMonkey.
Data Analysis Plan
Several steps were taken to ensure the organization, confidentiality, and meeting
assumptions of the statistical tests to facilitate the data management process. Morrow
(2009) suggested specifics on how to manage the data and to address shortfalls, like
missing data and assumptions’ requirements. The first step was to develop a data
codebook (SPSS template) to store the data for all the variables and sampling details. The
database template was created in SPSS from the data transferred from SurveyMonkey.
The access to my laptop was password-protected to support confidentiality protecting the
access to the collected data and the SPSS data template. Personal references from
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participants were cross-coded by SurveyMonkey with reference numbers to enhance
privacy and confidentiality.
The second step consisted of the cleaning of the data per the steps outlined by
Morrow (2009). Cleaning of the data refers to the process of minimizing biases and
calculation errors generated by the quality of the obtained data. A step-by-step approach
was followed by utilizing SPSS guides.
1. Outliers’ scores were identified to minimize biases and not relevant
information. Elimination of these outliers was the first task.
2. Verifying for normality of variables enhanced the review for outliers.
Achieving a normal distribution around the mean was an expected
assumption.
3. Missing data could impact the results of the analysis. The data was reviewed
to assure that the suggested level of not more than 5% missing data was
attained. The average of the individual responses was used to fill in the
missing data.
4. Transforming the data by means of reversing the Likert-Type scores provided
alignment and proper assessment of the Cronbach’s alpha to assess the
reliability of the scales by section or construct of the TPB.
5. Verifying for multicollinearity was done within the SPSS regression
application.
6. The Pearson coefficient was used to assure that the correlations between
variables were less than 0.8. In the event of a higher value of the correlation,
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the variables were evaluated by either combining them or eliminating one of
them.
7. For homogeneity of regression, SPSS was also used.
8. Linearity was verified by visually assessing the graphs of the data.
9. For the completed-usable responses, the participant had to complete over
95% of the questions in either the pilot study or the main study including the
demographics and FDA compliance questions at the end.
The application of regression analyses increased the complexity since two TPB
scenarios pre-FDA and post-FDA interventions were assessed. Maintaining separation of
the data for the two scenarios within the SPSS template was important. The number of
the questions within SurveyMonkey provided the vehicle to maintain the separation of
the data for the two TPB scenarios pre-FDA and post-FDA interventions. The application
of SPSS for the statistical analyses and all the corresponding assumptions of regression
analyses was utilized for both scenarios pre-FDA and post-FDA interventions.
Hypotheses Testing Plan
The two predictors used in this study were management behaviors and financial
indicators. The three sets of hypotheses related to these predictors were listed below. The
outcome variable was the level of compliance with the FDA regulations.


Correlations between management behaviors (independent) and compliance
(dependent):
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H1₀: r = 0. There is no difference in management behaviors towards
compliance at pharmaceutical firms, as a result of FDA enforcement actions
in the U.S.
H1₁: r ≠ 0. There are differences in management behaviors towards
compliance at pharmaceutical firms, as a result of FDA enforcement actions
in the U.S.
The null hypothesis, H1₀, implies that the value of the correlation coefficient is
zero, r = 0 indicating that there is no correlation or way to predict compliance from
management behaviors. The alternate hypothesis, H1₁, considering a two-tailed
distribution, is r ≠ 0 or r <> 0 indicating that there is a correlation or way to predict
compliance from management behavior. The significance level to test the hypotheses had
a value for α of .05%. The number of unique correlations in the correlation matrix were
based on the three constructs in the TPB questionnaire.


Correlations between financial indicators (independent) and compliance
(dependent):
H2₀: r = 0. There is no difference in compliance with FDA related to
financial indicators at pharmaceutical firms, as a result of FDA enforcement
actions in the U.S.
H2₁: r ≠ 0. There are differences in compliance with FDA related to
financial indicators before and after the FDA intervention.
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The null hypothesis, H2₀, indicates the value of the correlation coefficient is zero,
r = 0 indicating that there is no correlation or way to predict compliance from the seven
financial indicators. The alternate hypothesis, H2₁, considering a two-tailed distribution,
is r ≠ 0 or r <> 0 indicating that there is a correlation or way to predict compliance from
the seven financial indicators. The significance level to test the hypotheses had a value
for α of .05%. The number of unique correlations in the correlation matrix were based on
the seven financial indicators.


Financial indicators (independent) impact on compliance (dependent):
H3₀: β₁ = β₂ = … = β7 = 0. There is no impact in compliance with FDA
related to seven financial indicators at pharmaceutical firms, as a result of
FDA enforcement actions in the United States.
H3₁: At least one β ≠ 0. There is an impact in compliance with FDA related
to at least one of the seven financial indicators before and after the FDA
enforcement actions in the United States.
The seven financial indicators for the test of Hypothesis 3 were the cost of goods,

investment in facility and equipment, process compliance, sales, revenues, market value,
and stockholder’s equity. SPSS was used to generate the models. The βs in Hypothesis 3
were the regression coefficients of the following multiple regression equation:

Y  0  1 X1  2 X 2  3 X 3  4 X 4  5 X 5  6 X 6  7 X 7  
Where,
Y= FDA related compliance

(3)
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X1 = Cost of goods
X2 = Investment
X3 = Process compliance
X4 = Change in sales
X5 = Change in revenues
X6 = Change in market value of the firms
X7 = Change in stockholders equity
ԑ = Error of the regression
For the TPB data and financial indicators in Likert-type scales, aggregate
comparison, factor analysis and Cronbach’s alpha were utilized. For the regression
analyses, the standard linear regression in SPSS was the approach assessing the models.
ANOVA, t testing, Durbin-Watson statistics, and collinearity statistics were statistical
methods that were applied through SPSS for this study. Durbin-Watson supported the
independent assumption. Collinearity statistics provided, through variance inflation factor
(VIF) and tolerance, the support to indicate if the assumption was met or not.
Summary
Chapter 3 discussed and described the research method and design. The selection
of the quantitative methodology for the study was discussed. The sampling plans were
discussed for both the pilot study and the main study. The validity and reliability of the
survey instrument were described, and the relation to the variables of the study discussed.
The intended population was further defined by the information from the FDA. The size
of the sampling units (participants) determination was assessed by three mechanisms.
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ISPE member’s database was indicated as the source of the participants meeting the
criteria for selection. The steps to ensure confidentiality and protection of the participants
were enumerated. Plan for data collection and data analysis to address the research
questions were described including the statistical approach.
Chapter 4 presents the results of the pilot and the main study. Discussion on the
pilot study is used to facilitate key concepts to support the three construct of the TPB for
the design of the final questionnaire. The application of three correlations between the
three construct of the theory of planned behavior and the FDA compliance addresses
RQ1. Analyses through correlations and linear regressions of seven financial indicators
provide the insight to the assess RQ2 and RQ3. The findings and the resulting null testing
are presented.
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Chapter 4: Results
This quantitative study sought to learn to what extent, if any, management
behaviors and financial pressures at pharmaceutical firms correlated with or predicted
compliance with the FDA regulations avoiding interruptions in the supply of some
essential patented or generic pharmaceutical drugs in the U.S. From the review of the
literature, the gap consisted on the limited available research providing awareness and
guidance to managers in their decision and their risk assessment process, regarding their
FDA compliance responsibility, corporate financial mandate, and stakeholders’
expectations. This research was driven by the limited information on what were the
interdependencies or correlations between the need to grow revenue and the intent to
behave within the senior management decision process
The behavior by management, related to the quality of drugs to meet their
intended quality, integrity, strength, and purity influences the level of compliance of the
firms’ operations. The pressures of enhancing productivity, funding research, supporting
marketing plans, and reducing the cost of goods also influences the firms’ compliance
performance. The application of enforcement actions by the FDA on the firms was used
as the treatment event to reestablish the expected level of compliance. A shift in the
relationship between the variables was expected after the FDA intervention, highlighting
the new level of compliance.
The independent variables that could lead to enforcement actions by the FDA
were set as management behaviors of the pharmaceutical managers and the firms’
financial indicators. The treatment event was the application of the enforcement action by
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the FDA. The level of compliance of the pharmaceutical companies was the dependent
variable. In the study, the conditions before the FDA intervention in the pharmaceutical
firms were compared to the post-conditions after the FDA intervention to predict
compliance with the CGMP regulations. The research questions were formulated on three
foci:


Correlations between management behaviors (independent) and compliance
(dependent)



Correlations between financial indicators (independent) and compliance
(dependent):



Financial indicators (independent) impact on compliance (dependent).

Research questions were answered based on the null hypotheses testing in
Chapter 4. Despite the low rate of participation in the main study, the null hypotheses
were rejected. For RQ1, the theory of planned behavior (Ajzen, 1991) was applied. The
three behavioral constructs led to the execution of three correlations with the outcome of
compliance with FDA regulations. For RQ2, seven correlations were conducted between
the selected financial indicators and the outcome of compliance. For RQ3, some of the
assumptions for the regression equations were not met avoiding any generalization from
the models.
Chapter 4 contains the data collected and the results of the pilot study and the
main study questionnaire. The pilot study elements like population, data collection, and
feedback are presented. The outcome and impact of the pilot study on the final
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questionnaire are discussed. Regarding the final study questionnaire, the data collection
process, the length of the study, the IRB approvals, and the limited participation are
presented.
Pilot Study
A pilot study was conducted to examine clarity of survey questions, to collect
feedback on the questionnaire’s structure, and to identify essential beliefs that were used
in the Likert-type scales. Ajzen (2002) indicated that a pre-work was required to define
the behaviors of interest for the proper design of the TPB survey instrument. Through the
pilot study, I identified essential management behaviors towards compliance with FDA
regulations. These management behaviors were incorporated into the Likert-type
questions suggested by Ajzen (2016) for the main survey questionnaire. The pilot study
also collected feedback about financial indicators of the pharmaceutical firms.
Demographics of participants, the degree of compliance, and the type of FDA
interventions were requested in the pilot survey instrument.
The pilot study questionnaire confirmed the effectiveness and completeness of the
order of the sections. The structure of the pilot questionnaire consisted of four sections.
The first and second sections related to the TPB initial assessment of attitudes, social
influences, and perceived behavioral controls. This section tested the clarity of the Likerttype questions and the open-ended questions to identify attributes of attitudes, social
influences, and controls to finalize the main study questionnaire as indicated by Ajzen
(2002). Also, the first two sections included a table to collect financial results of the firms
before and after the FDA intervention or action. The intent was to identify information
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before and after an FDA intervention in the firms. The third section consisted of the
demographics questions. Finally, the fourth section pursued clarification on the outcome
of any FDA interventions or actions in the firms in the past five-six years.
The instructions for pilot study questionnaire in SurveyMonkey included an initial
question to allow the participant to proceed or stop their participation after reading the
instructions to the questionnaire. This question ensured the voluntary participation of the
person highlighting the understanding of the level of confidentiality and the positive
social benefit if participating in the study. The instructions were part of the
SurveyMonkey questionnaire. The number of questions in the pilot study questionnaire
were 44. The questions consisted of Likert-type scales, open-ended questions, and tables
to select responses.
Pilot Study Population
The pilot study participants, to qualify as a participant, had to comply with the
same participants’ criteria that applied to the main study. Participants were selected from
executives and operational management levels who had the authority to make compliance
and financial decisions within pharmaceutical firms. The pilot study participants’
selection process was based on convenience sampling from individuals known to me. The
number of participants invited to the pilot study was 21.
The need to ensure sufficient and reliable replies from the pilot study required
recruiting participants who provide useful feedback within 14 days. The pilot survey
commenced on January 5, 2016, and was closed on January 17, 2016.
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From the 21 invitations sent by using SurveyMonkey, 20 of the invitations were
opened by the intended participants and one was not opened. Of the 20 invitations that
were opened to read the consent form, 13 participants accepted the consent form and
proceeded to the survey. After reading the instruction, nine of the 13 participants
accepted to proceed to the questionnaire and five did not initiate the survey. The
participation results attained eight completed surveys and one partial-completed survey.
The eight completed surveys provided a response rate of 38%. The eight responses to the
pilot study represented about 5% of the initially targeted usable responses of 160 for the
main study.
Pilot Study Data Collection
The pilot study was conducted similarly to the same intended instrument for the
main study. The pilot study was administered through SurveyMonkey, an electronic
survey tool chosen to collect data and facilitate analysis. Trust and desire to participate
was pursued by an initial e-mail sent to the selected 21 invitees to the pilot study. Then, a
consent form for participation was sent via SurveyMonkey as approved by the Walden
University’s IRB.
The pilot study also provided feedback on the effectiveness and completeness
related to the message of confidentiality. Of the 21 SurveyMonkey invitations sent, 20
invitations were opened, 13 accepted the consent from, but five participants decided not
to participate in the survey after reading the instructions. The consent form with the
questionnaire instructions provided adequate space for the participants to voluntarily
decide if they would participate or not. With the 38% rate of participation in the pilot
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study, the participation in the main study was expected to reach the initial target of 160
completed questionnaires out of about 1144 invitations with a projected rate of
participation of about 15%.
Pilot Study Demographics
The demographics of the pilot study indicated a reasonable representation of the
role of responsibility and area of expertise. The demographics questions where located at
the end of the pilot study. Appendix E shows the percentage distribution of the relevant
demographics. The decisions makers’ titles indicated the participation of directors, vicepresidents, and one executive. The educational level included bachelors and doctorate
degrees. The functional areas within the pharmaceutical firms represented covered
quality, manufacturing, and others like technical services. The demographics of the pilot
study’s participants ensured a representative source of essential management behaviors
that were incorporated to the Likert-type scaled of the final questionnaire.
Pilot Study Data Treatment
The collected data in the pilot study was initially assessed via the results review
section through SurveyMonkey. Then, the data was transferred to an Excel template to
facilitate the assessment of the open-ended questions to identify management behaviors
related to decision makers through the frequency of words appearance in the responses.
The open-ended questions led to essential concepts to support the three constructs in the
main study regarding TPB Likert-type questions. The collected data was also transferred
to an SPSS data table to facilitate the intended statistical assessments for correlations and
regression analyses.
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Pilot Study Data Analysis
The data analysis consisted on how to manage the data while addressing
shortfalls, like missing data and assumptions’ requirements. The first step was to develop
a data codebook (SPSS template) to store the data for all the variables and sampling
details. The database template was created in SPSS from the data transferred from
SurveyMonkey. The access to my laptop was password-protected to support
confidentiality by protecting the access to the collected data and the SPSS data template.
There was no need to cross-code any personal references from participants since the
collected data from SurveyMonkey provided reference numbers to enhance privacy and
confidentiality of the participants
The second step consisted of the cleaning of the data per the steps outlined by
Morrow (2009). Cleaning of the data refers to the process of minimizing biases and
calculation errors generated by the quality of the obtained data. A step-by-step approach
was followed when using SPSS analysis.
1. Outliers’ scores were initially assessed with the intent to apply Windsorizing.
None of the Likert-type scores or financial data tables from the pilot study nor
the main study required to apply Windsorizing approach. In the SPSS
analysis, for just caution and only when requested a 2 sigma was applied.
2. Verifying for normality of variables enhanced the review for outliers. SPSS
Explore function was applied to identify if normal distribution assumption
was met.
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3. Transforming the data by means of reversing the Likert-Type scores provided
alignment and proper assessment of the Cronbach’s alpha to understand the
reliability of the scales.
4. The data was reviewed for each variable’s Likert-type questions in the SPSS
template to ensure that the suggested level of not more than 5% missing data
was present. If needed for less than 5% of the data, the estimated average of
the data was used to fill in the missing data.
5. For completed-usable responses, the participant had to complete over 95% of
the questions in either the pilot study or the main study including the
demographics and FDA compliance questions at the end.
6. For partial responses, an organized approached was implemented. This
approach consisted in the separation of the collected data in the SPSS template
by each of the two scenarios: pre-FDA and post-FDA interventions. This
process allowed to consider those responses that only addressed the pre-FDA
scenario, but the participants decided not to continue to complete the
remainder of the questions.
7. Transforming the data by means of reversing the Likert-Type scores provided
alignment and proper assessment of the Cronbach’s Alpha to assess the
reliability of the scales by section or construct of the TPB.
8. For the correlation analyses, Pearson and Kendal coefficients were conducted.
9. Verifying for multicollinearity was done within the SPSS application. The
Pearson coefficient was used. In the event of a higher value than .8 of the
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correlation values, the variables were evaluated by either combining them or
eliminating one of them.
10. For homogeneity of regression, SPSS was used.
11. Linearity was initially verified by visually assessing the graphs of the data.
The application of regression analysis increased the complexity since two
scenarios pre-FDA and post-FDA interventions were assessed. Maintaining separation of
the data for the two scenarios within the SPSS template was important. The number of
the questions within SurveyMonkey provided the vehicle to maintain the separation of
the data for the two TPB scenarios pre-FDA and post-FDA interventions. The application
of SPSS for the statistical analyses and all the corresponding assumptions of regression
analyses were considered in each scenario: pre- and post-FDA intervention.
Open-ended questions. An assessment of the eight open-ended questions was
conducted. All the eight responses were read and assessed for common words and time
repeated by the respondents. The responses were tabulated in an Excel table to tabulate
frequency and categories related to the three construct of the TPB. The responses were
anonymous since SurveyMonkey maintained the names of the participants not linked to
the responses, as selected by me during the formulation of the questionnaire.
SurveyMonkey provided confirmation of the word frequency. The high frequently used
words were similar in my tabulation and in the SurveyMonkey’s output.
The selected words and topics from the open-ended questions provided the prework indicated by Ajzen (2002) to define the behaviors and constructs of interest for the
suitable design of the TPB main survey instrument. By applying the words and topics to
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the three constructs of the beliefs (attitudes), normative, and perceived behavioral control
sections of the TPB questionnaire by Ajzen (2016), the Likert-type questions were
modified providing the expected questionnaire structure for the main study.
Through the pilot study, the identified words and topics highlighted relationships,
attitudes, and perceived controls to be asked in the main study. In the formulation of the
Likert-type questions, I focused on management attitudes, motivation factors, peer
influences, and behavioral controls towards compliance with FDA regulations. The
questions were formulated to enhance the before and after scenarios regarding an FDA
intervention or action. These constructs were incorporated into the Likert-type questions
suggested by Ajzen (2016) for the final questionnaire. This process led to a significant
increase in the number of Likert-type questions in the final questionnaire from 44 to 133
questions.
Assessment of Likert-type questions. Likert-type scales were used to assess
constructs of the TPB liked beliefs (attitudes), normative beliefs, and perceived
behavioral controls. To attain an internally consistent scale, the approach to obtain the
Discriminative Power (Frankfort-Nachmias & Nachmias, 2008) for the pilot study was
considered. Because there were only eight questions covering the TPB constructs for the
pilot study, the applicability of the Discriminative Power was considered not adequate to
challenge the internal consistency of the Likert-type scales.
The pilot study’s Likert-type scales were directed to demonstrate the adequacy of
the TPB approach to develop the main study questionnaire. Table 4 presents the
constructs, the variables, and the corresponding means and standard deviations
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corresponding to pre-FDA intervention. The means are skewed towards the high side of
the range of 1 to 7. The standards deviations could be considered homogenous except for
q0007_0001 whose standard deviation was above 2.00 while all other values were below
1.30.
Table 4
Pre-FDA Intervention
TPB
Constructs
Attitudes

Mean

My compliance with CGMP regulations before the
last FDA intervention was

SPSS
Name
Q0002_
0001

6.00

Standard
Deviations
1.118

My compliance with CGMP regulations before the
last FDA made me feel

Q0003_
0001

5.89

1.269

Most people who are important to me approve me
being in compliance with CGMP regulations before
the last FDA intervention

Q0004_
0001

6.44

0.726

Most people likes me being in compliance with
CGMP regulations before the last FDA intervention

Q0005_
0001

6.44

0.726

I was confident that I was in compliance with
CGMP regulations before the last FDA intervention

Q0006_
0001

5.89

1.167

Being in compliance with CGMP regulations
before the FDA intervention was up to me

Q0007_
0001

5.00

2.345

Intention

I intended to be in compliance with CGMP
regulations before the last FDA intervention

Q0008_
0001

7.00

0.000

Previous
Behavior

Prior to the last FDA intervention I have being in
compliance with CGMP regulations

Q0009_
0001

6.33

1.000

Perceived
Norms

Perceived
Behavioral
Controls

Variable Name

Table 5 presents the constructs, the variables, and the corresponding means and
standard deviations corresponding to post-FDA intervention. The means are skewed
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towards the high side of the range of 1 to 7. All the standards deviations could be
considered homogenous which is different from the pre-FDA intervention.
Table 5
Post-FDA Intervention
TPB
Constructs
Attitudes

Mean

My compliance with CGMP regulations after the
last FDA intervention was

SPSS
Name
Q0022_
0001

6.50

Standard
Deviations
0.756

My compliance with CGMP regulations after the
last FDA made me feel

Q0023_
0001

6.00

1.773

Most people who are important to me approve me
being in compliance with CGMP regulations after
the last FDA intervention

Q0024_
0001

6.25

1.165

Most people likes me being in compliance with
CGMP regulations after the last FDA intervention

Q0025_
0001

6.63

0.744

I was confident that I was in compliance with
CGMP regulations after the last FDA intervention

Q0026_
0001

6.38

0.774

Being in compliance with CGMP regulations after
the FDA intervention was up to me

Q0027_
0001

4.88

1.885

Intention

I intended to be in compliance with CGMP
regulations after the last FDA intervention

Q0028_
0001

6.75

0.463

Previous
Behavior

Prior to the last FDA intervention I have being in
compliance with CGMP regulations

Q0029_
0001

6.63

0.518

Perceived
Norms

Perceived
Behavioral
Controls

Variable Name

Initially, Pearson’s coefficient was utilized to understand the internal consistency
of the Likert-type scales by establishing how close the different elements of the scales are
to each other. Also, the correlation between each subset of the construct was obtained and
listed to establish the dependencies within each construct. Table 6 presents the Pearson
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correlation for the TPB constructs for the pre-FDA intervention in the pilot study. The
question q0009-0001, regarding perceived behavioral control, had non-significant
correlations with any other variables with p values from 0.443 to 0.903. Also, question
q0005-0001 regarding influence from or by peers was non-significant with the participant
beliefs and attitudes (q0003-001) towards compliance with r = 0.602, p = 0.086.
Table 6
Pearson’s Correlation pre-FDA Intervention
q0002_ q0003_ q0004_ q0005_ q0006_ q0007_ q0008_ q0009_
0001
q0002_ Pearson Correlation
0001
Sig. (2-tailed)
N
q0003_ Pearson Correlation
0001
Sig. (2-tailed)
q0004_ Pearson Correlation
0001
Sig. (2-tailed)
q0005_ Pearson Correlation
0001
Sig. (2-tailed)
q0006_ Pearson Correlation
0001
Sig. (2-tailed)
q0007_ Pearson Correlation
0001
Sig. (2-tailed)
q0008_ Pearson Correlation
0001
Sig. (2-tailed)
q0009_ Pearson Correlation
0001
Sig. (2-tailed)

1
9
**

0001
.881**

0001
.923**

0001
.769*

0001
.767*

0001
-.048

.002

.000

.015

.016

9

9

9

9

1

**

.602
.086
.763*
.017
1

*

.881
.002
.923**
.000
.769*
.015
.767*
.016
-.048
.903
.c
.
**
.894

.874**
.002
.602
.086
.750*
.020
.168
.666
.c
.
**
.919

.001

.000

.874
.002
1

.763*
.017
.803**
.009
.073
.851
.c
.
**
.975

.803**
.009
-.293
.443
.c
.
.631

.000

.068

.750
.020
.803**
.009
.803**
.009
1
.091
.815
.c
.
*
.786
.012

.c

0001
.894**

.903

.

.001

9

9

9

.168
.666
.073
.851
-.293
.443
.091
.815
1

c

**

.c
.
.213
.582

0001

.

.
.c
.
.c
.
.c
.
c
.
.
c
.
.c

.919
.000
.975**
.000
.631
.068
.786*
.012
.213
.582
.c
.
1

.

**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).
c. Cannot be computed because at least one of the variables is constant.

Table 7 presents the Pearson’s correlation for the TPB constructs for the postFDA intervention in the pilot study. The question q0027-0001, regarding perceived
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behavioral control, had non-significant correlations with all other variables with p values
from 0.522 to 0.909. In the post-FDA, all variables had at least one Pearson’s correlation
that was non-significant.
Table 7
Pearson’s Correlation post-FDA Intervention

q0022_ Pearson Correlation
0001 Sig. (2-tailed)

q0022_ q0023_ q0024_ q0025 q0026 q0027_ q0028_ q0029_
0001
0001
0001 _0001 _0001 0001
0001
0001
1
.640
.324 .889** .889**
.050
.816*
.913**
.088

.433

.003

.003

.906

8
1

8
.208

8
.650

8
.542

8
-.171

.622

.081

.166

.686

.005

.023

1

.453

.700

-.049

.397

.178

.259

.053

.909

.330

.674

1

*

.267

**

.696

.016

.522

.001

.055

-.064

*

.788*

N
q0023_ Pearson Correlation
0001 Sig. (2-tailed)

8
.640

q0024_ Pearson Correlation
0001 Sig. (2-tailed)

.324

.208

.433

.622

q0025_ Pearson Correlation
0001 Sig. (2-tailed)

**

.650

.453

.003

.081

.259

q0026_ Pearson Correlation
0001 Sig. (2-tailed)

.088

.889
.889

**

.542

.700

.806

*

.806

1

.013

.002

8

8
.778*

.870

.933

**

.726

.003

.166

.053

.016

q0027_ Pearson Correlation
0001 Sig. (2-tailed)

.050

-.171

-.049

.267

-.064

.906

.686

.909

.522

.881

q0028_ Pearson Correlation
0001 Sig. (2-tailed)

.816

*

**

**

*

.013

.005

.330

.001

.041

.772

q0029_ Pearson Correlation
0001 Sig. (2-tailed)

.913**

.778*

.178

.696

.788*

-.201

.745*

.002

.023

.674

.055

.020

.633

.034

.870

.397 .933

**. Correlation is significant at the 0.01 level (2-tailed).

.726

.881

.041

.020

1

.123

-.201

.772

.633

1

.745*

.123

.034
1

*. Correlation is significant at the 0.05 level

(2-tailed).

Considering the small number of participants, skewness and kurtosis were used to
assess the distribution of the variables. In the scenario of pre-FDA intervention, the
skewness results were all negative indicating that there was a cluster at the higher end of
the scales (Field, 2009). Kurtosis was used to measure the degree to which scores cluster
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in the tails of a frequency distribution. Kurtosis’ values were both positive and negative.
Positive kurtosis values indicate that the distribution tends to peak at the tails due to the
high number of scores in the tail. Negative kurtosis values signal few scores in the tails
and a flat distribution (Field, 2009). In the scenario of post-FDA intervention, the
skewness results were also all negative indicating that there was a cluster at the higher
end of the scales (Field, 2009). The kurtosis’ values were also both positive and negative.
The non-normal distribution in six out of seven distributions was significant as
confirmed by using Kolmogorov-Smirnov and Shapiro-Wilk in SPSS. Table 8 shows the
results of the Kolmogorov-Smirnov and Shapiro-Wilk tests for the pre-FDA intervention.
For the post-FDA intervention in Table 9, the results for Kolmogorov-Smirnov and
Shapiro-Wilk tests are illustrated. In a similar manner, the non-normality is confirmed
with seven of eight variables being significant.
Table 8
Test of Normalityb pre-FDA Intervention
Kolmogorov-Smirnova
q0002_0001
q0003_0001
q0004_0001
q0005_0001
q0006_0001
q0007_0001

Statistic
.259
.313
.333
.333
.316
.248

q0009_0001
.303
a. Lilliefors Significance Correction

df
9
9
9
9
9
9

Shapiro-Wilk
Sig.
.083
.011
.005
.005
.010
.119

Statistic
.844
.795
.763
.763
.792
.827

df
9
9
9
9
9
9

9
.017
.710
9
b. q0008_0001 is constant. It has been omitted.

Sig.
.065
.018
.008
.008
.017
.042
.002
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Table 9
Test of Normality post-FDA Intervention
Kolmogorov-Smirnova

Shapiro-Wilk

q0022_0001

Statistic
.371

df
8

Sig.
.002

Statistic
.724

df
8

Sig.
.004

q0023_0001

.339

8

.007

.668

8

.001

q0024_0001

.365

8

.002

.724

8

.004

q0025_0001

.443

8

.000

.601

8

.000

q0026_0001

.300

8

.033

.798

8

.027

q0027_0001

.225

8

.200*

.908

8

.343

q0028_0001

.455

8

.000

.566

8

.000

q0029_0001

.391

8

.001

.641

8

.000

*. This is a lower bound of the true significance. a. Lilliefors Significance Correction

The distribution of the scores was skewed or non-normal in most cases. The
results of Kolmogorov-Smirnov and Shapiro-Wilk tests indicated the non-normality of
the data. Kendall’s correlation coefficient, τ, was used to understand the correlation
between the variables. Kendall’s Tau is a non-parametric measure that also applies to a
small number of scores that rank in a similar manner.
Despite the non-normal characteristics of the variables, Kendall Tau correlation
results confirmed the observation from the Pearson’s correlation coefficients for the preFDA intervention. Question q0007-0001, regarding perceived behavioral control, had
non-significant correlations with any other variables with p values from 0.456 to 0.906.
However, the correlations were all negative when compared to the Pearson’ coefficients.
All other Kendall’s Tau correlations were significant including participant believes and
attitudes (q0005-001) for the pre-FDA intervention. In the case of the post-FDA scenario,
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Kendall’s Tau correlations maintained the same direction of the Pearson correlation and
also signaled q0027-0001 with non-significant correlations with all other variables. Table
10 and Table 11 present Kendall’s correlation coefficient, τ, for both the pre-FDA and
post-FDA interventions, respectively.
Table 10
Kendall’s Correlation pre-FDA Intervention

Kendall's tau
q0002_ Correlation Coefficient
0001
Sig. (2-tailed)

q0002_ q0003 q0004_ q0005_ q0006 q0007_ q0008 q0009
0001 _0001 0001
0001 _0001 0001 _0001 _0001
**
**
1.000 .837
.867
.749* .593
-.105
. .867**

N
q0003_ Correlation Coefficient
0001
Sig. (2-tailed)
q0004_ Correlation Coefficient
0001
Sig. (2-tailed)
q0005_ Correlation Coefficient
0001
Sig. (2-tailed)

.837

.

.006

.006

.018

.056

.726

.

.006

9

9

9

9

9

9

9

9

1.000

*

*

.453

-.107

.

.762*

.017

.032

.149

.724

.

.017

1.000

*

*

-.039

.012

.023

.901

1.000

*

**

.006

.

**

*

.867

.762

.762

.006

.017

.

*

*

*

.749

.018

.682

.826

.682
.826

.736
.736

. 1.000**
.

.

-.232

.

*

.826

.032

.012

.

.023

.456

.

.012

*

*

1.000

-.036

.

.736*

q0006_ Correlation Coefficient
0001
Sig. (2-tailed)

.593

.453

.056

.149

.023

.023

.

.906

.

.023

q0007_ Correlation Coefficient
0001
Sig. (2-tailed)

-.105

-.107

-.039

-.232

-.036

1.000

.

-.039

.726

.724

.901

.456

.906

.

.

.901

q0008_ Correlation Coefficient
0001
Sig. (2-tailed)

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

q0009_ Correlation Coefficient
0001
Sig. (2-tailed)

**

*

**

*

*

-.039

.

1.000

.023

.901

.

.

.867

.006

.762

.736

1.000

.017

**. Correlation is significant at the 0.01 level (2-tailed).
*. Correlation is significant at the 0.05 level (2-tailed).

.

.736

.826

.012

.736

119
Table 11
Kendall’s correlation post-FDA Intervention

Kendall's tau
q0022_ Correlation Coefficient
0001
Sig. (2-tailed)

q0022 q0023 q0024 q0025 q0026 q0027 q0028 q0029
_0001 _0001 _0001 _0001 _0001 _0001 _0001 _0001
1.000 .857*
.400 .807* .835* -.049 .770* .939**
.

.013

.244

.022

.017

.883

.034

.010

8

8

8

8

8

8

8

8

q0023_ Correlation Coefficient
0001
Sig. (2-tailed)

.857*

1.000

.333

.719*

.703*

-.094

.816*

.913*

.013

.

.322

.038

.040

.770

.022

.010

q0024_ Correlation Coefficient
0001
Sig. (2-tailed)

.400

.333

1.000

.588

.703*

.047

.544

.304

.244

.322

.

.089

.040

.884

.127

.393

q0025_ Correlation Coefficient
0001
Sig. (2-tailed)

.807*

.719*

.588

1.000

.700*

.222 .961**

.716

.022

.038

.089

.

.047

.503

.009

.051

q0026_ Correlation Coefficient
0001
Sig. (2-tailed)

.835*

.703*

.703*

.700*

1.000

-.092

.662

.770*

.017

.040

.040

.047

.

.779

.068

.034

q0027_ Correlation Coefficient
0001
Sig. (2-tailed)

-.049

-.094

.047

.222

-.092

1.000

.173

-.155

.883

.770

.884

.503

.779

.

.611

.649

q0028_ Correlation Coefficient
0001
Sig. (2-tailed)

.770*

.816*

.544

.961**

.662

.173 1.000

.745*

.034

.022

.127

.009

.068

.611

.

.049

q0029_ Correlation Coefficient
0001
Sig. (2-tailed)

.939**

.913*

.304

.716

.770*

-.155

.745*

1.000

.010

.010

.393

.051

.034

.649

.049

.

N

*. Correlation is significant at the 0.05 level (2-tailed).

**. Correlation is significant at the 0.01 level (2-tailed).
Analysis of Cronbach's alpha to determine the reliability of the scales from the
pilot study questionnaire was conducted for both scenarios: pre-FDA and post-FDA
interventions. The data was analyzed by applying SPSS and by using Field (2009) as a
reference. Cronbach's alpha is not a validity measure. The values for Cronbach’s alpha
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range from 0 to 1. Cronbach’s alpha provides the means to assess if a given scale item
impacts the overall total subscale reliability. Reversing the phrasing of a negative scale
item improved the Cronbach’s values. For the pre-FDA scenario in Table 12, the
Cronbach’s alpha was .800 which infers good reliability. For the post-FDA intervention,
Table 13 presented a Cronbach’s alpha with a value of .726.
Table 12
Cronbach’s alpha pre-FDA Intervention

Cronbach's alpha
.800

Cronbach's alpha Based on
Standardized Items
.909

N of Items
7

Table 13
Cronbach’s alpha pre-FDA Intervention

Cronbach's alpha
.726

Cronbach's alpha Based on
Standardized Items
.887

N of Items
8

Table 14 presented the SPSS function to identify the effect of the Cronbach’s
alpha if a given item was deleted for the pre-FDA scenario. The values in the last column
in Table 14 have a range from .714 to .953. The question q0007_0001, if removed, could
have a significant favorable impact in the overall Cronbach’s alpha from .800 to .953.
Also, in Table 14, all values for Corrected Item-Total Correlation represented the
correlations between each item and the total score. These correlation values need to be at
or above 0.3, as per Field (2009). In this subscale, all values are over 0.3 except for
q0007_0001. In the event of any value below 0.3, the item should be assessed, including
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being eliminated. Item q0007_0001 represented the concept that the person has no
perceived control in complying with the FDA regulations in the pre-FDA intervention.
Table 14
Cronbach’s Adjustments pre-FDA Intervention

q0002_
0001
q0003_
0001
q0004_
0001
q0005_
0001
q0006_
0001
q0007_
0001
q0009_
0001

Scale Mean if
Item Deleted
36.0000

Scale Variance if Corrected Item- Squared Multiple Cronbach's alpha
Item Deleted
Total Correlation
Correlation
if Item Deleted
27.250
.771
.904
.736

36.1111

25.111

.847

.957

.714

35.5556

30.028

.872

.998

.750

35.5556

32.528

.536

.982

.785

36.1111

26.861

.767

.939

.735

37.0000

30.500

.058

.500

.953

35.6667

27.000

.914

.998

.721

Table 15 presented the SPSS function to identify the effect of the Cronbach’s
alpha if a given item was deleted for the post-FDA scenario. The values in the last
column in Table 15 have a range from .649 to .859. The question q0027_0001, if
removed, could have a significant favorable impact in the overall Cronbach’s alpha from
.726 to .859. Also in Table 15, all values for Corrected Item-Total Correlation
represented the correlations between each item and the total score. These correlation
values need to be at or above 0.3, as per Field (2009). In this subscale, all values are over
0.3 except for q0027_0001. In the event of any value below 0.3, the item should be
assessed, including being eliminated. Item q0027_0001 represented the concept that the
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person has no perceived control in complying with the FDA regulations in the post-FDA
intervention.
Table 15
Cronbach’s adjustments post-FDA Intervention

q0022_0
001
q0023_0
001
q0024_0
001
q0025_0
001
q0026_0
001
q0027_0
001
q0028_0
001
q0029_0
001

Scale Mean if Item
Deleted
43.5000

Scale Variance if
Item Deleted
21.714

Corrected Item-Total
Correlation
.811

Cronbach's alpha if
Item Deleted
.649

44.0000

17.429

.502

.693

43.7500

22.786

.347

.713

43.3750

21.125

.924

.633

43.6250

21.982

.783

.654

45.1250

25.268

-.043

.859

43.2500

23.643

.920

.673

43.3750

24.268

.679

.688

Financial Indicators. The pilot study collected information regarding the
financial indicators of the firms. For comparison, the indicators prior and after the FDA
intervention or action were requested to the best recollection of the participants. The
requested information focused on the elements of decreased, no change, and increased.
The tables in the pilot study requesting the financial information scaled the responses to
ensure clarity on the responses.
The responses were collected from seven participants. The overall averages were
calculated to allow initial assessment of the clarity of the tables. Table 16 and Table 17
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below presents the averages of the responses. The averages projected the trend between
the prior and after the FDA intervention and actions.
Table 16
Before FDA: Financial Indicators
FNANCIAL OPERATING INDICATORS
COGS
Investment (Facility & Equipment)
Process compliance
Sales
Revenues
Averages
FINANCIAL INDICATORS
Actual sales (end of year prior to FDA)
Actual revenues (end of year prior to FDA)
Market values (end of year prior to FDA)
Stockholder's equity (end of year prior to FDA)
Averages

Decreased
14.3%
42.9%
28.6%
14.3%
14.3%
22.9%

No change
28.6%
28.6%
14.3%
42.9%
28.6%
28.6%

Increased
57.1%
28.6%
57.1%
57.1%
57.1%
51.4%

Decreased

No change

Increased

0.0%
0.0%
0.0%
0.0%
0.0%

28.6%
28.6%
28.6%
28.6%
28.6%

57.1%
57.1%
42.9%
57.1%
53.6%

Table 17
After FDA: Financial Indicators
FINANCIAL OPERATING INDICATORS
COGS
Investment (Facility & Equipment)
Process compliance
Sales
Revenues
Averages

Decreased
14.3%
0.0%
0.0%
14.3%
14.3%
8.6%

No change
28.6%
0.0%
0.0%
28.6%
28.6%
17.1%

Increased
57.1%
85.7%
85.7%
57.1%
57.1%
68.6%

FINANCIAL INDICATORS

Decreased

No change

Increased

0.0%
0.0%
0.0%
0.0%
0.0%

42.9%
28.6%
42.9%
42.9%
39.3%

57.1%
71.4%
57.1%
57.1%
60.7%

Actual sales (end of year after to FDA)
Actual revenues (end of after prior to FDA)
Market values (end of year after to FDA)
Stockholder's equity (end of year after to FDA)
Averages
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Reputation of the Firms and Management Changes. The last two questions in
the financial sections of the pilot study questionnaire requested the participants to provide
their opinion regarding two potential outcomes from the FDA interventions or actions.
These responses projected the impact on the firms’ reputation and the change
management process resulting from the FDA’s intervention or actions. Comparing results
in Table 18 and Table 19 allowed to conduct the assessment.
Table 18
Before FDA: Reputation and Management Change
Answer Options

Reputation of the
Firm
Management
change
answered question
skipped question

Decrease
of -50%
0

Decrease
of -5% to 49%%
1

0

0

No
Change
5
4

Increase of
+5% to
+49%%
1
5

Increase of +50%

Response
Count

0

7

0

7
7
2

Table 19
After FDA: Reputation and Management Change
Answer Options

Reputation of the
Firms
Management
change
answered question
skipped question

Decrease
of -50%
0

Decrease
of -5% to 49%%
2

0

0

No
Change
2
5

Increase of
+5% to
+49%%
3
2

Increase of +50%

Response
Count

0

7

0

7
7
2

FDA Experience. For the FDA experience of the firms, only six of the eight
completed questionnaires addressed the last six questions out of 44 total questions. This
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questions collected information regarding the firms experience with the FDA in the past
six years from 2010 through 2015. The six responders indicated that their firms had FDA
audits. The responses were assumed to be based on the best recollection of each of the
participants. In all years, the FDA issued 483 observations. In two events, the outcome of
the FDA intervention were audits with Official Action Indicated. On one occasion, the
FDA intervention consisted of a Warning Letter. To assess the overall result of the
responses, in the last two question the participants were asked to compare the firms’
compliance position with the FDA’s CGMP regulations before and after the FDA’s
interventions. The overall average reflected a favorable increase from 5.67 to 5.83 for a
favorable 2.8% increase in compliance with the FDA regulations.
Regression Analysis. Regression analyses were conducted to understand the
relationship between the financial indicators with the firms’ compliance position with the
FDA CGMP regulations. The financial indicators data were transformed within SPSS to
facilitate the linear equation. Seven financial indicators were included in the assessment.
Each indicator was considered as separate predictor model within SPSS analysis.
The assessment of the regression analysis was limited to 7 responses that made
difficult the analysis of the assumptions. For both scenarios, pre-FDA and post-FDA
interventions, multi-collinearity was the only assumption that could be confirmed as met.
None of the results for the F- ratio, t- test or ANOVA were significant indicating that
limited effectiveness of the model to predict the impact of the financial indicators in the
compliance of the firms. The lack of significance in the above tests could be used to
indicate that the model could not be used to generalize the outcome. The limited data
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could not be used to establish the heteroscedasticity assumption. The normal probability
plots indicated the non-normal distribution of variances for the pilot data.
Outcome from Pilot Study
The main outcome of the pilot study could be summarized in five points. First, the
concept of comparing the pre-FDA and post-FDA interventions was possible and
understood by the participants. Second, the open-ended questions provided important
elements to support the constructs of the TPB Likert-type questionnaire. The third point
referred to the effectiveness of the table approach to collect the financial indicators. The
table format was effective and led to the execution of the intended regression analysis
between these indicators and the dependent variable, compliance with the FDA
regulations. Regarding the fourth point, the pilot study data could not be used to finalize a
predicting model for the relation between compliance of the firms and the financial
indicators. Finally, the time to execute the pilot study was as planned and following the
IRB guidance including the approved consent form.
Final Study
The final study questionnaire consisted of four sections. The structure of the final
questionnaire although not identical followed the concepts of the pilot study. The first
sections related to the TPB initial assessment of attitudes, social influences, and
perceived behavioral controls prior to the FDA intervention in the pharmaceutical firms.
The first section also included a table to collect financial results of the firms before the
FDA intervention or action. The second section related to the TPB initial assessment of
attitudes, social influences, and perceived behavioral controls after the FDA intervention
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in the pharmaceutical firms including a table to collect financial results of the firms after
the FDA intervention or action. The intent of sections one and two was to identify
information before and after any FDA intervention in the firms. The third section
consisted of the demographics questions. Finally, the fourth section pursued clarification
on the experience with any FDA interventions or actions in the firms in the past five-six
years.
The instructions for the final study questionnaire in SurveyMonkey included an
initial question to allow the participant to proceed or stop their participation after reading
the instructions to the questionnaire. This question ensured the voluntary participation of
the person highlighting the understanding of the level of confidentiality and the positive
social benefit if participating in the study. The instructions were part of the
SurveyMonkey questionnaire. The number of questions in the main study questionnaire
were 133. The questions consisted of Likert-type scales and tables to select responses.
The numbers of questions in the final questionnaire were about three times more than in
the pilot questionnaire. The increase in the number of Likert-Type questions was driven
by the feedback from the open-ended questions from the pilot participants and the final
structure recommended by Ajzen (2016). Table 20 presents the questions distribution in
the final questionnaire.
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Table 20
Questions Final Questionnaire
Section

Scenario

First

Before the FDA

Number of Questions
61

Second

Before the FDA

61

Third

Demographics

6

Fourth

Experience with FDA

5
Total

133

The length of the final questionnaire turned out to be one of two major limiting
factors in the completeness of the questionnaires that were attempted by the participants
that decided to provide their information. Of the 45 participants that initiated the final
survey, only 21 completed the sections to the end. Feedback from several of these
participants was that the number of questions were too many. In some cases, the pre-FDA
and post-FDA scenarios were considered repeatable despite that it was indicated in the
instructions that this was part of the questionnaire structure to allow the comparison of
the pre-FDA and post-FDA scenarios. This concern of repeatability was highlighted by
one out of eight participants of the pilot study and was considered a threat by me.
Emphasis to highlight the confidentiality and the intended repeatability of questions in
the instruction did not prove to be effective in managing this factor regarding the survey
length.
The rate of participation in the final study based on 21 completed surveys was
1.9% from the original 1144 participants selected from the ISPE database following the
criteria of participants. If only the 79 participants that accepted to commence the survey
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are considered, the rate of initiating the survey on 21 completed surveys was 27.8%. The
low initiation rate of the survey was identified as the second major limiting factor for the
completeness of the final study where the target was to obtain about 160 versus 21
completed questionnaires for a performance of 13.1%. Although the pilot plant
participation was 38%, the final low participation in the final study was not expected.
The low participation and initiation rate impacted the data analysis and the basis
for judging the test of the hypotheses and the corresponding decisions regarding the null
statements. The data collected is presented and the potential null assessment was based
on the low rate of participation. Despite the consent form indicating the steps to protect
the confidentiality of the participants, I had no evidence to explain or conclude the low
participation and initiation rate at the stage of analyzing the data.
Population
The intended study population consisted of the pharmaceuticals firms that have
been impacted within the last five-six years by enforcement activities from the FDA in
the United States. The initial target were firms that had experienced FDA interventions
related to manufacturing CGMP violations. Since the data collection was directed to the
participants, the criteria for the pharmaceuticals firms also consisted in that they had
operations and that the firms were public companies.
The main criteria for the selection of participation was that the executives and
senior operational management of the pharmaceutical firms were expected to have the
authority to make compliance and financial decisions within the firms. The database of
potential participants was obtained from the members’ directory of the International
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Society of Pharmaceutical Engineers (ISPE). Sampling strategy targeted all ISPE
members that meet the criteria of participation. The self-disclosed title listed by the
members in the ISPE database was used for the determination of executives and
operational management.
Participants were selected by pharmaceutical firms, states, and alphabetical order
to create the participants’ Excel database. The participants’ e-mails as listed in the ISPE
database by the participants themselves were included in the Excel database. A total of
1144 participants were identified in the pharmaceutical firms within the USA. Finally, all
the pharmaceutical firms were confirmed to be public corporations by their participation
in a financial board disclosing stock market price to investors.
The survey for the final study commenced on February 12, 2016, and was closed
on April 19, 2016. Several reminders were sent in the first two weeks and after a second
review of the narratives by the IRB. The IRB second review lasted 38 days or half of the
time of the final study. Table 21 lists the message history of the final study regarding the
communication with the participants. A total of 5238 messages were sent requesting
participation and clarifying the need to have repeatable questions to cover the pre-FDA
and post-FDA interventions or actions.
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Table 21
Messages to Participants
Messages Sent

Date

Number of e-mails

Initial Invitation

2/12/2016

1144

First Reminder

2/15/2016

1052

Follow-up to Partials

2/17/2016

17

Second Reminder

2/20/2016

1022

Third Reminder

3/31/2016

987

Closure Note

4/13/2016

962

Closure note to Partials

4/16/2016

54

Total

5238

From the original 1144 invitations sent by using SurveyMonkey, 58 e-mails
bounced indicating that these e-mails were never received. An additional 50 participants
opted not to participate after reading the consent form. 608 of the invitations were opened
by the intended participants and no action was taken regarding their options to participate
or not to participate. 428 of the invitations were never opened by the recipients. Of the
608 invitations that were opened to read the consent form, 90 participants accepted the
consent form and proceeded to the survey. After reading the instruction, 79 of the 90
participants accepted to proceed to the questionnaire and 11 did not initiate the survey. Of
the 79 participants that moved to the first question of section one, only 45 initiated this
question. From the 45 participants that initiated the survey and after conducting the
missing data assessment, the participation results attained 21 completed surveys and 24
partial-completed survey. The 21 completed surveys provided a response rate of about
1.9% versus the original 1144 invitations. If the 79 participants are only considered, the
rate of participation was 27.8%.
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Data Collection
The final study was conducted following the same instrument of the pilot study.
The final study was administered through SurveyMonkey, an electronic survey tool
chosen to collect data and facilitate analysis. A consent form for participation was sent
via SurveyMonkey as approved by the Walden University’s IRB. Trust and desire to
participate was pursued through the narrative presented in the consent form including
access by the participant to Walden’s IRB office.
Of the 1144 SurveyMonkey invitations sent, 608 invitations were opened and 536
were either not recognized, e-mail bounced back, or the participant opted out of the
survey. Only 90 invitations accepted the consent from, but eleven participants decided
not to participate in the survey after reading the instructions. In addition, of the 79
participants that proceeded to read the first survey questions, only 45 initiated the
questions and 21 completed the survey’s 133 questions. The consent form with the
questionnaire instructions provided adequate space for the participants to voluntarily
decide if they would participate or not. With the 38% rate of participation in the pilot
study, the participation in the main study was expected to reach the initial target of 160
completed questionnaires out of about 1144 invitations with a projected rate of
participation of about 15%. The actual participation was 1.9% of the 1144 participants
selected form the ISPE database meeting the criteria of participants. Of the expected 160
completed surveys, only 21 surveys were completed with an additional 24 partially
completed surveys.

133
The data was collected and initially read through the SurveyMonkey analysis
section. I did not conduct any specific statistical analysis within the SurveyMonkey data
presentation. This data section was used to track the participation along the survey
period. The collected data was exported to SPCC for the data analysis of this final study.
The internal codification of SurveyMonkey was used to maintain and protect the
confidentiality of the participants.
Demographics
The demographics of the final study indicated a reasonable representation of the
role of responsibility and area of expertise within the selected participants. The
demographics questions where located on the third section of the final study. Appendix F
shows the percentage distribution of the relevant demographics. The decisions makers’
titles indicated the participation of managers, directors, vice-presidents, and one
executive. The educational level included high school diploma, bachelors, masters, MBA,
and doctorate degrees. The functional areas within the pharmaceutical firms represented
covered quality, manufacturing, engineering, and others like regulatory. The
demographics of the final study’s 21 participants ensured a representative source of
essential management behaviors that were incorporated to the Likert-type scaled of the
final questionnaire while recognizing the overall limited participation.
Data Treatment
The collected data in the final study was initially assessed via the results review
section through SurveyMonkey. The collected data was transferred to an SPSS data table
to facilitate the statistical assessments from correlations and regression analyses. The
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assessment within SurveyMonkey consisted mainly in tracking responses and the rate of
participation during the survey period. The SPSS database allowed to organize the
responses for the correlations analysis and the execution of the regression analyses of the
data for both the pre-FDA and post-FDA interventions and actions.
Data Analysis
The data analysis initial steps consisted on how to manage the data while
addressing shortfalls, like missing data and assumptions’ requirements. The low level of
completed responses limited the overall analysis. The first step was to develop a data
codebook (SPSS template) to store the data for all the variables and sampling details. The
database template was created in SPSS from the data transferred from SurveyMonkey.
The access to my laptop, it was password-protected to support confidentiality protecting
the access to the collected data and the SPSS data template. There was no need to crosscode any personal references from participants since the collected data from
SurveyMonkey provided reference numbers to enhance privacy and confidentiality of
participants.
The second step consisted of the cleaning of the data per the steps outlined by
Morrow (2009). Cleaning of the data refers to the process of minimizing biases and
calculation errors generated by the quality of the obtained data. A step-by-step approach
was followed for the SPSS analysis.
1. For the 45 original surveys that were initiated by participants, 24 surveys were
removed from the database since significant number of questions were not
completed by the participants.

135
2. For the remaining 21 surveys that answered questions in all the four sections of
the questionnaire, some questions were not answered by each participant.
Through SPSS, all missing data in the Likert-type scales were completed with the
corresponding average of each question. For the questions related to financial
indicators, any missing data was replaced with the response of “no change.” The
data was reviewed for each variable’s Likert-type questions in the SPSS template
to ensure that the suggested level of not more than 5% missing data was present
for each participant in each of the two Likert-type sections of the survey.
3. The Outliers’ scores were initially assessed with the intent to apply Windsorizing.
None of the Likert-type scores or financial data tables from the main study
required to apply the Windsorizing approach. In the SPSS analysis, for just
caution and only when requested a 2 sigma was applied.
4. The data was reviewed for each variable’s Likert-type questions in the SPSS
template to ensure that the suggested level of not more than 5% missing data was
present. If needed for less than 5% of the data, the estimated average of the data
was used to fill in the missing data. In the case of more than 5% missing data for a
given variable, the data for that participant was not included in the analysis.
5. For completed-usable responses, the participant had to complete over 95% of the
questions in either the pilot study or the main study including the demographics
and FDA compliance questions at the end.
6. For partial responses, an organized approached was implemented. This approach
consisted in the separation of the collected data in the SPSS template by each of
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the two scenarios: pre-FDA and post-FDA interventions. This process allowed to
consider those responses that only addressed the pre- scenario, but the participants
decided not to continue to complete the remainder of the questions.
7. Transforming the data by means of reversing the Likert-Type scores provided
alignment and proper assessment of the Cronbach’s alpha to assess the reliability
of the scales by section or construct of the TPB.
8. Linearity was verified by visually assessing the graphs of the data.
9. Verifying for multicollinearity was done within the SPSS application.
10. For homogeneity of regression, SPSS was used.
11. Linearity was initially verified by visually assessing the graphs of the data.
The application of regression analysis increased the complexity since two
scenarios pre-FDA and post-FDA interventions were assessed. Maintaining separation of
the data for the two scenarios within the SPSS template was important. The number of
the questions within SurveyMonkey provided the vehicle to maintain the separation of
the data for the two scenarios pre-FDA and post-FDA interventions. The application of
SPSS for the correlations analysis and all the corresponding assumptions of regression
analysis were considered in both scenarios: pre-FDA and post-FDA interventions.
Research Question 1 (RQ1). To what extent, if any, does management behaviors
(independent) correlate to compliance (dependent) with FDA regulations at the
pharmaceutical firms in the United States?
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 H1₀: r = 0. There is no difference in management behaviors towards
compliance at pharmaceutical firms, as a result of FDA enforcement actions in
the U.S.


H1₁: r ≠ 0. There are differences in management behaviors towards
compliance at pharmaceutical firms, as a result of FDA enforcement actions in
the U.S.

One method of assessing the predictability of behaviors is by applying the theory
of planned behavior. Ajzen (1991) developed TPB to provide a model of measuring
attitudes and dispositions to predict behavior. TPB infers the existence of a direct
relationship between intention and actual behavior. Also, attitudes and norms can explain
any behavior following the principles of TPB. The study applied TPB to understand and
predict the intention of pharmaceutical management to comply with the FDA regulations.
According to TPB, three types of beliefs direct and influence human behavior:
salient beliefs or attitudes (b), normative beliefs (n), and perceived behavioral control (c)
(Ajzen, 2002). The interrelations between these beliefs influence the intention towards a
given behavior. Intentions are the predecessors of behaviors (Ajzen, 1991). The relation
between intention and behavior depends on the strength of the attitude from behavioral
beliefs, the social pressures leading to subjective beliefs, and the level of perceived
control that the person has in front of the decision process. Actual behavioral control
results from the limitations or obstacles performing the intention. If adequate control
exists, an individual’s intention predicts the actual behavior, as a direct outcome. These
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constructs were incorporated into the Likert-type questions suggested by Fishbein and
Ajzen (2010) for the main survey questionnaire.
All Likert-type scales were selected by me to be unipolar (1 to 7) to avoid
potential biases by having a negative implication with ratings in a -3 to +3 scale. The first
section of the questionnaire was to assess the overall expected outcome regarding the
expected compliance with the FDA regulations pre-FDA and post-FDA interventions. A
total of 61 questions were included in this section for each scenario. Table 22 presents the
average and standard deviations for these Likert-Type questions for each participant. All
averages were skewed to the high side of the 1 to 7 Likert-type scales.
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Table 22
Outcome pre-FDA and post-FDA intervention
pre-FDA
Ave. outcome
6.7
5.6
5.0
6.9
6.4

SD
1.94
0.97
1.41
0.32
1.07

post-FDA
Ave.
Outcome
7.0
6.6
5.5
6.7
4.1

6
7
8
9
10
11

6.4
6.8
6.2
6.6
6.5
6.3

1.90
0.42
0.92
0.85
0.96
1.25

6.7
6.7
5.9
6.7
6.4
6.2

0.95
0.95
1.10
0.84
1.26
1.87

12
13
14
15
16
17

5.7
6.3
6.4
5.6
6.7
5.5

1.42
1.06
1.90
0.70
0.48
0.71

6.9
6.6
6.9
5.7
6.4
5.9

0.32
0.97
0.17
0.67
0.70
0.32

18
19
20
21

6.0
5.8
6.4
5.5

0.82
0.63
0.70
0.53

6.0
5.9
6.1
6.6

0.82
0.74
1.45
0.52

Participants
1
2
3
4
5

intervention

intervention
SD
0.00
0.97
0.97
0.48
0.88

The overall attitude regarding the beliefs was defined as the sum of the products
of the individual beliefs, b, and the corresponding strength, e (Fishbein and Ajzen, 2010).
The projected relation was based on A = Ʃ bᵢ * eᵢ. Letter A corresponds to the overall
attitude towards the given behavior. In the study, the overall behavior towards
compliance with the FDA regulations was the target. Tables 23 and 24 present the
calculation for the overall attitude A for both pre-FDA and post-FDA interventions.
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Table 23
Overall Attitude pre-FDA
Beliefs

Ave. b

SD

Ave. e

SD

Ave. be

SD

Max

Min

Cheaper

3.80

2.04

6.57

1.12

24.98

14.76

49

1

Reliable

6.10

0.94

5.38

1.07

33.26

9.86

49

1

Product quality

6.50

0.97

6.24

1.00

40.64

9.34

49

1

Supply

6.38

1.07

6.57

1.33

42.24

11.73

49

1

Competitive

6.00

1.34

6.81

0.51

41.10

10.05

49

1

Accomplishment

6.29

0.96

6.62

0.59

41.76

8.14

49

1

Effective

6.19

0.81

6.95

0.22

43.10

6.15

49

1

Information

6.33

1.02

5.76

0.94

36.67

9.06

49

1

Tension

4.30

2.08

6.67

0.58

29.15

14.98

49

1

Overworked

3.48

2.04

5.95

1.02

20.67

12.34

49

1

Attitude =

353.56

490

Table 24
Overall Attitude post-FDA
Ave. b

SD

Ave. e

SD

Ave. be

SD

Max

Min

Cheaper

Beliefs

3.80

1.89

6.76

0.70

25.31

12.59

49

1

Reliable

5.62

1.53

5.71

0.85

32.48

11.15

49

1

Product

6.05

1.43

6.86

0.36

41.71

10.86

49

1

Supply

6.14

1.20

3.95

2.13

23.67

13.27

49

1

Competitive

5.95

1.40

6.52

0.75

39.43

11.70

49

1

Accomplishment

6.19

0.98

6.62

0.59

41.19

8.45

49

1

Effective

6.00

0.95

6.81

0.51

41.05

8.04

49

1

Information

5.86

1.20

5.95

0.92

35.05

9.98

49

1

Tension

4.35

1.71

6.71

0.64

29.26

12.16

49

1

Overworked

3.45

1.86

5.86

1.06

20.39

12.01

49

1

Attitude =

329.53

490

The overall normative beliefs, N, was defined as the sum of the products of the
individual normative beliefs, n, and the corresponding strength, m (Fishbein and Ajzen.
2010). The projected relationship based on summarized N = Ʃ nᵢ * mᵢ. Letter N
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corresponds to the overall attitude towards the given normative belief towards a behavior.
In the study, the overall behavior towards compliance with the FDA regulations was the
target. Table 25 and Table 26 present the calculation for the overall normative beliefs N
for both pre-FDA and post-FDA interventions.
Table 25
Overall Normative Belief pre-FDA
Normative

Ave. B

SD

Ave. e

SD

Ave.
Be

SD

SR MGT
PEERS
BUSS ASSOC
DIRECT/MAN
SUP
PARENTS
FRIENDS
SR MGT
BUSS ASSOC
BUSS ASSOC

7.00
6.81
6.76
6.81
6.86
4.10
3.95
6.95
6.67
6.14

0.00
0.40
0.62
0.51
0.36
2.41
2.33
0.22
0.66
1.56

6.86
5.71
5.81
6.86
6.86
5.48
5.71
6.86
5.81
5.81

0.48
1.62
1.25
0.48
0.48
2.06
1.62
0.48
1.25
1.25

48.00
38.86
39.33
46.86
47.14
25.14
24.19
47.76
39.10
35.86

3.35
11.19
9.33
5.60
5.03
17.80
16.58
4.35
10.33
12.41

Normative =

392.24

Ma
x

Mi
n

49
49
49
49
49
49
49
49
49
49

1
1
1
1
1
1
1
1
1
1

490

Table 26
Overall Normative Belief post-FDA
Normative

Ave. n

SD

Ave. m

SD

Ave. nm

SD

Max

Min

SR MGT

6.48

0.68

6.71

0.72

43.62

7.12

49

1

PEERS

6.71

0.46

5.90

1.04

39.82

8.56

49

1

BUSS ASSOC

6.48

1.21

5.43

1.54

35.19

12.40

49

1

DIRECT/MAN
SUP

6.71

0.56

6.71

0.72

45.19

6.74

49

1

6.81

0.40

6.71

0.72

45.86

6.36

49

1

PARENTS

3.81

2.66

4.48

2.44

21.95

19.59

49

1

FRIENDS

4.15

2.22

5.90

1.04

25.09

14.96

49

1

SR MGT

6.95

0.22

6.71

0.72

46.75

5.68

49

1

BUSS ASSOC

6.32

0.78

5.43

1.54

34.74

12.42

49

1

BUSS ASSOC

5.53

1.91

5.43

1.54

15.06

49

1

Normative =

30.18
368.39

490
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The overall perceived control behaviors, PBC, was defined as the sum of the
products of the individual perceived control beliefs, p, and the corresponding strength, c
(Fishbein & Ajzen, 2010). The projected relationship was based on PBC = Ʃ pᵢ * cᵢ.
Letters PBC correspond to the overall attitude towards the given perceived behavioral
control towards a behavior. In the study, the overall behavior towards compliance with
the FDA regulations was the target. Table 27 and Table 28 present the calculation for the
overall perceived behavioral control PBC for both pre-FDA and post-FDA interventions.
Table 27
Overall PBC pre-FDA
Control

Ave. p

SD

Ave. c

SD

Ave. pc

SD

Max

KNOWLEDGE

3.14

2.22

3.65

2.17

9.75

8.81

49

KNOWLEDGE

6.90

0.30

3.65

2.17

25.12

15.09

49

EVENTS

3.29

1.59

6.33

0.86

21.43

11.83

49

FEEL

5.50

1.47

6.38

0.97

35.93

12.41

49

FAMILY

4.80

1.81

6.29

0.96

31.03

13.51

49

GOALS

4.65

1.53

6.05

1.40

27.45

10.55

49

BUDGET

4.24

2.14

6.00

1.30

26.10

15.14

49

DATELINES

3.29

2.19

6.00

1.30
Attitude =

18.67
195.47

13.10
392

49

Min
1
1
1
1
1
1
1
1
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Table 28
Overall PBC post-FDA
Control

Ave. p

SD

Ave. c

SD

Ave. pc

SD

Max

Min

KNOWLEDGE

3.95

2.13

3.48

2.16

12.24

9.37

49

1

KNOWLEDGE

6.71

0.64

3.48

2.16

23.24

14.90

49

1

EVENTS

3.81

1.50

5.62

1.86

22.29

12.02

49

1

FEEL

5.40

1.43

5.75

1.61

31.91

13.52

49

1

FAMILY

5.10

1.73

5.75

1.64

30.10

14.60

49

1

GOALS

3.55

1.77

5.75

1.51

19.07

9.59

49

1

GOALS

4.79

1.75

5.50

1.88

27.09

14.77

49

1

DATELINES

3.19

2.04

5.50

1.88

16.45

11.80

49

1

Control =

182.38

392

On Table 29, the summary of the results was listed for both the pre-FDA and
post-FDA interventions. The maximum value for each construct was included. Also, the
percent of the maximum attained by each construct was listed. Although the average
outcome tended to be slightly higher towards compliance from 88% to 90%, the TPB
constructs tended to be 3-5% lower for the post-FDA intervention versus the maximum
points to be attained in each scale.
Table 29
Overall Results for TPB constructs

Pre-FDA
Post-FDA
Max
Pre-FDA
Post-FDA

Outcome
6.16
6.27
7
88%
90%

A
353.56
329.53
490
72%
67%

N
392.24
368.39
490
80%
75%

PBC
195.47
182.38
392
50%
47%
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This data indicated that the probable effect of the FDA intervention in the
participants’ behavior was inversed. While the expected outcome of compliance was
improved, the impact on the behavioral constructs were negative. Although the
participants’ beliefs of being in compliance was reduced after the FDA intervention, the
lost in influence from peers’ opinions and the reduction on the influence of perceived
controls provided a final favorable impact on the outcome of enhanced compliance with
FDA regulations. These trends allowed for a better compliance expectation after the FDA
intervention.
An attempt to assess if a prediction could be obtained from the three constructs of
behavior regarding the responses to the outcome of compliance by the participants,
correlation analyses were conducted for both scenarios, pre-FDA and post-FDA
interventions. Also, following the TPB, a linear regression analysis was performed using
SPSS to generate and assess if prediction models could be applied to compare both
scenarios. For the regression analysis, the SPSS forced entry approach was used to
present the contribution to the model. The order of the constructs followed the TPB order
of beliefs (attitudes), normative beliefs, and perceived behavior controls (PBC).
Considering the small number of participants, skewness and kurtosis were used to
assess the distribution of the variables. In the scenario of pre-FDA intervention, the
skewness results were negative indicating that there was a cluster at the higher end of the
scales (Field, 2009). Kurtosis was used to measure the degree to which scores cluster in
the tails of a frequency distribution. For the pre-FDA, the kurtosis’ values were positive
and negative. Positive kurtosis values indicated that the distribution tended to peak at the
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tails due to the high number of scores in the tail. Negative kurtosis values signaled few
scores in the tails and a flat distribution (Field, 2009). In the scenario of post-FDA
intervention, the skewness results were also negative indicating that there was a cluster at
the higher end of the scales (Field, 2009). The kurtosis’ values were also positive and
negative.
The four variables were also assessed for their characteristics as a normal or nonnormal distribution. Kolmogorov-Smirnov and Shapiro-Wilk results were obtained in
SPSS. The results of the Kolmogorov-Smirnov and Shapiro-Wilk tests for the pre-FDA
intervention were all non-significant implying that the distribution of the four variables
were normal. See Table 30.
Table 30
Tests of Normality pre-FDA
Kolmogorov-Smirnova

Outcome_pre

Shapiro-Wilk

Statistic

df

Sig.

Statistic

df

Sig.

.180

21

.073

.936

21

.181

*

.984

21

.972

Beliefs_pre

.096

21

.200

Normative_pre

.176

21

.089

.922

21

.096

*

.976

21

.860

Control_pre
.123
21
* This is a lower bound of the true significance.
a. Lilliefors Significance Correction

.200

For the post-FDA intervention in Table 31, the results for Kolmogorov-Smirnov
and Shapiro-Wilk tests are illustrated. Results were non-significant indicating a tendency
to normal distribution for three independent variables: beliefs (attitude), normative
beliefs, and perceived behavioral control. For the dependent variable outcome of
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compliance, the Shapiro-Wilk tests indicated a significant correlation indicating a nonnormal distribution different from the pre-FDA scenario.
Table 31
Tests of Normality post-FDA
Kolmogorov-Smirnova

Outcome_post
Beliefs_post
Normative_post

Shapiro-Wilk

Statistic

df

Sig.

Statistic

df

Sig.

.173

21

.099

.830

21

.002

21

.200

*

.971

21

.758

.200

*

.933

21

.160

.200

*

.973

21

.800

.124
.155

21

Control_post
.107
21
* This is a lower bound of the true significance.
a. Lilliefors Significance Correction

Pearson’s coefficient correlation was utilized to understand the internal
consistency of the Likert-type scales by establishing how close the different elements of
the scales are to each other. Also, the correlation between each subset of the construct
was obtained and listed to establish the dependencies within each construct. Table 32
presents the Pearson correlation for the pre-FDA intervention. The construct of beliefs
(attitudes) had the highest correlation with the outcome of compliance with a value of r =
0.633, p < 0.01. The other two construct, normative beliefs and perceived behavioral
control had non-significant correlations with r values of r = 0.328 and r = 0.183,
respectively.
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Table 32
Pre-FDA Correlations
Outcome_pre
Outcome_pre

Pearson
Correlation

1

Sig. (1-tailed)
Beliefs_pre

Normative_pre

Control_pre

Beliefs_pre Normative_pre
.633**
.328

Control_pre
.183

.001

.073

.213

21
1

21
.328

21
.243

.001
.328

.328

.074
1

.144
-.127
.292
1

N
Pearson
Correlation
Sig. (1-tailed)
Pearson
Correlation
Sig. (1-tailed)
Pearson
Correlation

21
.633**

.073
.183

.074
.243

-.127

Sig. (1-tailed)

.213

.144

.292

**. Correlation is significant at the 0.01 level (1-tailed).

Table 33 presents the Pearson’s correlation for the post-FDA intervention. The
construct of beliefs (attitudes) also had the highest correlation with the outcome of
compliance with a value of r = 0.693, p < 0.01. The other two construct, normative
beliefs and perceived behavioral control had non-significant correlations with r values of
0.294 and 0.303, respectively. Also, the construct of behavioral beliefs had a significant
correlation with the construct of perceived behavioral control with r = 0.376, p < 0.05.
This last significant correlation differed from the pre-FDA intervention where the
correlation was non-significant between these two constructs.
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Table 33
Post-FDA Correlations

Outcome_post

Pearson
Correlation

Outcome_post Beliefs_post
1
.693**

Sig. (1-tailed)
Beliefs_post

Normative_post

Control_post

Normative_pos
t
Control_post
.294
.303

.000

.098

.091

N
Pearson
Correlation
Sig. (1-tailed)
Pearson
Correlation
Sig. (1-tailed)
Pearson
Correlation

21
.693**

21
1

21
.332

21
.376*

.000
.294

.332

.071
1

.046
-.268

.098
.303

.071
.376*

-.268

.120
1

Sig. (1-tailed)

.091

.046

.120

**. Correlation is significant at the 0.01 level (1-tailed).
*. Correlation is significant at the 0.05 level (1-tailed).

The correlation data indicated a favorable change in correlation between the
outcome of compliance and beliefs (attitude) for before and after the FDA intervention of
about 9.5%. The value of r increased from 0.633 to 0.693 for the construct of beliefs
(attitude) towards compliance by the participants with significances of p < 0.01. The
other two independent constructs had non-significant correlations. The perceived
behavioral control non-significant correlation with the outcome of compliance also
increased by about 65% from the pre-FDA (r = 0.183) to the post-FDA scenario (r =
0.303). From the limited population that participated in the study, the null hypothesis was
rejected for RQ1.
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A regression analysis was conducted to establish a model with the TPB constructs
as predictors of the outcome of compliance of the firms with the FDA regulations. The
regression analyses were performed using SPSS for both scenarios: pre-FDA and postFDA. All assumptions were assessed to understand the robustness of the models.
For regression analysis, there were several assumptions that needed to be met
(Field, 2009). Meeting the assumptions allowed assessing if the conclusions were true for
a wider population. For a regression model to generalize beyond the sample population,
assumptions have to be met. The assumptions were assessed for each scenario: pre-FDA
and post-FDA interventions. The assessment was as follows:
1. Variable types: All predictor variables were quantitative or categorical (with
two categories), and the outcome variable was quantitative: continuous and
unbounded.
2. Non-zero variance: The predictors should had variation in value. They did not
have variances of 0.
3. Sample Size: The ratio of predictors to cases was expected to be significant
because of its impact on the value of R. This assumption was not met.
4. No perfect multicollinearity: There was no perfect linear relationship between
two or more of the predictors. The predictor variables did not highly
correlated.
5. Predictors are not correlated with external variables: External variables could
be present. In the model, not all contribution that could significantly influence
the outcome was identified. This assumption was not met.
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6. Homoscedasticity: At each level of the predictor variable(s), the variance of
the residual terms were constant. The SPSS graphs supported this assumption.
7. Independent errors: For any two observations the residual terms should be
independent. This assumption tested whether adjacent residuals are correlated.
The test statistic was allowed to vary between 0 and 4 with a value of 2
meaning that the residuals were uncorrelated.
8. Normally distributed errors: This assumption indicates that the differences
between the model and the observed data are most frequently zero or very
close to zero. The SPSS graphs did not support this assumption.
9. Independence: All of the values of the dependent variable were independent
of each other.
10. Linearity: The mean values of the dependent variable were represented in a
reasonable spread indicating a straight line. Assumption met.
The dependent variable was the outcome of compliance as indicated in the main
survey by the participants in the Likert-type scales for the TPB section. The values of the
behavioral construct variables were the values of the beliefs with the influence of the
corresponding strengths. For beliefs (attitude), the average product of b*e was used. For
normative beliefs, the average product of n*m was used. For perceived behavioral control
(control), the average product of p*c was used. This approached allowed to have a direct
relation in the model with the beliefs in each of the three constructs. The values of the
variables are presented in Table 34 for the pre-FDA scenario and post-FDA scenario.
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Table 34
Pre-FDA and Post-FDA scenario
pre-FDA behavioral constructs

post-FDA behavioral constructs

Participants

Ave. O

Ave. be

Ave. nm

Ave. pc

Ave. O

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

6.7
5.6
5.0
6.9
6.4
6.4
6.8
6.2
6.6
6.5
6.3
5.7
6.3
6.4
5.6
6.7
5.5
6.0
5.8
6.4
5.5

36.1
37.1
22.0
37.3
34.9
42.7
44.1
36.9
41.4
33.3
30.5
34.5
31.9
45.5
25.0
31.9
27.7
38.6
28.6
35.5
33.5

40.8
30.7
22.4
45.2
33.2
42.5
30.5
44.6
49.0
45.2
36.0
41.5
40.0
41.4
33.3
39.3
46.5
42.6
40.1
46.5
47.7

32.9
24.0
19.4
24.8
9.6
34.0
39.3
15.1
18.8
28.5
20.3
29.6
25.0
20.3
34.1
20.9
12.8
32.5
25.1
21.9
20.9

7.0
6.6
5.5
6.7
4.1
6.7
6.7
5.9
6.7
6.4
6.2
6.9
6.6
6.9
5.7
6.4
5.9
6.0
5.9
6.1
6.6

Ave. be

Ave. nm

36.8
32.4
21.4
34.9
24.4
35.2
42.0
23.6
38.2
34.4
29.8
32.3
35.8
44.8
25.6
33.7
26.7
40.6
29.8
35.0
34.6

27.4
32.0
22.1
44.5
27.7
33.1
24.7
34.4
45.5
44.8
32.5
37.8
38.6
40.6
24.6
41.3
48.3
41.7
41.0
44.2
46.9

Ave. pc
25.9
15.8
23.9
21.3
15.5
26.3
29.4
23.4
21.9
30.0
26.3
26.0
24.5
22.8
25.5
20.6
12.8
32.6
17.6
20.9
16.0

In the next step, the possible predicting models were evaluated for both FDA
scenarios. A model in a forced order was developed in SPSS for each scenario. Table 35
presents the model for the pre-FDA scenario. The correlation R between the variables and
the prediction R2 of how much of the dependent variable is contributed by each predictor
were obtained. Also, the assumption of independent errors was verified with the Durbin–
Watson statistic. The value of 2.21 was obtained, indicating that the assumption of
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independent errors could be considered as met. About the external variables, the R2
values of model 1 indicated that the predictors accounted for about 42% contribution to
the outcome variable, indicating that there were other external variables not included,
violating this assumption.
Table 35
Pre-FDA Model b
Change Statistics

Model
1

R
.649a

R
Adjusted
Square R Square

Std. Error
of the
Estimate

R Square
Change

F

Sig. F

Change df1 df2 Change

.421
.318
.42625
.421
4.115
a. Predictors: (Constant), Control_pre, Normative_pre, Beliefs_pre
b. Dependent Variable: Outcome_pre

3

17

DurbinWatson

.023

2.210

The adjusted R2 provided a way to understand how well the model could
generalize the scenario under review. The smallest the difference of the adjustment the
better the possibility for the model to represent the population, not just the sample. In
model 1, the value of R2 was 00.421 and was adjusted to about 32% for the contribution
of the three constructs. The F- ratio indicated the significance of the change with p <
0.05.
For the post-FDA scenario, the three TPB constructs were introduced in a forced
order as developed in SPSS. Table 36 presents the model for the post-FDA scenario.
Also, the assumption of independent errors was verified with the Durbin–Watson
statistic. The value of 2.066 was obtained, indicating that the assumption of independent
errors could be considered as met. About the “external variables,” the R2 values of model
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1 indicated that the predictors accounted for about 49% contribution to the outcome
variable, indicating that there are other external variables not included, violating this
assumption.
Table 36
Model b Summary post-FDA
Change Statistics
Adjusted
Mode
R
R
l
R Square Square
1
.701
.492
.402
a

Std. Error
R
of the
Square
F
Sig. F
Estimate
Change Change df1 df2 Change Durbin-Watson
.50620
.492
5.481
3
17
.008
2.066

a. Predictors: (Constant), Control_post, Normative_post, Beliefs_post
b. Dependent Variable: Outcome_post

The adjusted R2 provided a way to understand how well the model could
generalize the scenario under review. The smallest the difference of the adjustment the
better the possibility for the model to represent the population, not just the sample. In
model 1, the R2 = 0.492 was adjusted to 40.2% representing the adjustment to the overall
contribution of the three variables. The F-ratio provided the significance of the change, p
< 0.01.
The ANOVA challenged whether the models were better predictors of the
outcome than the guess based on the average means. The F-ratio indicated the ratio of the
accuracy of the model versus the means (Field, 2009). All values of F were lower above
one signaling that the model’s fits were good predictors than the guess from the means.
The models for both scenarios (pre-FDA and post-FDA) had an F-ratio that were
significant (p < 0.05) indicating that the outcome could unlikely happen by chance.
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The model parameters were then obtained by SPSS. Table 37 presents the slope
values, B, for each predictor (TPB constructs). Only beliefs had a significant value of p <
0.05. None of the other construct had a significant (p < 0.05) indicating a weak
contribution to the outcome. The smallest the significance of the B values the stronger the
contribution of the prediction to the outcome (Field, 2009). Regarding the standardized
beta (labeled as Beta, β), beliefs (β = 0.568), had the largest impact on the standard
deviation of the outcome of behavior towards compliance. The other two standardized
beta (labeled as Beta, β) were normative beliefs (β = 0.150) and PBC (β = 0.065).
Table 37
Models’ Parameters a pre-FDA
Unstandardized
Coefficients

Standardized
Coefficients

B
3.903

Std. Error
.742

Beta

t
5.259

Sig.
.000

Beliefs_pre

.049

.018

.568

2.769

.013

Normative_pre

.012

.015

.150

.750

.463

Control_pre

.004

.013

.065

.331

.745

Model
1
(Constant)

To assess how close is the B value of the sample to the B value of the population,
a level of confidence of 95% was selected. See Table 38. Only one of the constructs
(beliefs) had a spread between the upper and lower boundaries of the confidence limit not
crossing the value of zero implying that the construct was strong for the prediction of the
outcome of the model. Regarding the Collinearity Statistics, VIF values were all close to
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1.0 and tolerances were below 1.0. These results indicated that the models met the
assumption of collinearity.
Table 38
Models’ Parameters a pre-FDA
95.0%
Confidence
Interval for B

Collinearity
Statistics

Correlations

Lower
Bound
2.337

Upper
Bound
5.469

Zeroorder

Partial

Part

Tolerance

VIF

Beliefs_pre 2.769 .013

.012

.086

.633

.558

.511

.810

1.234

Normative_
pre

Model
1
(Constant)

t
Sig.
5.259 .000
.750

.463

-.021

.044

.328

.179

.139

.847

1.180

Control_pre .331

.745

-.024

.032

.183

.080

.061

.893

1.119

For the post-FDA scenario, Table 39 presents the slope values, B, for each
predictor (TPB constructs). Only beliefs had a significant value of p < 0.05. None of the
other construct had a significant (p < 0.05) indicating a weak contribution to the outcome.
The smallest the significance value, the stronger the contribution of the prediction to the
outcome (Field, 2009). Regarding the standardized beta (labeled as Beta, β), beliefs (β =
0.614), had the largest impact on the standard deviation of the outcome of behavior
towards compliance. The other two standardized beta (labeled as Beta, β) were normative
beliefs (β = 0.118) and PBC (β = 0.104).
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Table 39
Model Parameters a post-FDA

Unstandardized Coefficients
Model
1
(Constant)

Standardized
Coefficients

B
3.456

Std. Error
.858

Beta

t
4.031

Sig.
.001

Beliefs_post

.065

.023

.614

2.877

.010

Normative_post

.010

.017

.118

.576

.572

Control_post

.013

.026

.104

.499

.624

To assess how close is the B value of the sample to the B value of the population,
a level of confidence of 95% was selected. See Table 40. Only one of the constructs
(beliefs) had a spread between the upper and lower boundaries of the confidence limit not
crossing the value of zero implying that the construct was strong for the prediction of the
outcome of the model. Regarding the Collinearity Statistics, VIF values were all close to
1.0 and tolerances were below 1.0. These results indicated that the models met the
assumption of collinearity.
Table 40
Model Parameters a post-FDA

4.031

95.0% Confidence
Interval for B
Correlations
Lower
Upper ZeroBound
Bound order Partial
.001
1.647
5.266

Beliefs_post

2.877

.010

.017

.113

.693

.572

.498

.657

1.523

Normative_p
ost

.576

.572

-.025

.045

.294

.138

.100

.710

1.409

Control_post

.499

.624

-.043

.069

.303

.120

.086

.685

1.460

Sig.
Model
1
(Constant)

Collinearity
Statistics
Part

Tolerance

VIF
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To further assess the assumption of collinearity, a diagnostic was performed by
SPSS for both scenarios: pre-FDA and post-FDA. In both scenarios, all Eigenvalue were
below one. Only Eigenvalues below 1 were considered for the assessment of collinearity.
For the pre-FDA, the three constructs had their highest values in different dimensions for
the test of Variance Proportions. For the post-FDA, the three constructs also had their
highest values in different dimension also meeting the assumption of no multicollinearity.
The next step was to assess if any case had a significant influence or should be
considered as an outlier. Using SPSS, the case summary analysis was applied to both
scenarios: pre-FDA and post-FDA. The Mahalanobis Distance values did not show any
case to be of concerned. The Cook’s number expect for one (case 5) were below 1.0. But,
the Centered Leverage Values were all within the three times the expected value of 0.57.
None of the cases were excluded from the Cook’s numbers and DFBeta calculations by
SPSS indicating no undue influence from any of the cases in the model. In the post-FDA
scenario, all cases were included with values of Cook of +/-1.
All the values of DFBeta except case 5 and case 17 in the post-FDA were beyond
+/-1 but less than two implying that all other cases could be considering not having undue
influence in the regression models. For case 5 (post-FDA) and case 17 (post-FDA), the
Centered Leverage Values were within expectation leading to accept both cases as not
having undue influence in the model. Regarding the covariance ration, CVR, the limits of
1.57 and -0.42. All cases were within or not significantly apart from these values. Case 8
had a value of 2.0 but its Cook’s and Centered Value were well within expectations. No
case was found to have an undue influence in the model.
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For the assumptions of linearity and homoscedasticity, the plots assessed under
SPSS could be considered as supporting these assumptions. For the residual normality,
the graphs for both scenario had a subtle separation form the straight line implying lack
of normality. Since not all assumptions were met, the regression model for TPB cannot
be used to generalize beyond the sample of the study in either the pre-FDA or the postFDA intervention.
Research Question 2 (RQ2). To what extent, if any, do financial indicators
(independent) correlate to compliance (dependent) with FDA regulations at the
pharmaceutical firms in the United States?


H2₀: r = 0. There is no difference in compliance with FDA related to financial
indicators at pharmaceutical firms, as a result of FDA enforcement actions in
the U.S.



H2₁: r ≠ 0. There are differences in compliance with FDA related to financial
indicators, as a result of FDA enforcement actions in the U.S.

Seven correlations were performed with the seven financial indicators to
understand the possible correlations between these indicators and the dependent variable
outcome of compliance for each scenario: pre-FDA and post-FDA interventions. The
seven financial indicators for the test of Hypothesis 3 were the cost of goods, investment
in facility and equipment, process compliance, actual sales, actual revenues, market
value, and stockholder’s equity. The basis of the correlations was the firms’ level of
compliance as indicated by the participants both before and after the FDA intervention.
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The main study collected information regarding the financial indicators of the
firms. For comparison, the indicators prior and after the FDA intervention or action were
requested to the best recollection of the participants. The requested information focused
on the elements of decreased, no change, and increased. The tables in the study
requesting the financial information scaled the responses to ensure clarity on the
responses.
The financial responses were collected from the 21 participants. The overall
averages were calculated to allow initial assessment of the clarity of the tables. Table 41
below presents the averages of the responses for the pre-FDA scenario.
Table 41
Pre-FDA: Financial Indicators
FINANCIAL OPERATING INDICATORS
COGS

Decreased
14.3%

No change
61.9%

Increased
23.8%

4.8%

28.6%

66.7%

Process compliance
Averages

42.9%
20.7%

47.6%
46.0%

9.5%
33.3%

FINANCIAL INDICATORS

Decreased

No change

Increased

Actual sales (end of year prior to FDA)

47.6%

47.6%

4.8%

Actual revenues (end of year prior to FDA)

42.8%

52.4%

4.8%

Market values (end of year prior to FDA)

4.8%

42.9%

52.4%

Stockholder's equity (end of year prior to FDA)

14.3%

47.6%

38.1%

27.4%

47.6%

25.0%

Investment (Facility & Equipment)

Table 42 presents the responses for the post-FDA scenario. The average response
of the participants indicated that the financial indicators increased from the pre-FDA to
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the post-FDA intervention. The results showed that the financial operating indicators
“increased” from pre-FDA 33.3% to post-FDA 54.1%. The participants also indicated
that the financial indicators “increased” from pre-FDA 25 to post-FDA 38%. The
averages projected an increasing trend for financial indicators between the prior and after
the FDA intervention and action.
Table 42
Post-FDA: Financial Indicators
FINANCIAL OPERATING INDICATORS
COGS
Investment (Facility & Equipment)
Process compliance
Averages

Decreased
14.3%
9.5%
0.0%
7.9%

No change
52.4%
28.6%
42.9%
41.3%

Decreased

No change

Actual sales (end of year after to FDA)

4.8%

47.6%

47.7%

Actual revenues (end of after prior to FDA)

4.8%

47.6%

47.7%

Market values (end of year after to FDA)

14.3%

53.4%

33.3%

Stockholder's equity (end of year after to FDA)
Averages

19.0%
10.7%

57.1%
51.4%

23.8%
38.12%

FINANCIAL INDICATORS

Increased
33.3%
61.9%
67.1%
54.1%

Increased

To understand the distribution of the financial data, within the SPSS calculation,
the skewness and the kurtosis were obtained. In both scenarios of pre-FDA and post-FDA
interventions, the skewness results were all positive indicating that there was a cluster at
the left end of the scales (Field, 2009). Kurtosis was used to measure the degree to which
scores cluster in the tails of a frequency distribution. Kurtosis’ values were positive for
all the financial indicators on both scenarios. Positive kurtosis values indicates that the
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distribution tends to peaked at the tails due to the high number of scores in the tail.
Negative kurtosis values signals few scores in the tails and a flat distribution (Field,
2009).
The non-normal distribution in all the financial indicators were significant as
confirmed by indicated by the calculations for Kolmogorov-Smirnov and Shapiro-Wilk in
SPSS. All values for both scenarios were significant [(K-S): p < 0.001 and (S-W): p <
0.005] confirming that none of the financial indicators had a normal distribution. Table
43 shows the results of the Kolmogorov-Smirnov and Shapiro-Wilk tests for the pre-FDA
intervention. For the post-FDA intervention in Table 44, the results for KolmogorovSmirnov and Shapiro-Wilk tests were illustrated.
Table 43
Test of Normality pre-FDA Intervention
Kolmogorov-Smirnova
COGS_pre
Investment_fac_equip_pre
Compliance_pre
Sales_pre
Revenues_pre
Act_sales_pre
Act_revenues_pre
Market_value_pre
Stockholders_pre

Statistic
.322
.288
.273
.325
.325
.307
.312
.282
.252

a. Lilliefors Significance Correction

df
21
21
21
21
21
21
21
21
21

Sig.
.000
.000
.000
.000
.000
.000
.000
.000
.001

Shapiro-Wilk
Statistic
.779
.856
.774
.749
.749
.739
.742
.827
.796

df
21
21
21
21
21
21
21
21
21

Sig.
.000
.005
.000
.000
.000
.000
.000
.002
.001
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Table 44
Test of Normality post-FDA Intervention
Kolmogorov-Smirnova

Shapiro-Wilk

Statistic

df

Sig.

Statistic

df

Sig.

COGS_post

.277

21

.000

.797

21

.001

Investment_fac_equip_post

.377

21

.000

.697

21

.000

Compliance_post

.372

21

.000

.633

21

.000

Act_sales_post

.282

21

.000

.827

21

.002

Act_revenues_post

.282

21

.000

.827

21

.002

Market_value_post

.277

21

.000

.797

21

.001

Stockholders_post

.290

21

.000

.800

21

.001

a. Lilliefors Significance Correction

Despite the non-normal distribution, the Pearson Correlation was performed to
understand the possible correlation between the financial indicators for each scenario:
pre-FDA and post-FDA interventions. The basis of the correlations was the firms’ level
of compliance as indicated by the participants both before and after the FDA intervention.
The intent was to establish if there was a correlation between any of the financial
indicators with the level of compliance of the firms on both scenarios.
Of the seven financial indicators, the compliance of the firms prior to the FDA
intervention had a significant correlation at p < 0.05 with three of them considering a
one-tailed assumption due to the skewness of the data in the responses. Investment in
facility and equipment (r = |-0.468|, p < 0.05), compliance expenses (r = |-0.558|, p <
0.05), and stockholders’ equity (r = 0.392, p < 0.05) were significantly correlated to
compliance. In addition, facility and equipment and compliance expenses were
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significantly correlated to actual sales, actual revenues, and market value at p < 0.01.
Table 45 and 46 present the Pearson Correlation information for the pre-FDA and postFDA scenario, respectively.
Table 45
Pearson Correlations (pre-FDA)

q0133_000 Pearson
1
Correlation

Stock
q0133
Investment compli
Act_re Marke holde
_00 COGS _fac_equip ance_p Act_sales venues t_valu rs_pr
01
_pre
_pre
re
_pre
_pre e_pre
e
*
**
1 -.259
-.468 -.558
-.061 -.199 -.184 .392*

Sig. (1-tailed)
N
COGS_pre Pearson
Correlation
Sig. (1-tailed)
Investment Pearson
_fac_equip Correlation
__pre
Sig. (1-tailed)
complianc Pearson
e__pre
Correlation
Sig. (1-tailed)
Act_sales_ Pearson
pre
Correlation
Sig. (1-tailed)
Act_reven Pearson
ues_pre
Correlation
Sig. (1-tailed)
Market_va Pearson
lue_pre
Correlation
Sig. (1-tailed)
Stockholde Pearson
rs_pre
Correlation
Sig. (1-tailed)

.129

.016

.004

.397

.194

.212

.039

21
1

21
.258

21
.324

21
-.019

21
.103

21
.112

21
.174

.129
-.468*

.258

.130
1

.076
.824**

.467
.311

.328
.452*

.314 .225
.346 -.261

.016
-.558**

.130
.324

.824**

.000
1

.085
.508**

.020
.687**

.062 .127
.522** -.036

.004
-.061

.076
-.019

.000
.311

.508**

.009
1

.000
.933**

.008 .438
.703** .375*

.397
-.199

.467
.103

.085
.452*

.009
.687**

.933

.194
-.184

.328
.112

.020
.346

.000
.522**

.000
.703**

.772**

.212
.392*

.314
.174

.062
-.261

.008
-.036

.000
.375*

.000
.352

.039

.225

.127

.438

.047

.059

21
-.259

*. Correlation is significant at the 0.05 level (1-tailed).
**. Correlation is significant at the 0.01 level (1-tailed).

**

.000
1

.000
.772**

.047
.352

.000 .059
1 .565**

.565

**

.004

.004
1
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Table 46
Pearson Correlations (post-FDA)
COG Investmen
Market Stock
q0134 S_pos t_fac_equi Complian Act_sale Act_revenu _value holder
_0001
t
p_post
ce_post
s_post
es_post
_post s_post
q013 Pearson Corr.
1 -.024
-.190
-.263
-.059
-.059
.101 .374*
4_00 Sig. (1.459
.205
.125
.399
.399
.332
.047
01
tailed)
N

21

21

21

21

21

21

21

21

COG Pearson Corr. -.024
1
.206
.249
S_po Sig. (1.459
.185
.138
st
tailed)
Inves Pearson Corr. -.190
.206
1
.829**
tmen Sig. (1.205
.185
.000
t_fac tailed)
_equi
p_po
st
Com Pearson Corr. -.263
.249
.829**
1
plian Sig. (1.125
.138
.000
ce_p tailed)
ost
Act_ Pearson Corr. -.059
.010
.732**
.767**
sales Sig. (1.399
.482
.000
.000
_post tailed)
Act_ Pearson Corr. -.059
.010
.732**
.767**
reven Sig. (1.399
.482
.000
.000
ues_ tailed)
post
Mark Pearson Corr.
.101 -.082
.423*
.394*
et_va Sig. (1.332
.361
.028
.039
lue_p tailed)
ost
Stoc Pearson Corr. .374* .089
.272
.211
khol Sig. (1.047
.351
.116
.180
ders_ tailed)
post
*. Correlation is significant at the 0.05 level (1-tailed).
**. Correlation is significant at the 0.01 level (1-tailed).

.010
.482

.010
.482

-.082
.361

.089
.351

.732**
.000

.732**
.000

.423*
.028

.272
.116

.767**
.000

.767**
.000

.394*
.039

.211
.180

1

1.000**
.000

.552**
.005

.387*
.041

1.000**
.000

1

.552**
.005

.387*
.041

.552**
.005

.552**
.005

.387*

.387*

.749**

.041

.041

.000

1 .749**
.000

1
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The compliance of the firms after the FDA intervention only had a significant
correlation with stockholders’ equity (r = 0.374, p < 0.05) considering a one-tailed
assumption due to the skewness of the data in the responses. Similar to the pre-FDA
scenario, investment in facility and equipment and compliance expenses were
significantly correlated to actual sales, actual revenues, and market value at p < 0.01.
Compliance expenses was significantly correlated to all other indicators except for COGS
and stockholders’ equity implying the importance of compliance expense between the
indicators in both scenarios.
Since the distribution of the scores was skewed or non-normal as supported by the
results of Kolmogorov-Smirnov and Shapiro-Wilk tests, Kendall’s Tau correlation
coefficient, τ, was used to understand the correlation between the variables. Kendall’s
Tau is a non-parametric measure that applies to a small number of scores that also rank in
a similar manner (Field, 2009). The limited number of completed surveys of 21 also
signaled the use of Kendall’s correlation coefficient, τ.
Of the seven financial indicators and following Kendall’s correlation coefficient,
τ, the compliance of the firms prior to the FDA intervention had a significant correlation
at p < 0.05 with two of them considering a one-tailed assumption due to the skewness of
the data in the responses. Investment in facility and equipment (r = |-0.432|, p < 0.05) and
compliance expenses (r = |-0.497|, p < 0.01) were significantly correlated to compliance
of the firms. Also, facility and equipment and compliance expenses were significantly
correlated to actual sales, actual revenues, and market value at p < 0.01. Table 47
presents Kendall’s correlation coefficient, τ for the pre-FDA intervention.
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Table 47
Kendall’s correlation coefficient, τ (pre-FDA)

q0133
_0001

Corr. Coeff.
Sig. (1-tailed)

Stock
Investmen
Act_rev Marke holde
q0133_ COGS t_fac_equi complianc Act_sales enues_p t_valu rs_pr
0001
_pre
p__pre
e__pre
_pre
re
e_pre
e
*
**
1.000 -.253
-.432
-.497
-.061
-.201 -.193 .338
.

.110

.017

.008

.386

.170

.176

.051

21

21

21

21

21

21

21

21

COGS Corr. Coeff.
_pre
Sig. (1-tailed)

-.253

1.000

.235

.308

-.067

.067

.081

.158

.110

.

.123

.069

.375

.375

.348

.220

Invest Corr. Coeff.
ment_f
Sig. (1-tailed)
ac_equ
ip__pr
e

-.432*

.235

1.000

.816**

.367*

.501**

.017

.123

.

.000

.038

.008

compli Corr. Coeff.
ance__ Sig. (1-tailed)
pre

-.497**

.308

.816**

1.000

.565**

.008

.069

.000

.

.004

Act_sa Corr. Coeff.
les_pre Sig. (1-tailed)

-.061

-.067

.367*

.565**

1.000

.386

.375

.038

.004

.

**

**

**

N

.501

.713

.921

.406* -.111
.023

.292

.713** .568**

.107

.000

.003

.302

.921** .731** .418*
.000

Act_re Corr. Coeff.
venues
Sig. (1-tailed)
_pre

-.201

.067

.170

.375

.008

.000

.000

.

Market Corr. Coeff.
_value
_pre
Sig. (1-tailed)

-.193

.081

.406*

.568**

.731**

.815**

.176

.348

.023

.003

.000

Stockh Corr. Coeff.
olders_ Sig. (1-tailed)
pre

.338

.158

-.111

.107

.418*

.051

.220

.292

.302

.023

.000

.023

**

.388*

.000

.032

1.000 .815

1.000 .570*
*

*. Correlation is significant at the 0.05 level (1-tailed).
**. Correlation is significant at the 0.01 level (1-tailed).

.000

.

.003

.388* .570** 1.000
.032

.003

.
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The compliance of the firms after the FDA intervention had no significant
correlation with any of the financial indicators considering a one-tailed assumption due to
the skewness of the data in the responses. Similar to the pre-FDA scenario, investment in
facility and equipment and compliance expenses were significantly correlated to actual
sales, actual revenues, and market value at p < 0.01. Compliance expenses was
significantly correlated to all other indicators except for COGS and stockholders’ equity.
Table 48 presents Kendall’s correlation coefficient, τ.
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Table 48
Kendall’s correlation coefficient, τ (post-FDA)

q0134
_0001

Corr. Coeff.
Sig. (1tailed)

Stock
Investmen
Marke holde
q0134 COGS t_fac_equi Complianc Act_sales Act_revenue t_valu rs_po
_0001 _post
p_post
e_post
_post
s_post
e_post st
1.000 -.033
-.212
-.248
-.059
-.059
.067 .329
.

.436

.154

.125

.388

.388

.373

.055

21

21

21

21

21

21

21

21

COGS Corr. Coeff.
_post Sig. (1tailed)

-.033

1.000

.227

.269

.015

.015

-.046

.085

.436

.

.136

.104

.470

.470

.412

.339

Invest
ment_f
ac_equ
ip_pos
t

-.212

.227

1.000

.858**

.728**

.728**

.422*

.246

.154

.136

.

.000

.000

.000

.021

.117

Compl Corr. Coeff.
iance_ Sig. (1post
tailed)

-.248

.269

.858**

1.000

.779**

.779**

.420*

.213

.125

.104

.000

.

.000

.000

.025

.160

Act_sa Corr. Coeff.
les_po
Sig. (1st
tailed)

-.059

.015

.728**

.779**

1.000

1.000** .546**

.327

.388

.470

.000

.000

.

Act_re Corr. Coeff.
venues Sig. (1_post tailed)

-.059

.015

.728**

.779**

1.000**

.388

.470

.000

.000

.

.

Market Corr. Coeff.
_value
_post Sig. (1tailed)

.067

-.046

.422*

.420*

.546**

.546**

.373

.412

.021

.025

.004

.004

Stockh Corr. Coeff.
olders Sig. (1_post tailed)

.329

.085

.246

.213

.327

.327 .734** 1.000

.055

.339

.117

.160

.056

.056

N

Correlation
Coefficient
Sig. (1tailed)

.

.004

.056

1.000 .546**

.327

.004

.056

1.000 .734*
*

**. Correlation is significant at the 0.01 level (1-tailed).
*. Correlation is significant at the 0.05 level (1-tailed).

.

.000

.000

.
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The null hypothesis, H2₀, was rejected for RQ2 in the pre-FDA intervention since several
correlations were proven to be significant to at least p < 0.05. The Kendall’s correlation
coefficient, τ indicated that prior to the FDA intervention there were two financial
indicators that influence the compliance of the firms with the FDA regulations.
Investment in facility and equipment and compliance expenses were significantly
correlated to the level of compliance. Also, investment in facility and equipment, as well
as compliance expenses, correlated significantly with sales, revenues, and market value
with p < 0.01.
The test for the null hypothesis, H2₀, for RQ2 was difficult to be assessed for the
post-FDA scenario. The limited number of participants was also a factor not allowing a
definite result. The Pearson correlation indicated that the compliance of the firms had a
significant correlation with stockholders’ equity (p < 0.05). For the Kendall’s correlation
coefficient, τ, the compliance of the firms had no significant correlation with any of the
financial indicators. The stockholders’ equity had a p significance value equal to 0.055.
The Kendall’s correlation coefficient indicated that investment in facility and equipment
and compliance expenses had significant correlations with actual sales, actual revenues,
and market value at p < 0.01. If the interdependencies between the indicators were used
to imply that complince expenses impact actual sales and actual revenues, the null
hypothesis could be rejected.
Research Question 3 (RQ3). To what extent, if any, do financial indicators
(independent) impact compliance (dependent) with FDA regulations at the
pharmaceutical firms in the United States?
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H3₀: β₁ = β₂ = … = β7 = 0. There is no impact in compliance with FDA
related to seven financial indicators at pharmaceutical firms, as a result of
FDA enforcement actions in the United States.



H3₁: At least one β ≠ 0. There is an impact in compliance with FDA related
to at least one of the seven financial indicators before and after the FDA
enforcement actions in the United States.

To address RQ3 and the null test, regression analyses were conducted to establish
a model with the financial indicators as predictors of level of compliance of the firms
with the FDA regulations. The regression analyses were performed using SPSS for both
scenarios: pre-FDA and post-FDA. All assumptions were assessed to understand the
robustness of the models.
Assumptions for Multiple Regression Analysis. For regression analysis, there
were several assumptions that needed to be met. Meeting the assumptions allowed
assessing if the conclusions were true for a wider population. For a regression model to
generalize beyond the sample population, assumptions have to be met (Field, 2009). The
assumptions were assessed for both scenarios: pre-FDA and post-FDA interventions. The
assessment of the assumptions was:
1) Variable types: All predictor variables were quantitative and the outcome
variable was quantitative: continuous and unbounded.
2) Non-zero variance: The predictors should had variation in value. They did not
have variances of 0.
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3) Sample Size: The ratio of predictors to cases was expected to be significant
because of its impact on the value of R. These assumption was not met.
4) No perfect multicollinearity: There was no perfect linear relationship between
two or more of the predictors in the pre-FDA scenario. The predictor variables did
not highly correlated. For the post-FDA, actual sales and actual revenues were
perfect correlated, SPSS removed actual revenues in the post-FDA model.
5) Predictors are not correlated with external variables: External variables could
be present. In the model, not all contribution that could significantly influence the
outcome was identified. This assumption was not met.
6) Homoscedasticity: At each level of the predictor variable(s), the variance of
the residual terms were constant. The SPSS graphs supported this assumption.
7) Independent errors: For any two observations the residual terms should be
independent. This assumption tested whether adjacent residuals are correlated.
The test statistic was allow to vary between 0 and 4 with a value of 2 meaning
that the residuals were uncorrelated.
8) Normally distributed errors: This assumption indicates that the differences
between the model and the observed data are most frequently zero or very close to
zero. The SPSS graphs did not support this assumption.
9) Independence: All of the values of the dependent variable were independent of
each other.
10) Linearity: The mean values of the dependent variable were represented in a
reasonable spread indicating a straight line. Assumption met.
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The dependent variable was the level of compliance as indicated in the main
survey. All 21 participants indicated that their firms had at least one FDA intervention in
the last 5-6 years. The FDA interventions consisted of No Action Indicated, Voluntary
Action Indicated, and Official Action indicated. The predictors or independent variables
were seven. Similar to the pilot study, in the main survey, the participants provided to
their best recollection the tendencies for the financial indicators regarding the FDA
interventions. As indicated in the Data Treatment section, missing values from the
participants were noted as no change to avoid influencing the tendencies of the
independent variables. The variables were listed in Table 49 and Table 50.
Table 49
Variables and Descriptive Statistics

Level of Compliance pre-FDA
COGS_pre
Investment_fac_equip_pre
compliance_pre
Act_sales_pre
Act_revenues_pre
Market_value_pre
Stockholders_pre

Mean
5.9524
.0952
.7619
.6667
.5714
.6190
.5238
.2381

Std. Deviation
.58959
.62488
.76842
.65828
.59761
.58959
.67964
.70034

N
21
21
21
21
21
21
21
21
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Table 50
Variables and Descriptive Statistics

Level of Compliance post-FDA
COGS_post
Investment_fac_equip_post
Compliance_post
Act_sales_post
Act_revenues_post
Market_value_post
Stockholders_post

Mean
6.0476
.1905
.5238
.5714
.4762
.4762
.1905
.0476

Std. Deviation
.58959
.67964
.67964
.50709
.67964
.67964
.67964
.66904

N
21
21
21
21
21
21
21
21

The descriptive statistics generated by SPSS provided a correlation matrix for
each FDA scenario. The matrix provided three elements: Pearson correlation between the
variables, the significance of the correlation, and the number of cases included in the
assessment. In Table 51, the correlation matrix lists the results for the pre-FDA scenario
of the 21 cases or completed questionnaires. The three variables with a high correlation
with the level of compliance of the firms were investment in facility and equipment (r = |0.468|, p < 0.05), compliance expenses (r = |-0.558|, p < 0.01) and stockholders’ equity (r
= 0.392, p < 0.05).
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Table 51
Variables and Descriptive Statistics

Pearson q0133_0001
Correlat COGS_pre
Investment_fa
ion
c_equip__pre
compliance__p
re
Act_sales_pre
Act_revenues_
pre
Market_value_
pre
Stockholders_
pre

Sig. (1tailed)

q0133_0001
COGS_pre
Investment_fa
c_equip__pre
compliance__p
re
Act_sales_pre
Act_revenues_
pre
Market_value_
pre
Stockholders_
pre

q0133 COG
_0001 S_pre
1.000 -.259
-.259 1.000
-.468
.258

Stoc
Investmen
Marke khol
t_fac_equi complianc Act_sale Act_reven t_valu ders_
p__pre
e__pre
s_pre
ues_pre e_pre pre
-.468
-.558
-.061
-.199 -.184 .392
.258
.324
-.019
.103 .112 .174
1.000
.824
.311
.452 .346 -.261

-.558

.324

.824

1.000

.508

.687

-.061
-.199

-.019
.103

.311
.452

.508
.687

1.000
.933

.933
1.000

-.184

.112

.346

.522

.392

.174

-.261

.
.129
.016

.129
.
.130

.004

.522 -.036
.703
.772

.375
.352

.703

.772 1.000

.565

-.036

.375

.352

.565

1.00

.016
.130
.

.004
.076
.000

.397
.467
.085

.194
.328
.020

.212
.314
.062

.039
.225
.127

.076

.000

.

.009

.000

.008

.438

.397
.194

.467
.328

.085
.020

.009
.000

.
.000

.000
.

.000
.000

.047
.059

.212

.314

.062

.008

.000

.000

.

.004

.039

.225

.127

.438

.047

.059

.004

.
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As indicated in the assessment of the financial indicators, the compliance of the
firms before the FDA intervention had a significant correlation at p < 0.05 with three of
the indicators considering a one-tailed assumption due to the skewness of the data in the
responses. Investment in facility and equipment, compliance expenses, and stockholders
equity were significantly correlated to compliance (p < 0.05). Also, compliance expenses
were significantly correlated to facility and equipment, actual sales, actual revenues, and
market value at p < 0.01. Since none of the correlation between different variables was
high (r = 0.9), the possibility of multicollinearity was considered low (Field, 2009).
In Table 52, the correlation matrix lists the results for the post-FDA scenario of
the 21 cases or completed questionnaires. Two variables with a high correlation with the
level of compliance of the firms were compliance expenses (r = |-0.263|, p = 0.125) and
stockholders’ equity (r = 0.374, p < 0.05). The compliance of the firms after the FDA
intervention only had a significant correlation with stockholders’ equity (p < 0.05)
considering a one-tailed assumption due to the skewness of the data in the responses.
Compliance expenses were significantly correlated to facility and equipment, actual sales,
actual revenues, and market value at p < 0.05. In the case of the post-FDA scenario, two
variables had a correlation of r = 1.0 generating the possibility of multicollinearity (Field,
2009). As a result, SPSS removed the financial indicator labeled as actual revenues to
compensate and improving the possibility of complying with the assumption of
multicollinearity.
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Table 52
Variables and Descriptive Statistics

Pearson q0134_0001
Correla COGS_pos
tion
Investment_f
ac_equip_pos
t

Stock
Investment
Act_rev Market holde
q0134_ COGS _fac_equip Complia Act_sales enues_p _value rs_po
0001 _post
_post
nce_post
_post
ost
_post
st
1.000 -.024
-.190
-.263
-.059
-.059
.101 .374
-.024

1.000

.206

.249

.010

.010

-.082

.089

-.190

.206

1.000

.829

.732

.732

.423

.272

Compliance_
post

-.263

.249

.829

1.000

.767

.767

.394

.211

Act_sales_po
st

-.059

.010

.732

.767

1.000

1.000

.552

.387

Act_revenues
_post

-.059

.010

.732

.767

1.000

1.000

.552

.387

Market_valu
e_post

.101

-.082

.423

.394

.552

.552

1.000

.749

.374

.089

.272

.211

.387

.387

.749

1.00

.
.459
.205

.459
.
.185

.205
.185
.

.125
.138
.000

.399
.482
.000

.399
.482
.000

.332
.361
.028

.047
.351
.116

.125

.138

.000

.

.000

.000

.039

.180

.399

.482

.000

.000

.

.000

.005

.041

.399

.482

.000

.000

.000

.

.005

.041

.332

.361

.028

.039

.005

.005

.

.000

.047

.351

.116

.180

.041

.041

.000

.

Stockholders
_post
Sig. (1- q0134_0001
tailed) COGS_post
Investment_f
ac_equip_pos
t
Compliance_
post
Act_sales_po
st
Act_revenues
_post
Market_valu
e_post
Stockholders
_post
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In the next step, following the hierarchical method of assessing the independent
variables, the predicting model was evaluated for both FDA scenarios. For the seven
financial indicators, a total of seven models in a hierarchical order were developed in
SPSS. Table 53 presented the model for the pre-FDA scenario. The correlation R
between the variables and the prediction R2 of how much of the dependent variable is
contributed by each predictor were obtained. Also, the assumption of independent errors
was verified with the Durbin–Watson statistic. The value of 1.53 was obtained, indicating
that the assumption of independent errors could be considered as met. In relation to
external variables, the R2 values of model 7 indicated that the predictors accounted for
60.7% contribution to the outcome variable, indicating that there are other external
variables not included, violating this assumption.
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Table 53
Model Summary h pre-FDA
Change Statistics
R
Adjusted R Std. Error of R Square
Model
R Square
Square
the Estimate Change F Change
a
1
.259
.067
.018
.58435
.067
1.361
2
.489 .239
.155
.54211
.172
4.076

Sig. F Durbindf1 df2 Change Watson
1 19
.258
1 18
.059

b

3
4

.564c
.617

.319
.381

.198
.226

.52789
.51858

.079
.063

1.982
1.616

1
1

17
16

.177
.222

.383
.386
.607

.178
.124
.395

.53457
.55198
.45868

.002
.003
.220

.057
.069
7.275

1
1
1

15
14
13

.815
.797
.018

d

5
6
7

.619e
.622f
.779

1.528

g

a. Predictors: (Constant), COGS_pre
b. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre
c. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre
d. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre, Act_sales_pre
e. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre, Act_sales_pre,
Act_revenues_pre
f. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre, Act_sales_pre,
Act_revenues_pre, Market_value_pre
g. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre, Act_sales_pre,
Act_revenues_pre, Market_value_pre, Stockholders_pre
h. Dependent Variable: q0133_0001

The adjusted R2 provided a way to understand how well the model could
generalize the scenario under review. The smallest the difference of the adjustment the
better the possibility for the model to represent the population, not just the sample. In
model 7, the R2 = 0.607 was adjusted to 0.395 or 39.5% representing a reduction of 0.212
or 21.2% of the overall contribution of the seven variables. The stockholder’s equity
added almost 32.1% in contribution in comparison to the previous six predictors.
Investment in facilities and equipment was the second largest contributor with 13.7%.
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These two predictors contributed 45.8% of the total 60.7% of all the financial indicators.
The F- ratio provided the significance of the change. Only model 7 had a significant Fratio of 7.28, p < 0.05. For model 2, COGS and investment on facilities and equipment
had a significance at p < 0.59, but still above the expectations.
For the post-FDA scenario, the hierarchical method of assessing the independent
variables was also followed. For the seven financial indicators, a total of seven models in
a hierarchical order were developed in SPSS. Table 54 presents the model for the postFDA scenario. The correlation R between the variables and the prediction R2 of how
much of the dependent variable is contributed by each predictor were obtained. Also, the
assumption of independent errors was verified with the Durbin–Watson statistic. The
value of 2.18 was obtained, indicating that the assumption of independent errors could be
considered as met. In relation to external variables, the R2 values of model 6 indicated
that the predictors accounted for about 30% contribution to the outcome variable,
indicating that there are other external variables not included, violating this assumption.
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Table 54
Model Summary g post-FDA
Std.
Change Statistics
Adjusted Error of
R
R
the
R Square
F
Sig. F
DurbinModel
R Square Square Estimate Change Change df1 df2 Change
Watson
a
1
.024 .001
-.052
.60474
.001
.011
1
19
.919
2
.191b .036
-.071
.61007
.036
.669
1
18
.424
c
3
.271 .073
-.090
.61560
.037
.678
1
17
.422
4
.362d .131
-.086
.61448
.058
1.062
1
16
.318
e
5
.394 .155
-.126
.62573
.024
.430
1
15
.522
f
6
.547 .299
-.001
.58987
.144
2.879
1
14
.112
2.175
a. Predictors: (Constant), COGS_post
b. Predictors: (Constant), COGS_post, Investment_fac_equip_post
c. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post
d. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post, Act_sales_post
e. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post,
Act_sales_post, Market_value_post
f. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post,
Act_sales_post, Market_value_post, Stockholders_post
g. Dependent Variable: q0134_0001

The adjusted R2 provided a way to understand how well the model could
generalize the scenario under review. The smallest the difference of the adjustment the
better the possibility for the model to represent the population, not just the sample. In
Model 6, the R2 = 0.299 was adjusted to -0.001 representing a very significant adjustment
to the overall contribution of the seven variables. This adjustment implied that the model
did not generalized beyond the sample. The stockholder’s equity contributed with 14.4%
in comparison to the 15.5% of the previous five predictors. Actual sales were the second
largest contributor with 5.8%. These two predictors contributed 20.2% of the total 29.9%
of the financial indicators for the post-FDA scenario. The F-ratio provided the
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significance of the change. None of the post-FDA models had a significance value less
than 0.05 affecting the robustness of the models.
The next test performed in SPSS was the calculation of the ANOVA for the seven
models. The ANOVA challenged whether the models were better predictors of the
outcome than the guess based on the average of the means. The F-ratio indicated the ratio
of the accuracy of the model versus the means (Field, 2009). For the pre-FDA scenario,
all values of F were above one signaling that the model’s fits are better predictors than
the guess from the means. In Table 55, only model 7 has an F-ratio that was significant to
p < 0.048 indicating the low probability of the outcome could happen by chance. Models
2, 3, and 4 had F-ratios that were non-significance at less than 0.09.
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Table 55
ANOVA a pre-FDA
Model
1

Sum of Squares
.465

df
1

Mean Square
.465

Residual

6.488

19

.341

Total

6.952

20

2

Regression
Residual
Total

1.663
5.290
6.952

2
18
20

3

Regression
Residual
Total

2.215
4.737
6.952

4

Regression
Residual
Total

5

6

7

F
1.361

Sig.
.258b

.831
.294

2.829

.085c

3
17
20

.738
.279

2.650

.082d

2.650
4.303
6.952

4
16
20

.662
.269

2.463

.087e

Regression
Residual
Total
Regression

2.666
4.287
6.952
2.687

5
15
20
6

.533
.286

1.866

.160f

.448

1.470

.258g

Residual

4.266

14

.305

Total

6.952

20

Regression

4.217

7

.602

2.864

.048h

Residual

2.735

13

.210

Total

6.952

20

Regression

a. Dependent Variable: q0133_0001
b. Predictors: (Constant), COGS_pre
c. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre
d. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre
e. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre, Act_sales_pre
f. Predictors: (Constant), COGS_pre, Investment_fac_equip__pre, compliance__pre, Act_sales_pre,
Act_revenues_pre

The ANOVA for the six models for the post-FDA intervention are presented in
Table 56. The ANOVA challenged whether the models were better predictors of the
outcome than the guess based on the average means. The F-ratio indicated the ratio of the
accuracy of the model versus the means (Field, 2009). For the post-FDA scenario, all
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values of F are below one signaling that the model’s fits are not good predictors than the
guess from the means. None of the models in the post-FDA scenario had an F-ratio that
was significant indicating that the outcome could happen by chance.
Table 56
ANOVA a post-FDA
Model
1

2

3

4

5

6

Sum of Squares
.004

df
1

Mean Square
.004

F
.011

Sig.
.919b

Residual

6.948

19

.366

Total

6.952

20

Regression
Residual

.253
6.699

2
18

.127
.372

.340

.716c

Total

6.952

20

Regression
Residual

.510
6.442

3
17

.170
.379

.449

.721d

Total
Regression
Residual

6.952
.911
6.041

20
4
16

.228
.378

.603

.666e

Total

6.952

20

Regression
Residual

1.079
5.873

5
15

.216
.392

.551

.735f

Total

6.952

20

Regression

2.081

6

.347

.997

.465g

Residual

4.871

14

.348

Total

6.952

20

Regression

a. Dependent Variable: q0134_0001
b. Predictors: (Constant), COGS_post
c. Predictors: (Constant), COGS_post, Investment_fac_equip_post
d. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post
e. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post, Act_sales_post
f. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post, Act_sales_post,
Market_value_post
g. Predictors: (Constant), COGS_post, Investment_fac_equip_post, Compliance_post, Act_sales_post,
Market_value_post, Stockholders_post
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The model parameters were then obtained by SPSS. For the pre-FDA scenario,
the model discussion was focused on model 7 since this model was the only one with
significance F-ratio in the ANOVA assessment. Table 57 presents the slope values, B,
for each predictor (financial indicator). Stockholders’ equity was the only B value that
was significant (p < 0.05) indicating a strong contribution to the outcome. The smallest
the significance of the B values the stronger the contribution of the prediction to the
outcome (Field, 2009). Regarding the standardized beta (labeled as Beta, β),
Stockholders equity (β = 0.760), compliance expense (β = |-0.754|), and market value (β
= |-0.624|) have the largest impact on the standard deviation of the outcome, the level of
compliance of the firms.
Table 57
Model 7 Parameters a pre-FDA

Model
7

Unstandardized

Standardized

Coefficients

Coefficients

B
6.065

Std. Error
.166

Beta

(Constant)

t
36.466

Sig.
.000

COGS_pre

-.218

.193

-.231

-1.127

.280

.365

.269

.476

1.356

.198

-.676

.393

-.754

-1.718

.110

Act_sales_pre

.029

.566

.029

.051

.960

Act_revenues_pre

.316

.733

.316

.431

.674

Market_value_pre

-.541

.295

-.624

-1.834

.090

Stockholders_pre

.640

.237

.760

2.697

.018

Investment_fac_equip__pre
compliance__pre

Dependent Variable: q0133_0001
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To assess how close is the B value of the sample to the B value of the population, a
level of confidence of 95% was selected as shown in Table 58. In model 7, only
stockholders’ equity had a small spread between the upper and lower boundaries of the
confidence limit and not crossing the value of zero. Having only one indicator with these
characteristics implied that the model was not strong for the prediction of the outcome of
the model. Regarding the Collinearity Statistics, actual revenues had a VIF value
significantly above 10 (17.732) with a tolerance below 0.2 (0.056). For actual sales, the
VIF value was slightly above 10 (10.872) with a tolerance below 0.1 (0.092). These
results highlighted a potential problem in meeting the assumption of collinearity.
Table 58
pre-FDA Confidence and Collinearity
95.0% Confidence
Interval for B

Model
7

Lower

Upper

Bound

Bound

Collinearity
Correlations

Statistics

Partia
Zero-order

l

Part

Tolerance

VIF

(Constant)

5.705

6.424

COGS_pre

-.636

.200

-.259

-.298

-.196

.720

1.389

Investment_fac_equip_

-.216

.947

-.468

.352

.236

.246

4.068

compliance__pre

-1.526

.174

-.558

-.430

-.299

.157

6.376

Act_sales_pre

-1.194

1.252

-.061

.014

.009

.092 10.872

Act_revenues_pre

-1.267

1.898

-.199

.119

.075

.056 17.732

Market_value_pre

-1.178

.096

-.184

-.453

-.319

.262

3.820

.127

1.152

.392

.599

.469

.381

2.622

_pre

Stockholders_pre
Dependent Variable: q0133_0001
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Table 59 presents the slope values, B, for each predictor (financial indicator).
None of the B values had a significance (p < 0.05) indicating that none of the B values
had a strong contribution to the outcome. The smallest the significance of the B values
was for the stockholders’ equity (p = 0.112). The smallest the significance value, the
stronger the contribution of the prediction to the outcome (Field, 2009). Regarding the
standardized beta (labeled as Beta, β), stockholders’ equity (β = 0.611) had the largest
impact on the standard deviation of the outcome, the level of compliance of the firms.
Table 59
Model 6 Parameters a post-FDA

Model
6
(Constant)

Unstandardized
Coefficients
B
Std. Error
6.266
.202

Standardize
d
Coefficients
Beta

t
31.00
0

Sig.
.000

COGS_post

.004

.222

.004

.016

.988

Investment_fac_eq
uip_post

-.066

.363

-.076

-.182

.858

Compliance_post

-.433

.546

-.372

-.792

.441

Act_sales_post

.178

.356

.205

.500

.625

Market_value_post

-.252

.339

-.291

-.743

.470

Stockholders_post

.538

.317

.611

1.697

.112

Dependent Variable: q0134_0001a
To assess how close is the B value of the sample to the B value of the population,
a level of confidence of 95% was selected as shown in Table 60. In model 6, none of the
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predictors had a spread between the boundaries not crossing the value of zero. Having no
indicator with these characteristics implied that the model was not strong for the
prediction of the outcome of the model. Regarding the Collinearity Statistics, none of the
VIF value was significantly above 10, and all tolerances were above 0.1 with a tolerance
below 0.2. These results implied that there should not be a concern of not meeting the
assumption of collinearity for the post-FDA scenario after excluding actual revenues
from the predictors.
Table 60
post-FDA Confidence and Collinearity
95.0% Confidence
Interval for B

Correlations

Statistics

Lower

Upper

Zero-

Bound

Bound

order

Partial

Part

Tolerance

VIF

(Constant)

5.833

6.700

COGS_post

-.473

.480

-.024

.004

.004

.762

1.312

Investment_fac_equi

-.845

.713

-.190

-.049

-.041

.286

3.501

Compliance_post

-1.605

.739

-.263

-.207

-.177

.227

4.412

Act_sales_post

-.585

.942

-.059

.133

.112

.297

3.365

Market_value_post

-.980

.476

.101

-.195

-.166

.327

3.060

Stockholders_post

-.142

1.219

.374

.413

.380

.386

2.591

Model
6

Collinearity

p_post

To further assess the assumption of collinearity, a diagnostic was performed by
SPSS for both scenarios: pre-FDA and post-FDA. In both scenarios, the Eigenvalue for
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COGS was higher than one. Only Eigenvalues below one were considered for the
assessment of Variance Proportions. For the pre-FDA in Table 61, several indicators had
their highest value in dimension 8 implying that the model did not meet the assumption
of no multicollinearity. For the post-FDA in Table 62, investment in facility and
equipment and actual sales had their highest value in dimension 6 implying a challenge
to the assumption of no multicollinearity.
Table 61
Collinearity a pre-FDA
Variance Proportions
Act_ Mark Stock
Investme
Act_ reven et_val holde
Dimensio Eigenvalu Conditio (Constan COG nt_fac_eq complian sales ues_p ue_pr rs_pr
n
e
n Index
t)
S_pre uip__pre ce__pre _pre
re
e
e
1
5.090
1.000
.01
.00
.00
.00
.00
.00
.00
.00
2

1.125

2.127

.00

.01

.02

.01

.00

.00

.01

.17

3

.995

2.261

.01

.62

.00

.00

.00

.00

.00

.02

4

.376

3.678

.74

.00

.00

.00

.01

.00

.03

.04

5

.219

4.826

.02

.18

.10

.01

.07

.02

.12

.11

6

.112

6.747

.18

.15

.06

.09

.00

.00

.74

.62

7

.067

8.691

.05

.02

.73

.52

.07

.01

.01

.03

8

.016

17.662

.00

.01

.08

.36

.85

.97

.08

.00

a. Dependent Variable: q0133_0001
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Table 62
Collinearity a post-FDA
Variance Proportions

Dimensio Eigenvalu
n
e
1
3.871

Conditi
COG Investmen
Act_ Market
on
(Constan S_pos t_fac_equi Complian sales _value Stockholder
Index
t)
t
p_post
ce_post _post _ post
s_post
1.000
.01
.01
.01
.01
.01
.01
.01

2

1.424

1.649

.03

.06

.00

.00

.00

.06

.11

3

.881

2.096

.01

.63

.00

.00

.01

.00

.05

4

.415

3.054

.67

.01

.06

.00

.05

.00

.04

5

.190

4.508

.01

.09

.00

.00

.07

.90

.67

6

.149

5.097

.00

.12

.55

.00

.63

.01

.05

7

.069

7.470

.27

.09

.37

.99

.22

.02

.07

a. Dependent Variable: q0134_0001

The next step was to assess if any case had a significant influence or should be
considered as an outlier. Using SPSS, the case summary analysis was applied to both
scenarios: pre-FDA and post-FDA. In the pre-FDA scenario for two cases, 5 and 18, the
Mahalanobis Distance values were 19.05 but the corresponding Centered Leverage Value
were within the expected value of 0.36. The two cases were excluded from the Cook’s
and DFBeta calculations by SPSS indicating the over influence of these two cases in the
model. In the post-FDA scenario, all cases were included with values of Cook at or below
+/-1 and values of DFBeta in expectations implying that all cases could be considering
not having undue influence in the regression model for the post-FDA scenario.
For the assumptions of linearity and homoscedasticity, some of the plots assessed
under SPSS could be considered as supporting these assumptions. For the residual
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normality, the graphs for both scenario divert from the straight line implying lack of
normality. Since not all assumptions were met, the regression models for the financial
indicators cannot be used to generalize beyond the sample of the study in either the preFDA or the post-FDA intervention.
Reputation of the Firms and Management Changes.
The last two questions in the financial sections of the main study questionnaire
requested the participants to provide their opinion regarding the potential outcomes from
the FDA interventions or actions. These responses projected the impact on the firms’
reputation and the change management process resulting from the FDA’s intervention or
actions. Comparing results in Table 63 and Table 64 allowed to conduct the assessment.
Table 63
Before FDA: Reputation and Management Change
Answer
Options

Decrease
of -50%

Decrease
of -5% to
-49%%

No
Change

Increase of
+5% to
+49%%

Increase of
-+50%

0

1

12

6

2

21

0

1

9

8

3

21

Reputation
of the Firm
Management
change

Response
Count

answered question

21

skipped question

0
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Table 64
After FDA: Reputation and Management Change
Answer
Options

Decrease
of -50%

Reputation of
the Firms
Management
change
answered question

No
Change

0

Decrease
of -5% to
-49%%
2

Increase of
-+50%

Response
Count

10

Increase of
+5% to
+49%%
6

0

18

0

3

8

6

2

18
18

skipped question

3

FDA Experience.
For the FDA experience of the firms, only the 21 completed questionnaires
addressed the last six questions out of 133 total questions. This questions collected
information regarding the firms experience with the FDA in the past six years from 2010
through 2015. The 21 responders indicated that their firms had FDA audits. The
responses were assumed to be based on the best recollection of each of the participants.
In all years, the FDA issued 483 observations. In five occasions, the outcome of the FDA
intervention were audits with Official Action Indicated. None of the 21 participants
reported warning letters nor consent decrees. To assess the overall result of the responses,
in the last two question the participants were asked to compare the firms’ compliance
position with the FDA’s CGMP regulations before and after the FDA’s interventions.
The overall average of firm’s compliance reflected a favorable increase of 1.7% from
5.95 to 6.05 in a scale of a maximum value of 7.
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A dependent-means t-test was applied to the two scenarios’ means: pre-FDA and
post-FDA considering that the same participants took part in both scenarios. Through
SPSS, a paired-samples t-test was conducted. The Pearson coefficient for the two
scenarios was large at r = 0.870, p < 0.01 implying that the same population was used for
the comparison. In Table 65, the results of the paired sample test are shown.
Table 65
Paired Sample Test

Pair 1

q0133_0001 q0134_0001

Paired Differences
95% Confidence
Interval of the
Std.
Difference
Std.
Error
Mean Deviation Mean
Lower
Upper
-.09524
.30079
.06564 -.23216
.04168

Sig.
(2t
df tailed)
-1.451 20 .162

The sign of the Mean was negative indicating that the mean of the compliance of
the firms after the FDA intervention was larger than before the FDA intervention. The
standard error was small at 0.066 with a negative t- test confirming that the mean of the
post-FDA was larger than the pre-FDA scenario. The level of compliance increased after
the FDA intervention as indicated by the means of the participants. Since the expected
compliance trend was to increase in value, the two-tailed significance was divided by two
to obtained a one-tailed non-significance value of p = 0.081. The value of p represented
the probability that the value of t of -1.451 could be experienced if the null hypothesis
could not be rejected (no difference between these means). The prediction of this test
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indicated that the compliance of the firms should increase by the FDA intervention, at
t(20) = -1.451, p = 0.081.
The 95% confidence interval of the differences for this t- test indicated the frame
within which the true mean difference could be found (Field, 2009). This test’s true mean
difference lied between -0.232 and + 0.042. The problem with this interval was that it
contained zero between the two boundaries implying that the true value of the differences
could be zero at 95% confidence limit. I calculated with SPSS at what confident interval
limit the true value of the mean difference could be considered as not being zero. At 80%
confident interval, the mean differences could be considered as unlikely to be equal to
zero.
Inconsistencies Applied to Data Analysis
In the statistical analyses for research questions one and two, the data analysis
was consistent with the pilot study. For the financial indicators analysis, the approach
was similar for both scenarios: before and after the FDA intervention. No inconsistencies
were noted or applied to these analyses. In the case of assumptions, any non-compliance
with the regression assumptions was discussed in the data analysis section.
Reliability Analysis of Questionnaire
Analysis of Cronbach's alpha to determine the reliability of the scales from the
main study questionnaire was conducted for both scenarios: pre-FDA and post-FDA
interventions. The data was analyzed by applying SPSS and by using Field (2009) as a
reference. Cronbach's alpha is not a validity measure. The values for Cronbach’s alpha
range from 0 to 1. Cronbach’s alpha provides the means to assess if a given scale item
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impacts the overall total subscale reliability. Reversing the phrasing of a negative scale
item improved the Cronbach’s values.
The main questionnaire was divided into four section for conducting the
reliability assessment with the Cronbach’s alpha in SPSS. This approach allowed to focus
in each major section of the questionnaire depending on the scenario that was under
review. The four section were the pre-FDA Likert-type scales, the pre-FDA financial
indicators, the post-FDA Likert-type scales, and the post-FDA financial indicators. The
four Cronbach’s alpha values were above .8. An assessment of the Corrected Item-Total
Correlation as well as the Cronbach's alpha if Item Deleted for the four subscales did not
provide a substantial improvement to the overall Cronbach's alpha values. Table 66
presents the four subscales and the corresponding Cronbach's alphas.
Table 66
Cronbach's alpha values for the Sub-scales

Pre-FDA Likert-type (TPB)

Cronbach's alpha
.828

Cronbach's alpha
Based on
Standardized Items
.929

Post-FDA Likert-type (TPB)

.855

.939

58

Pre-FDA Financial
Post-FDA Financial

.874
.901

.879
.904

9
9

N of Items
57

Research Questions
The two group of predictors used in the study were management behaviors and
financial indicators in the two scenarios: pre-FDA and post-FDA interventions. The three
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sets of hypotheses related to these predictors were listed below. The dependent variable
was the level of compliance with the FDA regulations.
Research Question 1
To what extent, if any, does management behaviors (independent) correlate to
compliance (dependent) with FDA regulations at the pharmaceutical firms in the
United States?


H1₀: r = 0. There is no difference in management behaviors towards
compliance at pharmaceutical firms, as a result of FDA enforcement actions in
the U.S.



H1₁: r ≠ 0. There are differences in management behaviors towards
compliance at pharmaceutical firms, as a result of FDA enforcement actions in
the U.S.

According to TPB, three types of beliefs direct and influence human behavior:
beliefs (b), normative beliefs (n), and perceived behavioral control (c) (Ajzen, 2002). The
interrelations between these beliefs influence the intention towards a given behavior.
Three correlations between the outcome of compliance and the three constructs of the
TPB were performed instead of the original strategy of only one correlation. The null
hypothesis, H1₀, was rejected for RQ1 in the pre-FDA and post-FDA interventions for the
three constructs of the TPB. Correlations were found not equal to zero (r ≠ 0). The
significance of the correlations varied and not all met the expectation, p < 0.05.
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In the Pearson correlation for the pre-FDA intervention, the construct of beliefs
(attitudes) had the highest correlation with the outcome of compliance with a value of r =
0.633, p < 0.01. The other two construct, normative beliefs and perceived behavioral
control had non-significant correlations with r values of r = 0.328 and r = 0.183,
respectively. For the post-FDA intervention, the construct of beliefs (attitudes) also had
the highest correlation with the outcome of compliance with a value of r = 0.693, p <
0.01. The other two construct, normative beliefs and perceived behavioral control had
non-significant correlations with r values of 0.294 and 0.303, respectively. Also, the
construct of behavioral beliefs had a significant correlation with the construct of
perceived behavioral control with r = 0.376, p < 0.05. This last significant correlation
differed from the pre-FDA intervention where the correlation was non-significant
between these two constructs.
The correlation data indicated a favorable change in correlation between the
outcome of compliance and behavioral beliefs (attitude) for before and after the FDA
intervention of about 9.5%. The value of r increased from 0.633 to 0.693 for the construct
of beliefs (attitude) towards compliance by the participants with significances of p < 0.01.
The other two independent constructs had non-significant correlations. The perceived
behavioral control non-significant correlation with the outcome of compliance also
increased by about 65% from the pre-FDA (r = 0.183) to the post-FDA scenario (r =
0.303). From the limited population that participated in the study, the null hypothesis was
rejected for RQ1.
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A regression analysis was also conducted to establish if there was a linear model
of the three TPB constructs as predictors of the outcome of compliance of the firms with
the FDA regulations. For the pre-FDA scenario, the R2 = 0.421 and was adjusted to about
32% for the contribution of the three constructs. The F- ratio indicated the significance of
the change with p < 0.05. For the post-FDA scenario, the R2 = 0.492 was adjusted to
40.2% representing the adjustment to the overall contribution of the three independent
variables. The F-ratio provided the significance of the change, p < 0.01.
Research Question 2
To what extent, if any, do financial indicators (independent) correlate to
compliance (dependent) with FDA regulations at the pharmaceutical firms in the
United States?


H2₀: r = 0. There is no difference in compliance with FDA related to financial
indicators at pharmaceutical firms, as a result of FDA enforcement actions in
the U.S.



H2₁: r ≠ 0. There are differences in compliance with FDA related to financial
indicators, as a result of FDA enforcement actions in the U.S.

Seven Pearson Correlations were performed with the seven financial indicators to
understand the possible correlations between these indicators and the dependent variable
outcome of compliance for each scenario: pre-FDA and post-FDA interventions. The
basis of the correlations was the firms’ level of compliance as indicated by the
participants both before and after the FDA intervention. The null hypothesis, H2₀, was
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rejected for RQ2 in the pre-FDA and post-FDA interventions. Correlations were found
that were not equal to zero (r ≠ 0). The significance of the correlations varied and not all
met the expectation, p < 0.05.
Pre-FDA Intervention. Of the seven financial indicators, the compliance of the
firms prior to the FDA intervention had a significant Pearson correlation at p < 0.05 with
three of them considering a one-tailed assumption due to the skewness of the data in the
responses. Investment in facility and equipment (r = |-0.468|, p < 0.05), compliance
expenses (r = |-0.558|, p < 0.05), and stockholders’ equity (r = 0.392, p < 0.05) were
significantly correlated to compliance. In addition, facility and equipment and
compliance expenses were significantly correlated to actual sales, actual revenues, and
market value at p < 0.01.
Since the distribution of the scores was skewed or non-normal as supported by
the results of Kolmogorov-Smirnov and Shapiro-Wilk tests, Kendall’s Tau correlation
coefficient, τ, was used to understand the correlation between the variables. Of the seven
financial indicators and following Kendall’s correlation coefficient, τ, the compliance of
the firms prior to the FDA intervention had a significant correlation at p < 0.05 with two
of them considering a one-tailed assumption due to the skewness of the data in the
responses. Investment in facility and equipment (r = |-0.432|, p <0.05) and compliance
expenses (r = |-0.497|, p < 0.01) were significantly correlated to compliance of the firms.
Also, facility and equipment and compliance expenses were significantly correlated to
actual sales, actual revenues, and market value at p < 0.01. The null hypothesis, H2₀, was
rejected for RQ2 in the pre-FDA intervention.
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Post-FDA Intervention. The compliance of the firms after the FDA intervention
only had a significant Pearson correlation with stockholders’ equity (r = 0.374, p < 0.05)
considering a one-tailed assumption due to the skewness of the data in the responses.
Similar to the pre-FDA scenario, investment in facility and equipment and compliance
expenses were significantly correlated to actual sales, actual revenues, and market value
at p < 0.01. Compliance expenses was significantly correlated to all other indicators
except for COGS and stockholders’ equity implying the importance of compliance
expense between the indicators.
From the Kendall’s coefficient, τ, the compliance of the firms had no significant
correlation with any of the financial indicators in the post-FDA scenario. The
stockholders’ equity had a significance value equal to 0.055. The Kendall’s correlation
coefficient indicated that investment in facility and equipment and compliance expenses
had significant correlations with actual sales, actual revenues, and market value at p <
0.01. Since the interdependencies between the indicators also indicated that significant
correlations between compliance expenses with actual sales and actual revenues, the
rejection of the null hypothesis was supported for the RQ2 for the post-FDA intervention.
Research Question 3
To what extent, if any, do financial indicators (independent) impact compliance
(dependent) with FDA regulations at the pharmaceutical firms in the United
States?
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H3₀: β₁ = β₂ = … = β7 = 0. There is no impact in compliance with FDA
related to seven financial indicators at pharmaceutical firms, as a result of
FDA enforcement actions in the United States.



H3₁: At least one β ≠ 0. There is an impact in compliance with FDA related
to at least one of the seven financial indicators before and after the FDA
enforcement actions in the United States.

The seven financial indicators for the test of Hypothesis 3 were the cost of goods,
investment in facility and equipment, process compliance, actual sales, actual revenues,
market value, and stockholder’s equity. The regression analyses were directed to test H3₀
for pre-FDA and post-FDA. The βs in Hypothesis 3 were the regression coefficients of
the following multiple regression equation:

Y  0  1 X1  2 X 2  3 X3  4 X 4  5 X5  6 X6  7 X7  
Where,
Y= FDA related compliance
X1 = Cost of goods
X2 = Investment
X3 = Process compliance
X4 = Change in sales
X5 = Change in revenues
X6 = Change in market value of the firms
X7 = Change in stockholders equity

(4)
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ԑ

= Error of the regression

The null hypothesis, H3₀, was rejected for the pre-FDA and post-FDA scenarios.
All indicators had a β value indicating a slope not equal to zero. Since not all assumptions
were met, the regression models for the financial indicators cannot be used to generalize
beyond the sample of the study in the pre-FDA and post-FDA interventions.
Pre-FDA Intervention. The null hypothesis, H3₀, was rejected for the pre-FDA
intervention scenario. All indicators had a β value indicating a slope not equal to zero.
The R2 = 0.607 was adjusted to 0.395 or 39.5% representing a reduction of 0.212 or
21.2% of the overall contribution of the seven variables. The stockholder’s equity added
almost 32.1% in contribution in comparison to the previous six predictors. Investment in
facilities and equipment was the second largest contributor with 13.7%. The
stockholder’s equity and investment in facilities and equipment contributed about 45.8%
of the total 60.7% of all the financial indicators.
For the ANOVA assessment, all values of F-ratio were above one signaling that
the model’s fits are better predictors than the guess from the means. Also, the model had
an F-ratio that was significant to p < 0.048 indicating the low probability of the outcome
could happen by chance. Since not all assumptions were met, the regression model for the
financial indicators cannot be used to generalize beyond the sample of the study in the
pre-FDA intervention.
Post-FDA Intervention. The null hypothesis, H3₀, was rejected for the post-FDA
intervention scenario. All indicators had a β value indicating a slope not equal to zero.
The stockholders’ equity contributed with 14.4% in comparison to the 15.5% of the
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previous five predictors. Actual sales were the second largest contributor with 5.8%.
These two predictors contributed 21.2% of the total 29.9% of the financial indicators for
the post-FDA scenario.
For the ANOVA assessment, all values of F-ratio were below one signaling that
the model’s fits were not better predictors than the guess from the means. None of the
models in the post-FDA scenario had an F-ratio that was significant indicating that the
outcome could happen by chance. Since not all assumptions were met, the regression
model for the financial indicators cannot be used to generalize beyond the sample of the
study in the pre-FDA intervention.
Regarding the comparison between the pre-FDA and post-FDA scenarios, the
contribution of the seven indicators diminished from 60.7% to 29.9%. Other contributors
not considered in the initial model impacted the post-FDA scenario like inventory, cost of
supplies, and capacity. These potential other financial contributors could have become
evident to the participants lowering the model effectiveness after the FDA intervention.
Summary
In Chapter 4, the pilot study, the data collection, the data analysis were discussed.
The limited level of participation in the main study was presented with the corresponding
demographics. Despite the limited participation, decisions were presented for the three
tests of the null hypotheses.
RQ1 considered the three constructs of the theory of plan behavior. The limited
participation with 21 completed questionnaires impacted the analysis by limiting the
depth of the trends. Considering the correlations of the three constructs of the TPB with
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the outcome of compliance, the null hypothesis, H1₀, of RQ1 was rejected. Based on the
correlation found between the financial indicators with the level of compliance of the
firms, the null hypothesis, H2₀, for research questions two was rejected for both
scenarios: pre-FDA and post-FDA. The slopes in the regression models for RQ3 rejected
the null hypothesis, H3₀. Both regression models cannot be used to generalize beyond the
sample of the study.
Chapter 5 presents the conclusion and potential interdependencies between the
different data analyses that were conducted in Chapter 4. Limitations that were found and
potential areas for future studies were discussed. The conclusion of the study was
presented.
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Chapter 5: Discussion, Conclusions, and Recommendations
This quantitative study sought to learn to what extent, if any, management
behaviors and financial pressures at pharmaceutical firms correlated with or predicted
compliance with the FDA regulations avoiding interruptions in the supply of some
essential patented or generic pharmaceutical drugs in the U. S. In Chapter 4, the pilot
study, the data collection, and the data analysis were discussed. The limited level of
participation in the main study was presented with the corresponding demographics.
Despite the limited participation, decisions were presented for the three tests of the null
hypotheses. RQ1 focused on the concepts of the theory of plan behavior (Ajzen, 1991).
With the available and limited data, the null hypothesis, H1₀, of RQ1 was rejected. Based
on the correlation found between the seven financial indicators and the level of
compliance of the firms, the null hypothesis, H2₀, for RQ2 was rejected for both
scenarios: pre-FDA and post-FDA. The slopes in the regression models for RQ3 rejected
the null hypothesis, H3₀. Both regression models cannot be used to generalize beyond the
sample of the study.
The nature of the study intended to address the research questions to raise
management’s awareness avoiding interruptions in the supply of some essential patented
or generic pharmaceutical drugs. The study highlighted that (a) avoiding FDA actions
provides business sustainability and (b) compliance is a competitive advantage for
pharmaceutical companies. The design of the research sought to predict the outcome of
the dependent variable, that is, compliance with FDA regulations.
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The behavior by management, related to the quality of drugs to meet their
intended quality, integrity, strength, and purity influenced the level of compliance of the
firm’s operations. Also, the pressures of enhancing productivity, funding research,
supporting marketing plans, and reducing the cost of goods impacted the firm’s
compliance performance. The application of enforcement actions by the FDA on the
firms was used as the treatment event reinforcing the expected level of compliance. A
shift in the relationship between the variables was observed in the correlations and the
linear regressions after the FDA intervention, highlighting the new level of compliance.
The independent variables that could lead to enforcement actions by the FDA
were set as management behaviors of the pharmaceutical managers and the firms’
financial indicators. The treatment event was the application of the enforcement action by
the FDA. The level of compliance of the pharmaceutical company was the dependent
variable. In the study, the conditions before the FDA intervention in the pharmaceutical
firms were compared to the conditions after the FDA intervention to predict compliance
with the CGMP regulations. The research questions were formulated on three focus:


Correlations between management behaviors (independent) and compliance
(dependent)



Correlations between financial indicators (independent) and compliance
(dependent):



Financial indicators (independent) impact on compliance (dependent).
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Interpretation of the Findings
The specific problem addressed in this study related to shortfalls in compliance
performance and product quality leading to medicine shortages that affected patients’
treatment and health. Pollack (2013) expressed that shortfall in investment decisions for
enhancing quality systems and the limited manufacturing capacity were the drivers
causing medicine shortages. Price competition to attain market share, financial benefits
on market value, and management incentives skewed against investing in plant
improvements drove pharmaceutical manufacturing leaders’ decisions and behaviors
away from compliance (Asotra, Cossin, & Yacobi, 2012). Senior leaders’ attitude
towards the lack of compliance and focus in quality systems seems to prevail in their
management decision-making process. Shortfalls in quality systems resulted from
extreme control over the cost of goods and a commitment to strong marketing programs.
Mehta (2013) suggested that implementing principles and guidelines as developed by the
International Conference on Harmonization could be a significant step in facilitating
senior leaders’ understanding of the compliance expectations. Correcting CGMP
violations by the pharmaceutical manufacturing leaders implies that productivityfinancial indicators need assessment and that management behaviors require
modification. Change management practices as described in chapter two could support
the change process, continuous improvement efforts, and deal with potential resistance to
change.
The findings despite the limited participation in the study supported the
arguments presented in the literature. Behaviors and financial indicators correlated with
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compliance with the FDA regulations. The application of the TPB, as well as the
correlations and regression analyses between financial indicators and compliance,
allowed me to reject the null hypotheses two and three to support the arguments in the
literature. Behaviors and approach to financial decisions were different between the preFDA and post-FDA interventions. Changes in the trend of the reputation of the firms and
changes in management also supported the findings.
TPB developed by Ajzen (1991) was utilized to assess behaviors of the
pharmaceutical managers. The central point of TPB is that there is a direct relationship
between intention and actual behavior. TPB highlights that any behavior could be
explained and that behaviors are not difficult to predict. For this study, the intention of
the pharmaceutical industry management to comply with the regulations of the FDA, as
well as managing the financial limitations and complexity, was an excellent scenario to
assess with TPB.
According to Langham, Paulsen, and Härtel (2012), TPB proposes a direct
relationship between intention and actual behavior. This relationship is essential to the
understanding of the willingness to comply and of the actual action of non-compliance.
Consequently, predicting intention to comply is as important as predicting the actual
compliance behavior. TPB also evaluates the topic of behavioral control, including the
concepts of perceived behavioral control and actual control. Perceived behavioral control
consists of the individual’s ability to control behavior and willingness to apply the
required behavior. Actual control is essential for investigating behaviors that require the
individual to overcome performance hurdles. Attitudes and values are specific elements

208
in this approach. Despite the limited participation, understanding the findings that lead to
the unwillingness to comply or drive to ignore compliance facilitated the assessment of
probable prevention measures accompanying any FDA intervention. By applying linear
regression to research questions one, TPB approach provided models to understand how
to predict behavior and reinforce the intention that could modify future compliance of the
firms.
The correlation of the financial indicators with compliance with the FDA
regulations prior to the FDA intervention in RQ2 provided insight on the levels of
interdependencies including the significance of the findings. Investment in facility and
equipment and compliance expenses demonstrated a significant correlation to compliance
with the FDA regulations. For the post-FDA scenario, the correlation coefficient
indicated that investment in facility and equipment and compliance expenses had
significant correlations with actual sales, actual revenues, and market value at p < 0.01. If
the interdependencies between the indicators were used to imply that compliance
expenses impact actual sales and actual revenues, the null hypothesis could be rejected in
the post-FDA scenario for RQ2.
The predictors for RQ3 were the seven financial indicators. The outcome variable
was the level of compliance with the FDA regulations. The null hypothesis, H3₀, was
rejected for both FDA intervention scenarios. All indicators had a B value indicating a
slope not equal to zero. Of the seven predictors for the pre-FDA intervention,
stockholders’ equity had an ANOVA value with significance to p < 0.05. The influence
of all participants (cases) in the regression model for the pre-FDA scenario was verified,
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and two were found to be outside the expectation based on the Mahalanobis Distance
values. For the post-FDA scenario, the influence of all cases of the regression model was
found to be within expectation.
For the assumptions of residual normality, linearity, and homoscedasticity, plots
assessed under SPSS could be considered supporting these assumptions in both FDA
scenarios. The lack of significance on the characteristics of the regression models
indicated that the models were not robust. The findings cannot be generalized and used
beyond the sample population since not all assumptions for the two linear regressions
were met. The low level of participation limited the precision on the assessment of the
assumptions of the regression model.
Research Question 1
To what extent, if any, does management behaviors (independent) correlate to
compliance (dependent) with FDA regulations at the pharmaceutical firms in the
United States?


H1₀: r = 0. There is no difference in management behaviors towards
compliance at pharmaceutical firms, as a result of FDA enforcement actions in
the U.S.



H1₁: r ≠ 0. There are differences in management behaviors towards
compliance at pharmaceutical firms, as a result of FDA enforcement actions in
the U.S.
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The null hypothesis, H1₀, was rejected for RQ1 in the pre-FDA and post-FDA
interventions. Correlations were found that were not equal to zero (r ≠ 0). The
significance of the correlations varied and not all correlations met the expectation, p <
0.05.
In the Pearson correlation for the pre-FDA intervention, the construct of
behavioral beliefs (attitudes) had the highest correlation with the outcome of compliance
with a value of r = 0.633, p < 0.01. The other two construct, normative beliefs and
perceived behavioral control, had non-significant correlations with values of r = 0.328
and r = 0.183, respectively. For the post-FDA intervention, the construct of behavioral
beliefs (attitudes) also had the highest correlation with the outcome of compliance with a
value of r = 0.693, p < 0.01. The other two construct, normative beliefs and perceived
behavioral control, had non-significant correlations with values of r = 0.294 and r =
0.303, respectively. Also, the construct of behavioral beliefs had a significant correlation
with the construct of perceived behavioral control with r = 0.376, p < 0.05. This last
significant correlation differed from the pre-FDA intervention where the correlation was
non-significant between these two constructs. This fact implied the influence on
individual beliefs and their own perception of controlling behaviors after the FDA
intervention.
The correlation data indicated a favorable change in correlation between the
outcome of compliance and behavioral beliefs (attitude) for before and after the FDA
interventions of about 9.5%. The value of r increased from 0.633 to 0.693 for the
construct of beliefs (attitude) towards compliance by the participants with significances
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of p < 0.01. The other two independent constructs had non-significant correlations. The
perceived behavioral control non-significant correlation with the outcome of compliance
also increased by about 65% from the pre-FDA (r = 0.183) to the post-FDA scenario (r =
0.303). The change in the r value for the perceived behavioral control construct led to the
change in significance with the outcome of compliance after the FDA intervention. From
the limited population that participated in the study, the null hypothesis was rejected for
RQ1.
A regression analysis was also conducted to establish if there was a linear model
of the three TPB constructs as predictors of the outcome of compliance of the firms with
the FDA regulations. For the pre-FDA scenario, the R2 = 0.421 and was adjusted to about
32% for the contribution of the three constructs. The F- ratio indicated the significance of
the change with p < 0.05. For the post-FDA scenario, the R2 = 0.492 was adjusted to
40.2% representing the adjustment to the overall contribution of the three independent
variables. The F-ratio provided the significance of the change, p < 0.01. For the ANOVA
assessment, the models for both scenarios (pre-FDA and post-FDA) had an F-ratio that
were significant (p < 0.05) indicating that the outcome could unlikely happen by chance.
For the comparison before and after the FDA intervention, the contribution of the
three constructs of the TPB increased from 42.1% to 49.2%. This increased in
contribution after the FDA intervention represented an overall 16.9% favorable impact on
the compliance of the firms with FDA regulations. For the participants of the study, the
FDA intervention influenced their behaviors towards compliance with the FDA
regulations in the United States. Since not all assumptions were met, the regression

212
model for TPB cannot be used to generalize beyond the sample of the study in either the
pre-FDA or the post-FDA interventions.
Research Question 2
To what extent, if any, do financial indicators (independent) correlate to
compliance (dependent) with FDA regulations at the pharmaceutical firms in the
United States?


H2₀: r = 0. There is no difference in compliance with FDA related to financial
indicators at pharmaceutical firms, as a result of FDA enforcement actions in
the U.S.



H2₁: r ≠ 0. There are differences in compliance with FDA related to financial
indicators, as a result of FDA enforcement actions in the U.S.

The null hypothesis, H2₀, was rejected for RQ2 in the pre-FDA and post-FDA
interventions. Correlations were found that were not equal to zero (r ≠ 0). The
significance of the correlations varied and not all met the expectation, p < 0.05.
Pre-FDA Intervention
The null hypothesis, H2₀, was rejected for RQ2 in the pre-FDA intervention. Of
the seven financial indicators, the compliance of the firms prior to the FDA intervention
had a significant Pearson correlation at p < 0.05 with three of them considering a onetailed assumption due to the skewness of the data in the responses. Investment in facility
and equipment (r = |-0.468|, p < 0.05), compliance expenses (r = |-0.558, p < 0.05), and
stockholders’ equity (r = 0.392, p < 0.05) were significantly correlated to compliance.

213
Also, facility and equipment and compliance expenses were significantly correlated to
actual sales, actual revenues, and market value at p < 0.01.
Since the distribution of the scores was skewed or non-normal as supported by
the results of Kolmogorov-Smirnov and Shapiro-Wilk tests, Kendall’s Tau correlation
coefficient, τ, was also used to understand the correlation between the variables. Of the
seven financial indicators and following Kendall’s correlation coefficient, τ, the
compliance of the firms prior to the FDA intervention had a significant correlation at p <
0.05 with two of them considering a one-tailed assumption due to the skewness of the
data in the responses. Investment in facility and equipment (r = |-0.432|, p <0.05) and
compliance expenses (r = |-0.497|, p < 0.01) were significantly correlated to compliance
of the firms. Also, facility and equipment and compliance expenses were significantly
correlated to actual sales, actual revenues, and market value at p < 0.01.
Post-FDA Intervention
The null hypothesis, H2₀, was also rejected for RQ2 in the post-FDA intervention.
The compliance of the firms after the FDA intervention only had a significant Pearson
correlation with stockholders’ equity (r = 0.374, p < 0.05) considering a one-tailed
assumption due to the skewness of the data in the responses. Similar to the pre-FDA
scenario, investment in facility and equipment and compliance expenses were
significantly correlated to actual sales, actual revenues, and market value at p < 0.01.
Compliance expenses were significantly correlated to all other indicators except for
COGS and stockholders’ equity implying the importance of compliance expense between
the indicators.
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From the Kendall’s correlation coefficient, τ, the compliance of the firms had no
significant correlation with any of the financial indicators in the post-FDA scenario. The
stockholders’ equity had a p significance value equal to 0.055. The Kendall’s correlation
coefficient indicated that investment in facility and equipment and compliance expenses
had significant correlations with actual sales, actual revenues, and market value at p <
0.01. Since the interdependencies between the indicators investment in facility and
equipment and compliance expenses indicated significant correlations with actual sales,
actual revenues, and market value, the rejection of the null hypothesis was supported for
the RQ2 for the post-FDA intervention.
Research Question 3
To what extent, if any, do financial indicators (independent) impact compliance
(dependent) with FDA regulations at the pharmaceutical firms in the United
States?


H3₀: β₁ = β₂ = … = β7 = 0. There is no impact in compliance with FDA
related to seven financial indicators at pharmaceutical firms, as a result of
FDA enforcement actions in the United States.



H3₁: At least one β ≠ 0. There is an impact in compliance with FDA related
to at least one of the seven financial indicators before and after the FDA
enforcement actions in the United States.

The seven financial indicators for the test of Hypothesis 3 were the cost of goods,
investment in facility and equipment, process compliance, actual sales, actual revenues,
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market value, and stockholder’s equity. The regression analyses were directed to test H3₀
for pre-FDA and post-FDA. The βs in Hypothesis 3 were the regression coefficients of
the following regression equation:

Y  0  1 X1  2 X 2  3 X 3  4 X 4  5 X 5  6 X 6  7 X 7  

(5)

Where,
Y= FDA related compliance
X1 = Cost of goods
X2 = Investment
X3 = Process compliance
X4 = Change in sales
X5 = Change in revenues
X6 = Change in market value of the firms
X7 = Change in stockholders equity
ԑ

= Error of the regression

The null hypothesis, H3₀, was rejected for the pre-FDA and post-FDA scenarios.
All indicators had a β value indicating a slope not equal to zero. Since not all assumptions
were met, the regression models for the financial indicators cannot be used to generalize
beyond the sample of the study in the pre-FDA and post-FDA interventions.
Pre-FDA Intervention
The null hypothesis, H3₀, was rejected for the pre-FDA intervention scenario. All
indicators had a β value indicating a slope not equal to zero. The R2 = 0.607 was adjusted
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to 0.395 or 39.5% representing a reduction of 0.212 or 21.2% of the overall contribution
of the seven variables. The stockholder’s equity and investment in facilities and
equipment contributed about 30% of the total 39.5% of all the financial indicators. For
the ANOVA assessment, all values of F-ratio were above one signaling that the model’s
fits were better predictors than the guess from the means. Also, the model had an F-ratio
that was significant to p < 0.048 indicating the low probability of the outcome could
happen by chance. Since not all assumptions were met, the regression model for the
financial indicators cannot be used to generalize beyond the sample of the study in the
pre-FDA intervention.
Post-FDA Intervention
The null hypothesis, H3₀, was rejected for the post-FDA intervention scenario. All
indicators had a β value indicating a slope not equal to zero. The R2 = 0.299 was adjusted
to -0.001 representing a very significant adjustment to the overall contribution of the six
variables. The stockholder’s equity contributed almost 15% in comparison to the 14% of
the other five predictors. Actual sales were the second largest contributor with about 6%.
These two predictors contribute about 21% of the total 29.8% of the financial indicators
in the post-FDA scenario.
For the ANOVA assessment, all values of F-ratio were below one signaling that
the model’s fits were not better predictors than the guess from the means. None of the
models in the post-FDA scenario had an F-ratio that was significant indicating that the
outcome could happen by chance. Since not all assumptions were met, the regression
model for the financial indicators cannot be used to generalize beyond the sample of the
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study in the pre-FDA intervention. Comparing the two scenarios, the contribution of the
financial indicators decreased from 60.7% to 29.9% indicating that other factors were
also perceived as contributing to the compliance model of the post-FDA model that were
not part of the initial pre-FDA model.
Limitations of the Study
The length of the main study proved to be a major limitation. The pilot study had
about 40 questions. The main study had 133 questions. The number of participants that
initiated the survey was about 90 of which 45 progressed through the questions. Only 21
participants provided completed surveys for the study. The participation rate of 1.9% was
a major impact to the completeness of the study. The assumptions for the linear
regressions in RQ3 were not met. The predicting models could not be generalized beyond
the participants.
The low level of participation limited the study depth and significance of the
findings. The rationale for the low participation could have been the sensitivity of the
topic in the pharmaceutical industry for the shortages of quality product to the patients.
Also, the participants could had concerns on the confidentiality of the survey despite the
consent form with the IRB endorsement. In the technical side of communications, the
internet firewalls in the pharmaceutical firms could had limited e-mails reaching the
participants.
The financials results after the FDA intervention in the pharmaceutical firms were
limited to the recollection and level of knowledge of the participants. The limited
participation was a major obstacle for the assessment of the financial indicators. The
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participants, depending on their knowledge and recollection, inferred the financial
information of the pharmaceutical firms depending on the type of the FDA intervention.
Recommendations
Overcoming the limitations of participation and completeness of the study is
considered as a specific recommendation. Regarding participation, an alternate approach
to the use of a professional organization is to recruit and obtain permission directly from
pharmaceuticals firms. This approach could provide some level of comfort in the
participants considering the direct clearance by the firms.
Completeness of the study depended on the length and number of questions. The
questions were perceived as repetitive as the participant assessed the pre-FDA and postFDA scenarios. This design of repetitiveness is part of the TPB survey structure (Fishbein
and Ajzen. 2010). The typical TPB survey provides about 50 to 60 questions to address
the three constructs of attitude, normative beliefs, and perceived behavior control. The
study targeted two scenarios to assess the research questions: pre-FDA and post-FDA
interventions. This design led to double the TPB questions. The remaining 10 to 15
questions were regarding financial indicators, FDA compliance, and demographics.
The total questions in the main study were 133. If the study had focused in just
the after the FDA intervention, the number of usable-complete surveys night have been
about 45 instead of 21. This number is still well below the initially targeted number of
160 completed surveys. One recommendation is to reduce the number of questions
further by focusing only on the construct of belief (attitude) in the study questionnaire
based on the correlation results. On RQ1, beliefs (attitude) had the highest value of
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correlation with the outcome of compliance for both FDA scenarios: r (pre-FDA) =
0.633, p < 0.01 and r (post-FDA) = 0.693, p < 0.01. The other two independent
constructs, normative beliefs and perceived behavioral control, had non-significant
correlations with the outcome of compliance in the evaluation of RQ1. This approach
could further reduce the complexity and the length of the questionnaire influencing the
number of usable-complete surveys. The concept of the behavior of the decision makers
remains as a significant element difficult to predict.
Recommendations for future research topics based on the models of regression
analysis from RQ3 with values of R2 = 0.607 (pre-FDA) and of R2 = 0.299 (post-FDA)
could include other operational financial variables to increase the predictors’ contribution
in the models. Other financial predictors to be included in the regression analysis could
be the inventory of goods, marketing costs, and cost of distribution. These topics were
found in the literature and on-going studies by professional organizations like ISPE. ISPE
(2014) in their publication on the shortage of medicines also suggested the topics of
inventory control, the supply of raw materials, the capacity of the manufacturing firms,
and harmonization of regulations in a global market.
All the 1144 participants that were invited to participate in the study were related
to pharmaceutical companies under the FDA regulations based on their self-disclosed
information in the ISPE’s database. Since every day the pharmaceutical firms are
operating in global markets and driving consolidations, future studies could be focused in
other major markets outside the United States. New manufacturing geographies have
developed in India and China for the supply of raw materials for the manufacturing of
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pharmaceuticals products. The literature that I found was mainly focused on the
American culture. Also, the regulations in other markets are different and evolving. Lack
of harmonization of regulations will add complexity to the future research. Future studies
could continue to be segmented by markets and cultures.
Based on RQ2, the financial indicators correlated with the outcome of compliance
with FDA regulations. Management decisions regarding these indicators could influence
compliance with the FDA interventions. Based on Kendall’s correlation coefficient, τ, the
compliance of the firms prior to the FDA intervention had a significant correlation with
investment in facility and equipment (r = |-0.432|, p < 0.05) and compliance expenses (r
= |-0.497|, p < 0.01). Also, facility and equipment and compliance expenses were
significantly correlated to actual sales, actual revenues, and market value at p < 0.01.
Assessment of pharmaceutical management’s behaviors should be conducted to consider
and accentuate the how to address these financial drivers.
In a future study, emphasis should be directed to understand better the influences
from normative beliefs and perceived control behaviors in management behaviors as
found in RQ1. Considering the trends of the responses, the overall Normative belief
indicated to have a stronger influence on the behavior towards the outcome of
compliance with 392/368 (pre-FDA/post-FDA) of a total of 490 points versus overall
PBC with a value of 195/182 (pre-FDA/post-FDA) of a total of 490 points. When
considering the managers’ behaviors, the influence of the opinion from supervisors,
peers, and relatives on behaviors was stronger than the perceived control in behaviors
from business related items like budget goals and datelines.
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Implications
This research study could be considered unique as it was directed to address an
area of limited research in management behaviors and on financial decision-making in
senior management in pharmaceuticals companies which could have led to significant
shortages of medicines in last 5-6 years. Drug shortage events increased from 61 in 2005
(Barlas, 2014) to 251 in 2011 (Food Drug Administration [FDA], 2013). Woodcock
(2012) signaled many of these medicine shortages as a direct consequence of shortfalls in
compliance with the FDA regulations.
The comparison of the correlations of the three construct of the TPB with the
outcome of compliance for the pre-FDA and post-FDA scenarios indicated that the FDA
intervention had influence in the participants’ behaviors. The correlation of the construct
of beliefs (attitude) was significant and increased by 9.5%. In the case of perceived
behavioral control, the correlation with the outcome of compliance increased by 65%
although it was not significant.
These trends implied that the FDA intervention impacted the participants’
perception on how could they control and influence their behavior for compliance with
the FDA regulations. The normative beliefs regarding others’ opinions did not show any
change in the correlation with compliance between the pre-FDA and post-FDA scenarios.
Peers, supervisors, and quality unit opinions did not alter their influence towards a
behavior of pro-compliance in the participants. The level of compliance increased after
the FDA intervention as indicated by the means of the participants’ responses. A
dependent-means t-test was applied to the two scenarios’ means: pre-FDA and post-FDA
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considering that the same participants took part in both scenarios. A negative sign to the
difference of the means indicated that the mean of the compliance of the firms after the
FDA intervention was larger than before the FDA intervention. A negative t- test
confirmed that the mean of the post-FDA was larger than the pre-FDA scenario.
In the regression model following the three construct from the theory of planned
behavior (TPB) in RQ1, the contribution of the three constructs increased after the FDA
intervention from 42.1% to 49.2%. This increase signaled that the desired behavior to be
in compliance with the FDA regulations was favorably impacted. The beliefs (attitude),
the normative beliefs (peers), and the perceived behavioral control provided a higher
prediction of behavior after the FDA intervention. These models could be used by
management to reinforce behaviors allowing a more robust application of the firm’s
quality systems to minimize drug shortages and to attain a more competitive position for
the firms.
In the seven correlations of the financial indicators in RQ2, the significant
correlation between stockholders’ equity in both pre-FDA and post-FDA interventions
signaled the relevance of the firms’ compliance with the FDA and the investors’
expectations of the firms’ reputation. Also, the favorable trend in perception of the firms’
reputation from the participants’ responses supported the concept that the firms could be
considered as having achieved a more favorable image by increasing its compliance with
the FDA regulations. In RQ2, the inverse correlation of investment on facility and
equipment and compliance expenses with the outcome of compliance could be
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considered as strong opinion that low level of compliance requires high level of
investment and compliance expenses.
In RQ3, the regression model after the FDA intervention was not robust in
comparison to the contribution of the variables in the pre-FDA scenario. The contribution
decreased from 60.7% to 29.9% indicating that other factors were also perceived as
contributing to the compliance model that were not part of the initial pre-FDA model.
Elements like inventory, cost of supplies, and capacity could be further limiting the postFDA model. This outcome of the study could provide insight into the management
decision process on what senior leaders’ should consider when dealing with financial
drivers that could limit the presence of effective quality systems in the pharmaceutical
manufacturing companies.
For pharmaceutical firms, the lack of compliance with the FDA regulations could
be devastating. The results from the lack of compliance could include impact on
reputation of the firms and an increase in the level of expenses to recover or achieve
remediation. These performance indicators typically also impact the market value of the
firms as shown in the correlations of RQ2. Regarding the reputation of the firms, the
average of the responses from the participants indicated a decreasing trend in the positive
ratings from eight to six between the pre-FDA and post-FDA interventions.
In the Pearson correlation for the pre-FDA scenario, investment in facility and
equipment (r = |-0.468|, p < 0.05) and compliance expenses (r = |-0.558|, p < 0.05) were
inversely correlated to complince of the firms. The lower the compliance of the firms
implied the higher the need to increase investment in facilities and equipment as the
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corresponding compliance. If the FDA intervention escalates into a consent decree, the
magnitude of all these elements could multiply and become an unacceptable historical
benchmark within the industry.
This study has the potential to highlight the desired behaviors in management and
accentuate the concept that compliance could avoid medicine shortages and be a
competitive business advantage for the pharmaceutical companies. In RQ1, the Pearson
correlation of beliefs (attitude) with the outcome of compliance was increased from r =
0.663 to r = 0.0693 for a 9.5% when comparing the pre-FDA and post-FDA scenarios.
The perceived behavioral control non-significant correlation with the outcome of
compliance also increased by about 65% from the pre-FDA (r = 0.183) to the post-FDA
scenario (r = 0.303). The normative beliefs driven by opinion from others did not shown
any significant change between the pre-FDA and post-FDA interventions.
In the regression analysis to the TPB constructs also in RQ1, the R of the models
increased from 42.1% to 49.2%. This increase in the contribution of the construct
behaviors in the prediction of compliance reinforced the concept that after the FDA
intervention, behaviors towards compliance were better recognized by the participants in
the study. These model could be used by management to reinforce behaviors allowing a
more robust application of the firms’ quality systems to minimize drug shortages and to
attain a more competitive position for the firms. Management should ensure clarity to
subordinates on the expected behavior and influence perceived controls to drive
compliance of the firms with the FDA regulations.

225
Through this study, I was able to influence pharmaceutical management’s
awareness on how their decisions, based on their attitudes and behaviors, impacted
compliance. The inverse relation of compliance of the firms versus investment in
facilities and compliance expense should be used to demonstrate that the higher the
compliance the lower these financial factors. Avoiding having low compliance with the
FDA regulations increases expenses and could lead to interruptions in the supply of some
essential patented drugs or generic pharmaceutical drugs. The desired management
behaviors should transform leadership tactics to meet the organization goals and mission,
while attaining compliance with the CGMP regulations.
The target of the study, as previously described, was directed to the positive social
change to avoid placing the patients in danger by not having medicine shortages. Becker
et al. (2013) found in their study that the incidents of oncological drug shortages affecting
patients’ treatments increased from 2010 to 2011. Also, stockholders’ equity, as
demonstrated in RQ2, could be affected if management does not recognize the
detachment from their mission leading to low compliance and the associated costs from
the FDA interventions. Considering that any generalization is limited to the sample of
participants and is based on the correlations and regression analyses conducted in this
study, if management performance continues with old practices and behaviors, leading to
poor product quality and further medicine shortages, the risk to patients and the losses to
stockholders could be unavoidable.
To project the complexity of addressing the change, change management
decision-making processes need to be implemented by the pharmaceutical management.
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The required change process to attain the desired state of avoiding medicine shortages
has to evolve through the typical change cycle of what, how, and why (Kezar, 2001). The
potential impact on stakeholders, especially medicine shortages to patients, constituted
the “why” to conduct this study. Influencing the organizational performance, through
modification of management behaviors and financial indicators, should minimize or
eliminate the stakeholders’ impact, leading to positive social change.
The study alignment to obtain positive social change was directed to encourage
managers of pharmaceutical organizations to operate and behave with a sound approach
to compliance with CGMP of the FDA. The main potential social impact was to avoid
having medicine shortages, due to non-compliance decisions by pharmaceutical
manufacturing management. The risk of affecting the patient health could be minimized
or eliminated by avoiding drug shortages as well as the supply of substandard patented or
generic medicines. Also, the inherent mistrust by the public on companies’ lack of
commitment towards social responsibilities could be neutralized or reduced enhancing
the reputation of the firms as indicated in the responses to the study.
Conclusion
This research study could be considered unique as it was directed to address an
area of limited research in management behavior and on the financial decision-making of
senior management in pharmaceuticals companies, which could have led to significant
shortages of medicines in last 5-6 years. Despite the limited participation, the outcome of
the study provided insight into the management decision process on what senior leaders’
behaviors should consider and accentuated the need to modify the approach to financial
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drivers. Emphasis should be directed to better understand the influence of the perceived
behavioral control versus normative beliefs. Enhancing decision making processes while
considering behaviors and the financial correlations could reinforce the presence of
effective quality systems in the pharmaceutical manufacturing companies eliminating or
minimizing medicine shortages.
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Appendix A: Permission to Reprint Figure 4 and TPB questionnaire
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Appendix B: Permission to Reprint Figure 5
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Appendix C: G*Power Calculations
F tests - Linear multiple regression: Fixed model, R² deviation from zero
Analysis: A priori: Compute required sample size
Input:
Effect size f²
= 0.125
α err prob
= 0.05
Power (1-β err prob)
= 0.95
Number of predictors
= 2
Output:
Noncentrality parameter λ = 15.8750000
Critical F
= 3.0692864
Numerator df
= 2
Denominator df
= 124
Total sample size
= 127
Actual power
= 0.9506401
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Appendix D: Permission from ISPE
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Appendix E: Pilot study demographics

Table E1

Table E2

Age Group of Participants

Management Decision-Makers

Answer
Options

Response
Percent

0.0%
20-30
0.0%
31-40
28.6%
41-50
42.9%
51-60
14.3%
60+
Prefer not to
14.3%
answer
Note: answered question: 7
skipped question: 2

Response
Count
0
0
2
3
1
1
7
2

Answer
Options

Response
Percent

Response
Count

Manager

0.0%

0

Director

57.1%

4

Vice President

28.6%

2

Executive

14.3%

1

President

0.0%

0

CEO

0.0%

0

Note: answered question: 7
skipped question: 2

Table E3

Table E4

Operational Function

Academic Background

Answer
Options

Response
Percent

Response
Count

Manufacturing

14.3%

1

Quality

57.1%

Logistics
Engineering
Other (please
specify)

Response
Percent

Response
Count

High School

0.0%

0

4

Bachelors

42.9%

3

0.0%

0

Masters

14.3%

1

0.0%

0

MBA

0.0%

0

Ph.D.
Other (please
specify)

42.9%

3

0.0%

0

28.6%

Note: answered question: 7
skipped question: 2

2

Answer
Options

Note: answered question: 7
skipped question: 2
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Appendix F: Main study demographics

Table F1

Table F2

Age Group of Participants

Management Decision-Makers

Answer
Options

Response
Percent

Response
Count

Answer
Options

Response
Percent

Response
Count

Manager

27.2%

6

59.1%

13

9.1%

2

20-30

0.0%

0

31-40

0.0%

0

41-50

31.8%

7

51-60

50.0%

11

Director
Vice
President

60+
Prefer not to
answer

13.6%

3

Executive

4.6%

1

President

0.0%

0

4.61%

1

CEO

0.0%

0

Note: answered question: 22

Note: answered question: 22
skipped question: 0

skipped question: 0

Table F3

Table F4

Operational Function

Academic Background

Answer
Options

Answer
Options

Response
Percent

Response
Count

4.6%
27.3%
40.9%
10.2%
9.0%

1
6
9
4
2

Response
Percent

Response
Count

Manufacturing

22.7%

5

High School

Quality

22.7%

5

Logistics

0.0%

0

Engineering
Other (please
specify)

40.9%

9

13.7%

3

Bachelors
Masters
MBA
Ph.D.
Other (please
0.0%
specify)
Note: answered question: 22
skipped question: 0

Note: answered question: 22
skipped question: 0

0

